


**CUMULATIVE
SUPPLEMENT 6
JUNE 2019**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2019

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**Cumulative Supplement 6
June 2019**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	x
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend.....	xii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**CUMULATIVE SUPPLEMENT 6
JUNE 2019**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the

"@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in

a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

G AND W LABORATORIES INC
 (G AND W LABS)

ACP NIMBLE BUYER INC
 (ACP NIMBLE)

G AND W LABORATORIES INC (G AND W LABS INC)	ACP NIMBLE BUYER INC (ACP NIMBLE)
IVAX PHARMACEUTICALS INC (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
RISING PHARMACEUTICALS INC (RISING PHARMS)	RISING PHARMA HOLDINGS INC (RISING)
SUN PHARMA GLOBAL FZE (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL INC (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA (TEVA PHARMS USA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA INC (TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WATSON LABORATORIES INC (WATSON LABS INC)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS INC)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS INC)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB2	209713	001
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001

LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001
-------------------------	-------	---------	-----	--------	-----

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and

those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20295 2724 (13.4%)	20580 2713 (13.2%)	20693 2729 (13.2%)		
MULTISOURCE	17571 (86.6%)	17867 (86.8%)	17964 (86.8%)		
THERAPEUTICALLY EQUIVALENT	17483 (86.1%)	17777 (86.4%)	17964 (86.8%)		
NOT THERAPEUTICALLY EQUIVALENT	88 (0.4%)	90 (0.4%)	85 (0.4%)		
EXCEPTIONS ¹	58 (0.3%)	58 (0.3%)	58 (0.3%)		
NEW MOLECULAR ENTITIES APPROVED	25	3	16		
NUMBER OF APPLICANTS	1133	1129	1132		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

@ ZYDUS PHARMS EQ 600MG BASE;300MG A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

>A> AB MSN LABS PVT LTD 250MG A210686 001 Jul 10, 2019 Jun NEWA
AB WOCKHARDT BIO AG 250MG A208380 001 Feb 27, 2019 Feb NEWA

ACARBOSE

TABLET;ORAL

ACARBOSE

>D> AB MYLAN 25MG A091053 001 Jan 06, 2011 Jun DISC
>A> @ 25MG A091053 001 Jan 06, 2011 Jun DISC
>D> AB 50MG A091053 002 Jan 06, 2011 Jun DISC
>A> @ 50MG A091053 002 Jan 06, 2011 Jun DISC
>D> AB 100MG A091053 003 Jan 06, 2011 Jun DISC
>A> @ 100MG A091053 003 Jan 06, 2011 Jun DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+ KEMPHARM 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Jan NEWA
+ 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Jan NEWA
+ KVK TECH INC 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Feb CAHN
+ 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb CAHN
+ 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Feb CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC 120MG/5ML;12MG/5ML A091238 001 Nov 10, 2011 Jan DISC

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>A> AA WES PHARMA INC 300MG;15MG A211610 001 Jun 27, 2019 Jun NEWA
>A> AA 300MG;30MG A211610 002 Jun 27, 2019 Jun NEWA
>A> AA 300MG;60MG A211610 003 Jun 27, 2019 Jun NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA WES PHARMA INC 325MG/15ML;7.5MG/15ML A211023 001 Mar 08, 2019 Feb NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ALVOGEN PINE BROOK 300MG;5MG A208540 001 Nov 08, 2018 Apr DISC
@ 300MG;7.5MG A208540 002 Nov 08, 2018 Apr DISC
@ 300MG;10MG A208540 003 Nov 08, 2018 Apr DISC
@ 325MG;2.5MG A209958 001 Oct 24, 2018 Apr DISC
@ 325MG;5MG A209958 002 Oct 24, 2018 Apr DISC
@ 325MG;7.5MG A209958 003 Oct 24, 2018 Apr DISC
@ 325MG;10MG A209958 004 Oct 24, 2018 Apr DISC
@ ELITE LABS INC 325MG;2.5MG A209924 001 Nov 16, 2018 May DISC
@ 325MG;5MG A209924 002 Nov 16, 2018 May DISC
@ 325MG;7.5MG A209924 003 Nov 16, 2018 May DISC
@ 325MG;10MG A209924 004 Nov 16, 2018 May DISC
@ UPSHER SMITH LABS 325MG;5MG A206484 001 Mar 24, 2017 Jan DISC
@ 325MG;7.5MG A206484 002 Mar 24, 2017 Jan DISC
@ 325MG;10MG A206484 003 Mar 24, 2017 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

@ MIKART INC 300MG/5ML;10MG/5ML A202142 001 Nov 27, 2018 May DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL		ACETAZOLAMIDE							
	@ ACCORD HLTHCARE	500MG		A207659	001	Oct 18, 2018	Apr	DISC	
AB	ALEMBIC PHARMS LTD	500MG		A210423	001	Feb 19, 2019	Feb	NEWA	
AB	CADILA	500MG		A205301	001	Jan 16, 2019	Mar	CAHN	
>A>	MYLAN	500MG		A203917	001	Jun 18, 2019	Jun	NEWA	
>D>	INJECTABLE;INJECTION								
>D>	ACETAZOLAMIDE SODIUM								
>D>	AP	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Jun	CAIN	
	AP		EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Apr	NEWA	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION		ACETAZOLAMIDE SODIUM							
	@ PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL		A205358	001	Jun 20, 2017	Apr	DISC	
>A>	AP	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Jun	CAIN	

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC		ACETIC ACID							
AT	SAPTALIS PHARMS	2%		A040607	001	Feb 24, 2005	May	CAHN	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC		ACETASOL HC							
>D>	AT	ACTAVIS MID ATLANTIC	2%;1%	A087143	001	Jan 13, 1982	Jun	DISC	
>A>	@		2%;1%	A087143	001	Jan 13, 1982	Jun	DISC	

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC		MIOCHOL							
	+ @ NOVARTIS	20MG/VIAL		N016211	001		Apr	CRLD	

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS		ACETYLCYSTEINE							
	@ MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)		A203624	001	Jun 19, 2015	Mar	DISC	
	TABLET, EFFERVESCENT;ORAL								
	CETYLEV								
	+ @ ARBOR PHARMS LLC	500MG		N207916	001	Jan 29, 2016	Mar	DISC	
	+ @	2.5GM		N207916	002	Jan 29, 2016	Mar	DISC	

ACITRETIN

CAPSULE;ORAL		SORIATANE							
	+ @ STIEFEL LABS INC	17.5MG		N019821	003	Aug 06, 2009	Jan	DISC	
	+ @	22.5MG		N019821	004	Aug 06, 2009	Jan	DISC	

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION		TUDORZA PRESSAIR							
>D>	+!	ASTRAZENECA PHARMS	0.4MG/INH	N202450	001	Jul 23, 2012	Jun	CAHN	
>A>	+!	CIRCASSIA	0.4MG/INH	N202450	001	Jul 23, 2012	Jun	CAHN	

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION		DUAKLIR PRESSAIR							
		ASTRAZENECA PHARMS	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Mar	NEWA	
		CIRCASSIA	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Apr	CAHN	

ACYCLOVIR

CAPSULE;ORAL		ACYCLOVIR							
AB	KENTON	200MG		A075090	001	Jan 26, 1999	Mar	CAHN	
	CREAM;TOPICAL								
	ACYCLOVIR								
AB	PERRIGO UK FINCO	5%		A208702	001	Feb 04, 2019	Jan	NFTG	
	ZOVIRAX								
AB	+!	BAUSCH	5%	N021478	001	Dec 30, 2002	Feb	CAHN	

	CREAM; TOPICAL							
	ZOVIRAX							
AB	+!	VIB	5%	N021478	001	Dec 30, 2002	Jan	CFTG
	OINTMENT; OPHTHALMIC							
	AVACLYR							
	+!	FERA PHARMS LLC	3%	N202408	001	Mar 29, 2019	Mar	NEWA
	OINTMENT; TOPICAL							
	ACYCLOVIR							
AB		CIPLA	5%	A211794	001	Jan 18, 2019	Jan	NEWA
>D>	AB	GLENMARK PHARMS LTD	5%	A205510	001	Jul 31, 2017	Jun	CAHN
>A>	AB	GLENMARK PHARMS SA	5%	A205510	001	Jul 31, 2017	Jun	CAHN
AB		PERRIGO UK FINCO	5%	A205659	001	Feb 20, 2019	Feb	NEWA
AB		ZYDUS PHARMS	5%	A205974	001	Mar 15, 2019	Mar	NEWA
	ZOVIRAX							
AB	+!	BAUSCH	5%	N018604	001	Mar 29, 1982	Feb	CAHN
	<u>ACYCLOVIR SODIUM</u>							
	INJECTABLE; INJECTION							
	ACYCLOVIR SODIUM							
	!	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018	Jan	CHRS
	!		EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018	Jan	CHRS
	<u>ACYCLOVIR; HYDROCORTISONE</u>							
	CREAM; TOPICAL							
	XERESE							
	+!	BAUSCH	5%;1%	N022436	001	Jul 31, 2009	Feb	CAHN
	<u>ADAPALENE; BENZOYL PEROXIDE</u>							
	GEL; TOPICAL							
	ADAPALENE AND BENZOYL PEROXIDE							
AB		PERRIGO UK FINCO	0.1%;2.5%	A205033	001	Jan 23, 2018	May	CAHN
	@	TARO	0.3%;2.5%	A209148	001	Oct 17, 2018	May	DISC
	<u>ADENOSINE</u>							
	INJECTABLE; INJECTION							
	ADENOSINE							
	@	LUITPOLD	3MG/ML	A090010	001	Apr 28, 2009	Mar	DISC
	<u>ALBENDAZOLE</u>							
	TABLET; ORAL							
	ALBENDAZOLE							
AB		ACTAVIS ELIZABETH	200MG	A208094	001	May 20, 2019	May	NEWA
AB		EDENBRIDGE PHARMS	200MG	A211117	001	May 14, 2019	Apr	NEWA
	<u>ALBUTEROL SULFATE</u>							
	POWDER, METERED; INHALATION							
	PROAIR DIGIHALER							
	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jan	NEWA
		PROAIR RESPICLICK						
	+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Jan	CPOT
	TABLET; ORAL							
	ALBUTEROL SULFATE							
AB		AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Mar	NEWA
AB			EQ 4MG BASE	A210948	002	Mar 15, 2019	Mar	NEWA
AB		APPCO PHARMA LLC	EQ 2MG BASE	A207046	001	Jun 29, 2018	Feb	CAHN
AB			EQ 4MG BASE	A207046	002	Jun 29, 2018	Feb	CAHN
	<u>ALFUZOSIN HYDROCHLORIDE</u>							
	TABLET, EXTENDED RELEASE; ORAL							
	ALFUZOSIN HYDROCHLORIDE							
AB		HERITAGE PHARMA	10MG	A079056	001	Jul 18, 2011	May	CAHN
	<u>ALISKIREN HEMIFUMARATE</u>							
	TABLET; ORAL							
	ALISKIREN HEMIFUMARATE							
AB		ANCHEN PHARMS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Mar	NFTG
AB			EQ 300MG BASE	A206665	002	Mar 22, 2019	Mar	NFTG
	TEKTURNA							
AB	+	NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Mar	CFTG
AB	+!		EQ 300MG BASE	N021985	002	Mar 05, 2007	Mar	CFTG

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb	NEWA
AB		300MG	A211820	002	Mar 12, 2019	Feb	NEWA

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

+ @	IRONWOOD PHARMS INC	200MG;200MG	N209203	001	Aug 18, 2017	Apr	DISC
+ @		300MG;200MG	N209203	002	Aug 18, 2017	Apr	DISC

ALPELISIB

TABLET; ORAL

PIQRAY

+	NOVARTIS PHARMS CORP	50MG	N212526	001	May 24, 2019	May	NEWA
+		150MG	N212526	002	May 24, 2019	May	NEWA
+	!	200MG	N212526	003	May 24, 2019	May	NEWA

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

+	@ EISAI INC	50MG	N019926	001	Dec 26, 1990	Feb	DISC
---	-------------	------	---------	-----	--------------	-----	------

AMBRISENTAN

TABLET; ORAL

AMBRISENTAN

AB	CIPLA	5MG	A210715	001	Apr 26, 2019	Apr	NEWA	
AB		10MG	A210715	002	Apr 26, 2019	Apr	NEWA	
AB	MYLAN	5MG	A208441	001	Mar 28, 2019	Mar	NFTG	
AB		10MG	A208441	002	Mar 28, 2019	Mar	NFTG	
AB	PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Mar	NEWA	
AB		10MG	A209509	002	Apr 10, 2019	Mar	NEWA	
AB	SIGMAPHARM LABS LLC	5MG	A208354	001	Apr 10, 2019	Mar	NEWA	
AB		10MG	A208354	002	Apr 10, 2019	Mar	NEWA	
AB	SUN PHARM	5MG	A210784	001	Mar 28, 2019	Mar	NFTG	
AB		10MG	A210784	002	Mar 28, 2019	Mar	NFTG	
AB	WATSON LABS INC	5MG	A208252	001	Mar 28, 2019	Mar	NFTG	
AB		10MG	A208252	002	Mar 28, 2019	Mar	NFTG	
AB	ZYDUS PHARMS	5MG	A210058	001	Mar 28, 2019	Mar	NFTG	
AB		10MG	A210058	002	Mar 28, 2019	Mar	NFTG	
	LETAIRIS							
AB	+	GILEAD	5MG	N022081	001	Jun 15, 2007	Mar	CFTG
AB	+	!	10MG	N022081	002	Jun 15, 2007	Mar	CFTG

AMIFAMPRIDINE

TABLET; ORAL

RUZURGI

+	!	JACOBUS PHARM CO INC	10MG	N209321	001	May 06, 2019	May	NEWA
---	---	----------------------	------	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB	WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Feb	CAHN
----	------------------	-----	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

TABLET; ORAL

AMICAR

AB	+	CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004	Feb	CHRS
AB	!	SUNNY PHARMTECH INC	1GM	A209060	002	Nov 27, 2018	Feb	CHRS

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Feb	CTEC
@	LUITPOLD	25MG/ML	A087600	001		Feb	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE
@ DR REDDYS

50MG/ML

A076163 001 Sep 05, 2003 May CAHN

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

AB STRIDES PHARMA EQ 2.5MG BASE
AB EQ 5MG BASE
AB EQ 10MG BASE

A077516 001 Jul 11, 2007 Apr CAHN
A077516 002 Jul 11, 2007 Apr CAHN
A077516 003 Jul 11, 2007 Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

>D> AB ZYDUS PHARMS EQ 2.5MG BASE; EQ 10MG BASE
>A> @ EQ 2.5MG BASE; EQ 10MG BASE
>D> AB EQ 2.5MG BASE; EQ 20MG BASE
>A> @ EQ 2.5MG BASE; EQ 20MG BASE
>D> AB EQ 2.5MG BASE; EQ 40MG BASE
>A> @ EQ 2.5MG BASE; EQ 40MG BASE
>D> AB EQ 5MG BASE; EQ 10MG BASE
>A> @ EQ 5MG BASE; EQ 10MG BASE
>D> AB EQ 5MG BASE; EQ 20MG BASE
>A> @ EQ 5MG BASE; EQ 20MG BASE
>D> AB EQ 5MG BASE; EQ 40MG BASE
>A> @ EQ 5MG BASE; EQ 40MG BASE
>D> AB EQ 5MG BASE; EQ 80MG BASE
>A> @ EQ 5MG BASE; EQ 80MG BASE
>D> AB EQ 10MG BASE; EQ 10MG BASE
>A> @ EQ 10MG BASE; EQ 10MG BASE
>D> AB EQ 10MG BASE; EQ 20MG BASE
>A> @ EQ 10MG BASE; EQ 20MG BASE
>D> AB EQ 10MG BASE; EQ 40MG BASE
>A> @ EQ 10MG BASE; EQ 40MG BASE
>D> AB EQ 10MG BASE; EQ 80MG BASE
>A> @ EQ 10MG BASE; EQ 80MG BASE

A207762 001 Jan 11, 2019 Jun DISC
A207762 001 Jan 11, 2019 Jun DISC
A207762 002 Jan 11, 2019 Jun DISC
A207762 002 Jan 11, 2019 Jun DISC
A207762 003 Jan 11, 2019 Jun DISC
A207762 003 Jan 11, 2019 Jun DISC
A207762 004 Jan 11, 2019 Jun DISC
A207762 004 Jan 11, 2019 Jun DISC
A207762 005 Jan 11, 2019 Jun DISC
A207762 005 Jan 11, 2019 Jun DISC
A207762 006 Jan 11, 2019 Jun DISC
A207762 006 Jan 11, 2019 Jun DISC
A207762 007 Jan 11, 2019 Jun DISC
A207762 007 Jan 11, 2019 Jun DISC
A207762 008 Jan 11, 2019 Jun DISC
A207762 008 Jan 11, 2019 Jun DISC
A207762 009 Jan 11, 2019 Jun DISC
A207762 009 Jan 11, 2019 Jun DISC
A207762 010 Jan 11, 2019 Jun DISC
A207762 010 Jan 11, 2019 Jun DISC
A207762 011 Jan 11, 2019 Jun DISC
A207762 011 Jan 11, 2019 Jun DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@ CIPLA EQ 2.5MG BASE; 10MG
@ EQ 5MG BASE; 10MG
@ EQ 5MG BASE; 20MG
@ EQ 10MG BASE; 20MG
@ MYLAN EQ 2.5MG BASE; 10MG
@ EQ 5MG BASE; 10MG
@ EQ 5MG BASE; 20MG
@ EQ 5MG BASE; 40MG
@ EQ 10MG BASE; 20MG
@ EQ 10MG BASE; 40MG
>D> AB TEVA PHARMS EQ 2.5MG BASE; 10MG
>A> @ EQ 2.5MG BASE; 10MG
>D> AB EQ 5MG BASE; 10MG
>A> @ EQ 5MG BASE; 10MG
>D> AB EQ 5MG BASE; 20MG
>A> @ EQ 5MG BASE; 20MG
>D> AB EQ 5MG BASE; 40MG
>A> @ EQ 5MG BASE; 40MG
>D> AB EQ 10MG BASE; 20MG
>A> @ EQ 10MG BASE; 20MG
>D> AB EQ 10MG BASE; 40MG
>A> @ EQ 10MG BASE; 40MG

A077215 001 Dec 07, 2018 May DISC
A077215 002 Dec 07, 2018 May DISC
A077215 003 Dec 07, 2018 May DISC
A077215 004 Dec 07, 2018 May DISC
A077375 001 May 21, 2010 Feb DISC
A077375 002 May 21, 2010 Feb DISC
A077375 003 May 21, 2010 Feb DISC
A079047 001 Jul 05, 2011 Feb DISC
A077375 004 May 21, 2010 Feb DISC
A079047 002 Jul 05, 2011 Feb DISC
A077179 001 May 18, 2007 Jun DISC
A077179 001 May 18, 2007 Jun DISC
A077179 002 May 18, 2007 Jun DISC
A077179 002 May 18, 2007 Jun DISC
A077179 003 May 18, 2007 Jun DISC
A077179 003 May 18, 2007 Jun DISC
A077179 005 Jul 05, 2011 Jun DISC
A077179 005 Jul 05, 2011 Jun DISC
A077179 004 May 18, 2007 Jun DISC
A077179 004 May 18, 2007 Jun DISC
A077179 006 Jul 05, 2011 Jun DISC
A077179 006 Jul 05, 2011 Jun DISC

AMLODIPINE BESYLATE; CELECOXIB

TABLET; ORAL
CONSENSI

+ COEPTIS EQ 2.5MG BASE; 200MG
+ EQ 5MG BASE; 200MG
+! EQ 10MG BASE; 200MG

N210045 001 May 31, 2018 Mar CAHN
N210045 002 May 31, 2018 Mar CAHN
N210045 003 May 31, 2018 Mar CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

	@	ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar	DISC
	@		EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar	DISC
	@		EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar	DISC
	@		EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar	DISC
>D>	AB	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Jun	DISC
>A>	@		EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Jun	DISC
>D>	AB		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Jun	DISC
>A>	@		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Jun	DISC
>D>	AB		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Jun	DISC
>A>	@		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Jun	DISC
>D>	AB		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Jun	DISC
>A>	@		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Jun	DISC

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr	CAHN
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr	CAHN
+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr	CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	DECATUR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Apr	CAHN
----	---------	------------------------------------	---------	-----	--------------	-----	------

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	!	PERRIGO ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	May	CAHN
----	---	----------------	-------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

AMMONIUM LACTATE

AB	!	PERRIGO ISRAEL	EQ 12% BASE	A075570	001	Jun 23, 2004	May	CAHN
----	---	----------------	-------------	---------	-----	--------------	-----	------

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

>D>	AB	TEVA	125MG/5ML	A061931	001		Jun	DISC
>A>	@		125MG/5ML	A061931	001		Jun	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	125MG/5ML;EQ 31.25MG BASE/5ML	A209371	001	Apr 19, 2019	Apr	NFTG	
AB		250MG/5ML;EQ 62.5MG BASE/5ML	A209371	002	Apr 19, 2019	Apr	NEWA	
AB	AUGMENTIN '125'							
AB	+	NEOPHARMA	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Apr	CFTG
AB	+	NEOPHARMA	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	May	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	May	NEWA
AB		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	May	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	May	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	May	NEWA

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	NEWA
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	May	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	May	NEWA

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	May	NEWA
AB		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	May	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	May	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	May	NEWA
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Apr	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Apr	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Apr	NEWA
AB		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Apr	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Apr	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Apr	NEWA
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	May	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	May	NEWA
AB		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	May	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	May	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	May	NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	AUROLIFE PHARMA LLC	5MG	A211639	001	Apr 17, 2019	Apr	NEWA
AA		10MG	A211639	002	Apr 17, 2019	Apr	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan	NEWA
+		10MG	N209905	002	Jan 30, 2019	Jan	NEWA
+		15MG	N209905	003	Jan 30, 2019	Jan	NEWA
+		20MG	N209905	004	Jan 30, 2019	Jan	NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

@	HERITAGE PHARMA	EQ 250MG BASE	A061502	001		May	CAHN
@		EQ 500MG BASE	A061502	002		May	CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB	FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Feb	CAHN
AB	KENTON	1MG	A078944	001	Jun 28, 2010	Mar	CAHN

ARIPIPRAZOLE

SOLUTION;ORAL

ARIPIPRAZOLE

AA	AUROBINDO PHARMA LTD	1MG/ML	A210479	001	Jan 29, 2019	Jan	NEWA
----	----------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

ARIPIPRAZOLE

AB	ALKEM LABS LTD	2MG	A207105	001	Feb 21, 2019	Feb	NEWA	
AB		5MG	A207105	002	Feb 21, 2019	Feb	NEWA	
AB		10MG	A207105	003	Feb 21, 2019	Feb	NEWA	
AB		15MG	A207105	004	Feb 21, 2019	Feb	NEWA	
AB		20MG	A207105	005	Feb 21, 2019	Feb	NEWA	
AB		30MG	A207105	006	Feb 21, 2019	Feb	NEWA	
>D>	AB	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Jun	DISC
>A>	@		2MG	A078607	001	Apr 28, 2015	Jun	DISC
>D>	AB		5MG	A078607	002	Apr 28, 2015	Jun	DISC
>A>	@		5MG	A078607	002	Apr 28, 2015	Jun	DISC
	@		10MG	A078608	001	Apr 28, 2015	May	DISC
	@		15MG	A078708	001	Apr 28, 2015	May	DISC
	@		20MG	A078708	002	Apr 28, 2015	May	DISC
	@		30MG	A078708	003	Apr 28, 2015	May	DISC
>D>	AB	ZYDUS PHARMS	2MG	A090472	001	Jan 07, 2019	Jun	DISC
>A>	@		2MG	A090472	001	Jan 07, 2019	Jun	DISC
>D>	AB		5MG	A090472	002	Jan 07, 2019	Jun	DISC
>A>	@		5MG	A090472	002	Jan 07, 2019	Jun	DISC
>D>	AB		10MG	A090472	003	Jan 07, 2019	Jun	DISC
>A>	@		10MG	A090472	003	Jan 07, 2019	Jun	DISC
>D>	AB		15MG	A090472	004	Jan 07, 2019	Jun	DISC
>A>	@		15MG	A090472	004	Jan 07, 2019	Jun	DISC
>D>	AB		20MG	A090472	005	Jan 07, 2019	Jun	DISC
>A>	@		20MG	A090472	005	Jan 07, 2019	Jun	DISC

TABLET;ORAL
ARIPIPIRAZOLE

>D>	AB		30MG	A090472	006	Jan 07, 2019	Jun DISC
>A>		@	30MG	A090472	006	Jan 07, 2019	Jun DISC

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB		APOTEX INC	50MG	A201514	001	Mar 25, 2019	Mar NEWA
AB			150MG	A201514	002	Mar 25, 2019	Mar NEWA
AB			250MG	A201514	003	Mar 25, 2019	Mar NEWA
AB		AUROBINDO PHARMA LTD	200MG	A206069	004	Dec 07, 2018	Mar NEWA
AB		MYLAN PHARMS INC	100MG	A200043	004	May 09, 2019	Apr NEWA
AB			200MG	A200043	005	May 09, 2019	Apr NEWA
AB		NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017	Apr CTEC

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP		STI PHARMA LLC	1MG/ML	A209873	001	May 06, 2019	Apr NEWA
----	--	----------------	--------	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

@	SIGMAPHARM LABS LLC	EQ 5MG BASE	A206107	001	Jul 17, 2018	Feb DISC
@		EQ 10MG BASE	A206107	002	Jul 17, 2018	Feb DISC

SAPHRIS

+	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb CTEC
+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb CTEC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	!	SANDOZ	770MG;60MG;50MG	A074654	002	Dec 31, 1996	May CTEC
AB		ORPHENGESIC FORTE					
AB		GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998	May CMFD

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

>D>	AB	GLENMARK PHARMS LTD	25MG;200MG	A210318	001	May 24, 2019	Jun CAHN
	AB		25MG;200MG	A210318	001	May 24, 2019	May NEWA
>A>	AB	GLENMARK PHARMS SA	25MG;200MG	A210318	001	May 24, 2019	Jun CAHN
	AB	LANNETT CO INC	25MG;200MG	A204552	001	Mar 20, 2019	Mar NEWA

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ZYDUS PHARMS	50MG;25MG	A210028	001	Mar 08, 2019	Feb NEWA
AB			100MG;25MG	A210028	002	Mar 08, 2019	Feb NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Mar CMFD
AB			25MG	A079017	002	Sep 17, 2010	Mar CMFD
AB			40MG	A079017	003	Sep 17, 2010	Mar CMFD
AB			60MG	A079017	004	Sep 17, 2010	Mar CMFD
AB			80MG	A079017	005	Sep 17, 2010	Mar CMFD
AB			100MG	A079017	006	Sep 17, 2010	Mar CMFD

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Feb NEWA
AB			EQ 20MG BASE	A204991	002	Mar 06, 2019	Feb NEWA
AB			EQ 40MG BASE	A204991	003	Mar 06, 2019	Feb NEWA
AB			EQ 80MG BASE	A204991	004	Mar 06, 2019	Feb NEWA
AB		MSN LABS PVT LTD	EQ 10MG BASE	A211933	001	Feb 08, 2019	Feb NEWA
AB			EQ 20MG BASE	A211933	002	Feb 08, 2019	Feb NEWA
AB			EQ 40MG BASE	A211933	003	Feb 08, 2019	Feb NEWA
AB			EQ 80MG BASE	A211933	004	Feb 08, 2019	Feb NEWA

ATOVAQUONESUSPENSION; ORAL
ATOVAQUONE

AB	ABHAI LLC	750MG/5ML	A210510	001	May 31, 2019	May	NEWA
----	-----------	-----------	---------	-----	--------------	-----	------

ATRACURIUM BESYLATEINJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Feb	CAHN
----	-----------	---------	---------	-----	--------------	-----	------

AP	HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Feb	CAHN
----	-----------	---------	---------	-----	--------------	-----	------

ATROPINESOLUTION; INTRAMUSCULAR
ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar	CPOT
---	---	----------------------	-------------------------	---------	-----	--------------	-----	------

+	!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar	CPOT
---	---	--	------------------------	---------	-----	--------------	-----	------

+	!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar	CPOT
---	---	--	----------------------	---------	-----	--------------	-----	------

+	!		EQ 2MG SULFATE/0.7ML	N017106	001		Mar	CPOT
---	---	--	----------------------	---------	-----	--	-----	------

ATROPINE

@	ABBVIE		EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar	CDFR
---	--------	--	----------------------	---------	-----	--------------	-----	------

ATROPINE SULFATESOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL
ATROPINE SULFATE

+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	May	CDFR
---	---	--------------------	---------------------	---------	-----	--------------	-----	------

AZACITIDINEPOWDER; INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Feb	NEWA
----	-----------	------------	---------	-----	--------------	-----	------

AZELAIC ACIDCREAM; TOPICAL
AZELEX

+	!	ALMIRALL	20%	N020428	001	Sep 13, 1995	Apr	CAHN
---	---	----------	-----	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
AZELASTINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019	Mar	NEWA
----	--------------------	-------	---------	-----	--------------	-----	------

AT	SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019	Mar	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

AB	HI TECH		EQ 0.125MG BASE/SPRAY	A207610	001	May 17, 2019	May	NEWA
----	---------	--	-----------------------	---------	-----	--------------	-----	------

AZITHROMYCINTABLET; ORAL
AZITHROMYCIN

AB	BIONPHARMA INC		EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb	NEWA
----	----------------	--	---------------	---------	-----	--------------	-----	------

AB			EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb	NEWA
----	--	--	---------------	---------	-----	--------------	-----	------

AB	CSPC OUYI		EQ 250MG BASE	A208250	001	Apr 17, 2019	Apr	NEWA
----	-----------	--	---------------	---------	-----	--------------	-----	------

BACLOFENTABLET; ORAL
BACLOFEN

AB	EYWA PHARMA	10MG		A211555	001	Feb 01, 2019	Jan	NEWA
----	-------------	------	--	---------	-----	--------------	-----	------

AB		20MG		A211555	002	Feb 01, 2019	Jan	NEWA
----	--	------	--	---------	-----	--------------	-----	------

BALSALAZIDE DISODIUMCAPSULE; ORAL
BALSALAZIDE DISODIUM
@ MYLAN

		750MG		A077807	001	Dec 28, 2007	Feb	DISC
--	--	-------	--	---------	-----	--------------	-----	------

TABLET; ORAL

BALSALAZIDE DISODIUM

	@ PAR PHARM INC	1.1GM		A206336	001	Sep 08, 2015	Apr	DISC
--	-----------------	-------	--	---------	-----	--------------	-----	------

	GIAZO							
--	-------	--	--	--	--	--	--	--

+	@ VALEANT PHARMS INTL	1.1GM		N022205	001	Feb 03, 2012	Apr	DISC
---	-----------------------	-------	--	---------	-----	--------------	-----	------

BARIUM SULFATEFOR SUSPENSION; ORAL
VARIBAR THIN LIQUID

+! BRACCO 81% (120GM/BOT) N208036 004 Apr 30, 2019 May NEWA

BELINOSTATPOWDER; INTRAVENOUS
BELEODAQ

+! ACROTECH 500MG/VIAL N206256 001 Jul 03, 2014 Mar CAHN

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE

@ HERITAGE PHARMA 5MG A076267 001 Feb 11, 2004 Feb CAHN

@ 10MG A076267 002 Feb 11, 2004 Feb CAHN

@ 20MG A076267 003 Feb 11, 2004 Feb CAHN

@ 40MG A076267 004 Feb 11, 2004 Feb CAHN

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC 5MG; 6.25MG A076342 001 Feb 11, 2004 May CAHN

@ 10MG; 12.5MG A076342 002 Feb 11, 2004 May CAHN

@ 20MG; 12.5MG A076342 003 Feb 11, 2004 May CAHN

@ 20MG; 25MG A076342 004 Feb 11, 2004 May CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

+! CEPHALON 25MG/VIAL N022249 002 May 01, 2009 Feb CTEC

+! 100MG/VIAL N022249 001 Mar 20, 2008 Feb CTEC

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA ASCENT PHARMS INC 100MG A211518 001 Feb 22, 2019 Feb NEWA

AA 150MG A211518 002 Feb 22, 2019 Feb NEWA

AA 200MG A211518 003 Feb 22, 2019 Feb NEWA

AA CSPC OUYI 100MG A202765 002 Aug 25, 2017 Feb CAHN

AA 200MG A202765 001 Jul 31, 2015 Feb CAHN

AA QINGDAO BAHEAL PHARM 100MG A210562 001 Nov 09, 2018 May CAHN

AA 150MG A210562 002 Nov 09, 2018 May CAHN

AA 200MG A210562 003 Nov 09, 2018 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>D> AB GLENMARK PHARMS 5%; 1% BASE A209252 001 Mar 14, 2019 Jun CMS1

>A> AB 5%; EQ 1% BASE A209252 001 Mar 14, 2019 Jun CMS1

AB 5%; 1% BASE A209252 001 Mar 14, 2019 Mar NEWA

AB PERRIGO UK FINCO 5%; EQ 1% BASE A202440 001 Sep 21, 2015 May CAHN

@ TARO 3.75%; EQ 1.2% BASE A208683 001 Jun 05, 2018 May DISC

ONEXTON

+! DOW PHARM 3.75%; EQ 1.2% BASE N050819 002 Nov 24, 2014 May CTEC

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

AKTIPAK

+! BIOFRONTERA 5%; 3% N050769 001 Nov 27, 2000 May CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

@ LUITPOLD 1MG/ML A091152 001 Mar 29, 2010 Feb DISC

TABLET; ORAL

BENZTROPINE MESYLATE

AA ! ASPEN GLOBAL INC 0.5MG A204713 001 Apr 14, 2015 Apr CHRS

AA ! 1MG A204713 002 Apr 14, 2015 Apr CHRS

AA ! 2MG A204713 003 Apr 14, 2015 Apr CHRS

@ OXFORD PHARMS 0.5MG A040706 002 Feb 14, 2008 Mar DISC

@ 1MG A040706 003 Feb 14, 2008 Mar DISC

TABLET;ORAL

BENZTROPINE MESYLATE

@ USL PHARMA 0.5MG
 @ 1MG
 @ 2MG

A040103 001 Dec 12, 1996 Apr DISC
 A040103 002 Dec 12, 1996 Apr DISC
 A040103 003 Dec 12, 1996 Apr DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT APOTEX INC 1.5%
 AT MICRO LABS 1.5%
 AT MYLAN 1.5%
 BEPREVE
 AT +! BAUSCH AND LOMB INC 1.5%

A206066 001 Mar 05, 2019 Feb NFTG
 A206220 001 Mar 18, 2019 Mar NEWA
 A206220 001 Mar 18, 2019 Apr CAHN
 N022288 001 Sep 08, 2009 Feb CFTG

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB PERRIGO ISRAEL EQ 0.05% BASE
 SPRAY;TOPICAL
 SERNIVO
 +! ENCORE DERMAT EQ 0.05% BASE/SPRAY

A076592 001 Dec 09, 2003 May CAHN
 N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB PERRIGO ISRAEL 0.064%;0.005%
 AB PERRIGO UK FINCO 0.064%;0.005%
 AB TOLMAR 0.064%;0.005%
 TACLONEX
 AB +! LEO PHARMA AS 0.064%;0.005%
 SUSPENSION;TOPICAL
 TACLONEX
 +! LEO PHARMA AS 0.064%;0.005%

A200174 001 Dec 12, 2014 Mar CAIN
 A200174 001 Dec 12, 2014 May CAHN
 A201615 001 Jan 14, 2013 Mar CAIN
 N021852 001 Jan 09, 2006 Mar CAIN
 N022185 001 May 09, 2008 Mar CAIN

BETHANECHOL CHLORIDE

TABLET;ORAL

DUVOID

AA CHARTWELL RX 10MG
 AA 25MG
 AA 50MG

A086262 001 Mar CAHN
 A086263 001 Mar CAHN
 A085882 003 Mar CAHN

BEXAROTENE

GEL;TOPICAL

TARGRETIN

>A> +! BAUSCH 1%
 >D> +! VALEANT LUXEMBOURG 1%

N021056 001 Jun 28, 2000 Jun CAHN
 N021056 001 Jun 28, 2000 Jun CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

>D> AB BOSCOGEN 50MG
 AB FRESENIUS KABI USA 50MG
 >A> AB KENTON 50MG

A091011 001 Jun 10, 2015 Jun CAHN
 A079045 001 May 13, 2010 Feb CAHN
 A091011 001 Jun 10, 2015 Jun CAHN

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT ALEMBIC PHARMS LTD 0.03%
 AT GLAND PHARMA LTD 0.03%
 >A> AT SOMERSET THERAPS LLC 0.03%

A210263 001 Apr 12, 2019 Apr NEWA
 A210126 001 Mar 22, 2019 Mar NEWA
 A207601 001 Jun 19, 2019 Jun NEWA

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP CIPLA EQ 15 UNITS BASE/VIAL

A209439 001 Mar 11, 2019 Feb NEWA

BORTEZOMIBPOWDER; INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

+ @ HOSPIRA INC 1MG/VIAL N209191 002 Dec 28, 2018 Mar DISC

BOSENTANTABLET; ORAL
BOSENTAN

AB	ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A206002	002	Apr 26, 2019	Apr	NFTG
AB	AMNEAL PHARMS CO	62.5MG	A209742	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A209742	002	Apr 26, 2019	Apr	NFTG
AB	NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A206987	002	Apr 26, 2019	Apr	NFTG
AB	PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A205699	002	Apr 26, 2019	Apr	NFTG
AB	SUN PHARM	62.5MG	A209324	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A209324	002	Apr 26, 2019	Apr	NFTG
AB	WATSON LABS INC	62.5MG	A207110	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A207110	002	Apr 26, 2019	Apr	NFTG
AB	WEST-WARD PHARMS INT	62.5MG	A208695	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A208695	002	Apr 26, 2019	Apr	NFTG
AB	ZYDUS PHARMS	62.5MG	A207760	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A207760	002	Apr 26, 2019	Apr	NFTG
TRACLEER							
AB	+ ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	Apr	CFTG
AB	+!	125MG	N021290	002	Nov 20, 2001	Apr	CFTG

>A> BREMELANOTIDE ACETATE

>A> SOLUTION; SUBCUTANEOUS

>A> VYLEESI (AUTOINJECTOR)

>A> +! AMAG PHARMS INC EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML) N210557 001 Jun 21, 2019 Jun NEWA

BRETYLIUM TOSYLATEINJECTABLE; INJECTION
BRETYLIUM TOSYLATE

>D>	!	ACADEMIC PHARMS INC	50MG/ML	A204386	001	Dec 21, 2018	Jun	CAHN
>A>	!	BAS ANDA	50MG/ML	A204386	001	Dec 21, 2018	Jun	CAHN

>A> BREXANOLONE

>A> SOLUTION; INTRAVENOUS

>A> ZULRESSO

>A> +! SAGE THERAP 100MG/20ML (5MG/ML) N211371 001 Jun 17, 2019 Jun NEWA

BRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AT SOMERSET THERAPS LLC 0.2% A208992 001 Mar 11, 2019 Feb NEWA

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

>A>	AT2	ALEMBIC PHARMS LTD	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun	NEWA
	AT2	!	HI TECH	A203395	001	Jan 22, 2014	May	CTEC
	AT2		INNOPHARMA LICENSING	A203368	001	Jun 03, 2019	May	NEWA

BUDESONIDECAPSULE; ORAL
BUDESONIDE

AB APPCO PHARMA LLC 3MG A207367 001 Apr 07, 2017 Feb CAHN

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> ORTIKOS

>A> + SUN PHARMA GLOBAL 6MG N211929 001 Jun 13, 2019 Jun NEWA

>A> +! 9MG N211929 002 Jun 13, 2019 Jun NEWA

TABLET, EXTENDED RELEASE; ORAL
UCERIS

AB +! SALIX 9MG N203634 001 Jan 14, 2013 Mar CAHN

BUMETANIDETABLET; ORAL
BUMETANIDE

AB	HERITAGE PHARMA	0.5MG	A074225	001	Apr 24, 1995	Feb	CAHN
AB		1MG	A074225	002	Apr 24, 1995	Feb	CAHN
AB		2MG	A074225	003	Apr 24, 1995	Feb	CAHN

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

>D>	AP	NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019	Jun	DISC
>A>		@	0.5%	A211096	001	Feb 19, 2019	Jun	DISC
	AP		0.5%	A211096	001	Feb 19, 2019	Feb	NEWA

INJECTABLE; SPINAL
BUPIVACAINE HYDROCHLORIDE

AP	B BRAUN MEDICAL INC	0.75%	A209087	001	Apr 02, 2019	Mar	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALVOGEN PINE BROOK	EQ 2MG BASE;EQ 0.5MG BASE	A205954	001	Jan 24, 2019	Jan	NEWA
AB		EQ 4MG BASE;EQ 1MG BASE	A205954	002	Jan 24, 2019	Jan	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205954	003	Jan 24, 2019	Jan	NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan	NEWA

FILM; SUBLINGUAL
CASSIPA

+	@	TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042	001	Sep 07, 2018	Mar	DISC
---	---	-----------------	--------------------------	---------	-----	--------------	-----	------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Jan	DISC
@		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014	Jan	DISC

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

>A>	AB	APNAR PHARMA LP	75MG	A075584	001	Feb 07, 2000	Jun	CAHN	
>A>	AB		100MG	A075584	002	Feb 07, 2000	Jun	CAHN	
		@	HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999	May	CAHN
		@		100MG	A075310	002	Nov 29, 1999	May	CAHN
>D>	AB	SANDOZ	75MG	A075584	001	Feb 07, 2000	Jun	CAHN	
>D>	AB		100MG	A075584	002	Feb 07, 2000	Jun	CAHN	

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB3	GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Jan	NEWA	
AB3		300MG	A211020	002	Jan 28, 2019	Jan	NEWA	
	@	YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Apr	DISC
	@		150MG	A211347	002	Oct 16, 2018	Apr	DISC
	@		200MG	A211347	003	Oct 16, 2018	Apr	DISC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Apr	NEWA
AB		7.5MG	A208972	002	Apr 16, 2019	Apr	NEWA
AB		10MG	A208972	003	Apr 16, 2019	Apr	NEWA
AB		15MG	A208972	004	Apr 16, 2019	Apr	NEWA
AB		30MG	A208972	005	Apr 16, 2019	Apr	NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb	NEWA	
AP	APOTEX INC	6MG/ML	A210448	001	May 07, 2019	Apr	NEWA	
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan	CAHN	
	@	HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Feb	DISC
AP	SHILPA MEDICARE LTD	6MG/ML	A210931	001	Apr 18, 2019	Apr	NEWA	

CAFFEINE CITRATE

SOLUTION;ORAL

CAFFEINE CITRATE

@ LUITPOLD

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A090064 001 Nov 20, 2009 Mar DISC

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB SUN PHARM

0.25MCG

A204556 001 Feb 21, 2019 Feb NEWA

AB

0.5MCG

A204556 002 Feb 21, 2019 Feb NEWA

CALCIUM ACETATE

TABLET;ORAL

CALCIUM ACETATE

AB CHARTWELL MOLECULAR

667MG

A202420 001 Feb 05, 2013 Jan CAHN

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP MEDEFIL INC

100MG/ML

A211553 001 May 01, 2019 Apr NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

>D> AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020183 001 Dec 04, 1992 Jun CRLD

>A> AT + 18.3MG/100ML;1.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020183 001 Dec 04, 1992 Jun CRLD

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>D> BAXTER HLTHCARE 18.3MG/100ML;2.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020183 002 Dec 04, 1992 Jun CRLD

>A> + 18.3MG/100ML;2.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020183 002 Dec 04, 1992 Jun CRLD

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

>D> BAXTER HLTHCARE 18.3MG/100ML;3.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020183 003 Dec 04, 1992 Jun CRLD

>A> + 18.3MG/100ML;3.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020183 003 Dec 04, 1992 Jun CRLD

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

>D> BAXTER HLTHCARE 18.3MG/100ML;4.25GM/100ML;5.08MG/1 00ML;538MG/100ML;448MG/100ML N020183 004 Dec 04, 1992 Jun CRLD

>A> + 18.3MG/100ML;4.25GM/100ML;5.08MG/1 00ML;538MG/100ML;448MG/100ML N020183 004 Dec 04, 1992 Jun CRLD

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

>D> AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N017512 004 Jun CRLD

>A> AT + 18.3MG/100ML;1.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N017512 004 Jun CRLD

>D> AT 25.7MG/100ML;1.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020163 001 Dec 04, 1992 Jun CRLD

>A> AT + 25.7MG/100ML;1.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020163 001 Dec 04, 1992 Jun CRLD

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>D> AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N017512 005 Jun CRLD

>A> AT + 25.7MG/100ML;2.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N017512 005 Jun CRLD

>D> AT 25.7MG/100ML;2.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020163 002 Dec 04, 1992 Jun CRLD

>A> AT + 25.7MG/100ML;2.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N020163 002 Dec 04, 1992 Jun CRLD

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

>D> @ BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N017512 011 Nov 18, 1985 Jun CRLD

>A> + @ 25.7MG/100ML;3.5GM/100ML;5.08MG/10 0ML;538MG/100ML;448MG/100ML N017512 011 Nov 18, 1985 Jun CRLD

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

>D> AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML;5.08MG/1 00ML;538MG/100ML;448MG/100ML N017512 006 Jun CRLD

>A> AT + 25.7MG/100ML;4.25GM/100ML;5.08MG/1 00ML;538MG/100ML;448MG/100ML N017512 006 Jun CRLD

>D> AT 25.7MG/100ML;4.25GM/100ML;5.08MG/1 00ML;538MG/100ML;448MG/100ML N020163 003 Dec 04, 1992 Jun CRLD

>A> AT + 25.7MG/100ML;4.25GM/100ML;5.08MG/1 00ML;538MG/100ML;448MG/100ML N020163 003 Dec 04, 1992 Jun CRLD

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	A 209338	001	Jan 28, 2019	Jan	NEWA
----	--------------------	--	----------	-----	--------------	-----	------

CAPECITABINE

TABLET; ORAL

CAPECITABINE

>A>	AB	SUN PHARM	150MG	A 204668	001	Jun 21, 2019	Jun	NEWA
>A>	AB		500MG	A 204668	002	Jun 21, 2019	Jun	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

>D>		@ BOSCOGEN	12.5MG	A 074677	004	May 30, 1997	Jun	CMFD
>A>	AB		12.5MG	A 074677	004	May 30, 1997	Jun	CMFD
>D>		@	25MG	A 074677	002	May 30, 1997	Jun	CMFD
>A>	AB		25MG	A 074677	002	May 30, 1997	Jun	CMFD
>D>		@	50MG	A 074677	001	May 30, 1997	Jun	CMFD
>A>	AB		50MG	A 074677	001	May 30, 1997	Jun	CMFD
>D>		@	100MG	A 074677	003	May 30, 1997	Jun	CMFD
>A>	AB		100MG	A 074677	003	May 30, 1997	Jun	CMFD

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

AB	+	SHIRE DEV LLC	100MG	N 020712	003	Sep 30, 1997	Jan	CAHN
AB	+		200MG	N 020712	001	Sep 30, 1997	Jan	CAHN
AB	+	!	300MG	N 020712	002	Sep 30, 1997	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		ZYDUS PHARMS	100MG	A 205571	001	Feb 07, 2019	Jan	NEWA
AB			200MG	A 205571	002	Feb 07, 2019	Jan	NEWA
AB			400MG	A 205571	003	Feb 07, 2019	Jan	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB		ALEMBIC PHARMS LTD	25MG; 100MG	A 210341	001	Jun 05, 2019	May	NEWA
AB			50MG; 200MG	A 210341	002	Jun 05, 2019	May	NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

>D>	AA	!	MIKART	4MG/5ML	A 040458	001	Apr 25, 2003	Jun	CTEC
>A>		!		4MG/5ML	A 040458	001	Apr 25, 2003	Jun	CTEC
>D>	AA		VINTAGE PHARMS	4MG/5ML	A 040814	001	Feb 26, 2008	Jun	DISC
>A>		@		4MG/5ML	A 040814	001	Feb 26, 2008	Jun	DISC

TABLET; ORAL

CARBINOXAMINE MALEATE

!	MIKART	6MG	A 207484	001	May 31, 2016	Mar	CHRS
---	--------	-----	----------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

AP		ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A 206775	001	Feb 09, 2017	May	CDFR
AP			150MG/15ML (10MG/ML)	A 206775	002	Feb 09, 2017	May	CDFR
AP			450MG/45ML (10MG/ML)	A 206775	003	Feb 09, 2017	May	CDFR
AP			600MG/60ML (10MG/ML)	A 206775	004	Feb 09, 2017	May	CDFR
		@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A 078732	001	Feb 06, 2012	Mar	CDFR
		@	150MG/15ML (10MG/ML)	A 078732	002	Feb 06, 2012	Mar	CDFR
		@	450MG/45ML (10MG/ML)	A 078732	003	Feb 06, 2012	Mar	CDFR
		@	600MG/60ML (10MG/ML)	A 078732	004	Feb 06, 2012	Mar	CDFR
AP		AKORN	50MG/5ML (10MG/ML)	A 090475	001	Jul 29, 2009	May	CDFR
AP			150MG/15ML (10MG/ML)	A 090475	002	Jul 29, 2009	May	CDFR
AP			450MG/45ML (10MG/ML)	A 090475	003	Jul 29, 2009	May	CDFR
AP			600MG/60ML (10MG/ML)	A 091268	002	Jul 28, 2010	May	CDFR
AP		CIPLA LTD	50MG/5ML (10MG/ML)	A 077861	001	Jan 18, 2007	May	CDFR
AP			150MG/15ML (10MG/ML)	A 077861	002	Jan 18, 2007	May	CDFR
AP			450MG/45ML (10MG/ML)	A 077861	003	Jan 18, 2007	May	CDFR

INJECTABLE; INTRAVENOUS
CARBOPLATIN

AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	May	CDFR
AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	May	CDFR
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	May	CDFR
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	May	CDFR
AP	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006	May	CDFR
AP		150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006	May	CDFR
AP		450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006	May	CDFR
	@	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004	Mar	CDFR
	@	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar	CDFR
	@	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004	Mar	CDFR
	@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar	CDFR
AP		450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Mar	CDFR
AP		450MG/45ML (10MG/ML)	A077266	003	Feb 15, 2006	May	CDFR
AP		600MG/60ML (10MG/ML)	A077266	004	Feb 15, 2006	May	CDFR
AP	GLAND PHARMA LTD	150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	May	CDFR
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	May	CDFR
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	May	CDFR
AP	HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	May	CDFR
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	May	CDFR
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	May	CDFR
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	May	CDFR
AP	HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	May	CDFR
AP		150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	May	CDFR
AP		450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	May	CDFR
AP		600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	May	CDFR
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	May	CDFR
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	May	CDFR
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May	CDFR
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May	CDFR
	@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Apr	CDFR
	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Apr	CDFR
	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Apr	CDFR
AP	MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May	CDFR
AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May	CDFR
AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May	CDFR
AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May	CDFR
	@	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar	CDFR
AP	! PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	May	CDFR
	@	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar	CDFR
AP	!	150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	May	CDFR
	@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar	CDFR
AP	!	450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	May	CDFR
	@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar	CDFR
AP	!	600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	May	CDFR
AP	PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	May	CDFR
AP		150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	May	CDFR
AP		450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	May	CDFR
AP		600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	May	CDFR
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	May	CDFR
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	May	CDFR
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	May	CDFR
AP	SUN PHARM	50MG/5ML (10MG/ML)	A077926	001	Sep 19, 2008	May	CDFR
AP		150MG/15ML (10MG/ML)	A077926	002	Sep 19, 2008	May	CDFR
AP		450MG/45ML (10MG/ML)	A077926	003	Sep 19, 2008	May	CDFR
	@ TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar	CDFR
	@	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar	CDFR
	@	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar	CDFR
AP	! TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May	CDFR
AP	!	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May	CDFR
AP	!	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May	CDFR
AP	!	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May	CDFR
AP	WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	May	CDFR
AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	May	CDFR
AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	May	CDFR
AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	May	CDFR
	PARAPLATIN						
+ @	CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CDFR
+ @		150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CDFR
+ @		450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CDFR
+ @		600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CDFR

INJECTABLE; IV (INFUSION)CARBOPLATIN

AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	May	CDFR
AP	HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Feb	CAHN
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Feb	CAHN
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Feb	CAHN
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Feb	CAHN
	@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar	DISC
	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar	DISC
	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar	DISC

CARBOPROST TROMETHAMINEINJECTABLE; INJECTION

>A>	CARBOPROST TROMETHAMINE						
>A> AP	DR REDDYS LABS LTD	EQ 0.25MG BASE/ML	A211941	001	Jul 02, 2019	Jun	NFTG
	HEMABATE						
>D>	+! PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001		Jun	CFTG
>A> AP	+!	EQ 0.25MG BASE/ML	N017989	001		Jun	CFTG

CARGLUMIC ACIDTABLET; ORALCARBAGLU

+!	RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	May	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

CARISOPRODOLTABLET; ORALCARISOPRODOL

>A>	@ ALLIED	350MG	A040245	001	Sep 08, 1997	Jun	CAHN
>D>	@ VINTAGE PHARMS	350MG	A040245	001	Sep 08, 1997	Jun	CAHN
	@	350MG	A040245	001	Sep 08, 1997	Feb	DISC

CARMUSTINEINJECTABLE; INJECTIONCARMUSTINE

AP	STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019	Mar	NEWA
----	----------------	------------	---------	-----	--------------	-----	------

CARTEOLOL HYDROCHLORIDESOLUTION/DROPS; OPHTHALMICCARTEOLOL HYDROCHLORIDE

@	BAUSCH AND LOMB	1%	A075546	001	Jan 20, 2000	May	DISC
!	SANDOZ INC	1%	A075476	001	Jan 03, 2000	May	CTEC

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUSCASPOFUNGIN ACETATE

@	CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018	Jan	DISC
@		70MG/VIAL	A209489	002	Jul 12, 2018	Jan	DISC

CEFIXIMEFOR SUSPENSION; ORALCEFIXIME

@	SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Feb	DISC
@		200MG/5ML	A206144	002	Nov 17, 2017	Feb	DISC
	SUPRAX						
AB	! LUPIN PHARMS	200MG/5ML	A065355	001	Apr 10, 2007	Apr	CHRS

CEFPODOXIME PROXETILFOR SUSPENSION; ORALCEFPODOXIME PROXETIL

!	AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan	CTEC
		EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan	CHRS
		EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan	CTEC
@	SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan	DISC
@		EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan	DISC

CEPHALEXINFOR SUSPENSION; ORALCEPHALEXIN

AB	ALKEM LABS LTD	EQ 125MG BASE/5ML	A210221	001	Mar 26, 2019	Mar	NEWA
AB		EQ 250MG BASE/5ML	A210221	002	Mar 26, 2019	Mar	NEWA

>D>	<u>CERITINIB</u>				
>D>	CAPSULE;ORAL				
>D>	ZYKADIA				
>D>	+!	NOVARTIS PHARMS CORP	150MG	N205755 001	Apr 29, 2014 Jun DISC
>A>	+ @		150MG	N205755 001	Apr 29, 2014 Jun DISC
	TABLET;ORAL				
	ZYKADIA				
	+!	NOVARTIS PHARMS CORP	150MG	N211225 001	Mar 18, 2019 Mar NEWA
	<u>CETIRIZINE HYDROCHLORIDE</u>				
	SYRUP;ORAL				
	CETIRIZINE HYDROCHLORIDE				
	@	LANNETT CO INC	5MG/5ML	A078496 001	Sep 25, 2009 May DISC
	@	PD PARTNERS	5MG/5ML	A078412 001	Jun 18, 2008 May CAHN
AA	!	PERRIGO PHARMS CO	5MG/5ML	A078398 001	Jun 17, 2008 May CAHN
AA		SAPTALIS PHARMS	5MG/5ML	A090191 001	Nov 12, 2009 Feb CAHN
AA		TORRENT	5MG/5ML	A078870 001	Apr 27, 2009 Jan CAHN
	<u>CHLORDIAZEPOXIDE HYDROCHLORIDE</u>				
	INJECTABLE;INJECTION				
	LIBRIUM				
	@	BAUSCH	100MG/AMP	N012301 001	Mar CAHN
	<u>CHLORHEXIDINE GLUCONATE</u>				
	SOLUTION;DENTAL				
	CHLORHEXIDINE GLUCONATE				
>A> AT		PD PARTNERS	0.12%	A074522 001	Dec 15, 1995 Jun CAHN
>D> AT		TEVA	0.12%	A074522 001	Dec 15, 1995 Jun CAHN
	<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE</u>				
	SOLUTION;ORAL				
	VITUZ				
AA	+!	PERSION	4MG/5ML;5MG/5ML	N204307 001	Feb 20, 2013 Apr CAHN
	<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
	SOLUTION;ORAL				
	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
>D> AA		PADDOCK LLC	4MG/5ML;5MG/5ML;60MG/5ML	A204627 001	Apr 29, 2014 Jun CHRS
>A> AA	!		4MG/5ML;5MG/5ML;60MG/5ML	A204627 001	Apr 29, 2014 Jun CHRS
	@	TORRENT	4MG/5ML;5MG/5ML;60MG/5ML	A206660 001	May 15, 2017 Jan CAHN
	ZUTRIPRO				
AA	+!	PERSION	4MG/5ML;5MG/5ML;60MG/5ML	N022439 001	Jun 08, 2011 Apr CAHN
	<u>CHLORPROPAMIDE</u>				
	TABLET;ORAL				
	CHLORPROPAMIDE				
	@	MYLAN	100MG	A088549 002	Jun 01, 1984 May DISC
	@		250MG	A088549 001	Jun 01, 1984 May DISC
	<u>CHLORTHALIDONE</u>				
	TABLET;ORAL				
	CHLORTHALIDONE				
>A> AB		AMNEAL PHARMS CO	25MG	A207204 001	Jul 01, 2019 Jun NEWA
>A> AB			50MG	A207204 002	Jul 01, 2019 Jun NEWA
AB		INVATECH PHARMA	25MG	A211063 001	Feb 26, 2019 Feb NEWA
AB			50MG	A211063 002	Feb 26, 2019 Feb NEWA
AB		ZYDUS PHARMS	25MG	A207813 001	May 10, 2019 Apr NEWA
AB			50MG	A207813 002	May 10, 2019 Apr NEWA
	<u>CHOLINE C-11</u>				
	INJECTABLE;INTRAVENOUS				
	CHOLINE C-11				
AP		DECATUR	4-33.1mCi/ML	A206319 001	Nov 13, 2015 Apr CAHN
	<u>CHOLINE FENOFIBRATE</u>				
	CAPSULE, DELAYED RELEASE;ORAL				
	FENOFIBRIC ACID				
	@	MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913 001	Mar 25, 2013 May DISC
	@		EQ 135MG FENOFIBRIC ACID	A200913 002	Mar 25, 2013 May DISC
>A> AB		TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469 001	Jul 05, 2019 Jun NEWA
>A> AB			EQ 135MG FENOFIBRIC ACID	A210469 002	Jul 05, 2019 Jun NEWA

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION
PHOSPHOCOL P32
@ CURIUM

5mCi/ML

N017084 001

Jan CAHN

CICLESONIDE

AEROSOL, METERED; INHALATION
ALVESCO

+! COVIS PHARMA BV 0.08MG/INH
+! 0.16MG/INH

N021658 002 Jan 10, 2008 Mar CAHN
N021658 003 Jan 10, 2008 Mar CAHN

AEROSOL, METERED; NASAL
ZETONNA

+! COVIS PHARMA BV 0.037MG/INH

N202129 001 Jan 20, 2012 Mar CAHN

SPRAY, METERED; NASAL
OMNARIS

+! COVIS PHARMA BV 0.05MG/INH

N022004 001 Oct 20, 2006 Mar CAHN

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX

AB PERRIGO ISRAEL 0.77%

A077364 001 Mar 03, 2006 May CAHN

SHAMPOO; TOPICAL
LOPROX

AT +! BAUSCH 1%

N021159 001 Feb 28, 2003 Apr CAHN

SOLUTION; TOPICAL
CICLOPIROX

AT ACELLA 8%

A078172 001 Sep 18, 2007 May CAHN

CIMETIDINE

TABLET; ORAL
CIMETIDINE

>D> AB APOTEX 200MG

A074890 001 Dec 18, 1998 Jun CAHN

>D> AB 300MG

A074890 002 Dec 18, 1998 Jun CAHN

>D> AB 400MG

A074890 003 Dec 18, 1998 Jun CAHN

>D> AB 800MG

A074890 004 Dec 18, 1998 Jun CAHN

>A> AB HIKMA 200MG

A074890 001 Dec 18, 1998 Jun CAHN

>A> AB 300MG

A074890 002 Dec 18, 1998 Jun CAHN

>A> AB 400MG

A074890 003 Dec 18, 1998 Jun CAHN

>A> AB 800MG

A074890 004 Dec 18, 1998 Jun CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE

@ PD PARTNERS EQ 300MG BASE/5ML

A075560 001 Mar 15, 2000 May CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL
CINACALCET HYDROCHLORIDE

AB ALKEM LABS LTD EQ 30MG BASE

A210570 001 May 17, 2019 May NEWA

AB EQ 60MG BASE

A210570 002 May 17, 2019 May NEWA

AB EQ 90MG BASE

A210570 003 May 17, 2019 May NEWA

>A> AB LUPIN LTD EQ 30MG BASE

A210548 001 Jun 28, 2019 Jun NEWA

>A> AB EQ 60MG BASE

A210548 002 Jun 28, 2019 Jun NEWA

>A> AB EQ 90MG BASE

A210548 003 Jun 28, 2019 Jun NEWA

CIPROFLOXACIN

INJECTABLE; INJECTION
CIPROFLOXACIN

@ DR REDDYS 200MG/20ML (10MG/ML)

A077782 001 Aug 28, 2006 May CAHN

@ 400MG/40ML (10MG/ML)

A077782 002 Aug 28, 2006 May CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CIPROFLOXACIN EXTENDED RELEASE

! ANCHEN PHARMS 212.6MG;EQ 287.5MG BASE

A078166 002 Nov 27, 2007 May CTEC

! 212.6MG;EQ 287.5MG BASE

A078166 002 Nov 27, 2007 May CHRS

AB ! 425.2MG;EQ 574.9MG BASE

A078166 001 Nov 27, 2007 May CHRS

@ ANI PHARMS INC 212.6MG;EQ 287.5MG BASE

A077417 001 Nov 30, 2010 May CAHN

@ 425.2MG;EQ 574.9MG BASE

A077809 001 Nov 30, 2010 May CAHN

@ MYLAN PHARMS INC 212.6MG;EQ 287.5MG BASE

A078183 001 Mar 22, 2007 May DISC

@ 425.2MG;EQ 574.9MG BASE

A078183 002 Mar 22, 2007 May DISC

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

	@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb	DISC
AP	NANJING KING-FRIEND	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr	NEWA
AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr	NEWA
AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr	NEWA
AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Apr	NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE						
	@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb	DISC
	@	EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb	DISC
AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791	001	Feb 20, 2019	Feb	NEWA
AP		EQ 10MG BASE/ML	A206791	002	Feb 20, 2019	Feb	NEWA
	NIMBEX PRESERVATIVE FREE						
AP	+! ABBVIE	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb	CTEC

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

	@ PD PARTNERS	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005	May	CAHN
	TABLET; ORAL						
	CITALOPRAM HYDROBROMIDE						
	@ HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004	May	CAHN
	@	EQ 10MG BASE	A077213	001	Mar 31, 2006	May	CAHN
AB		EQ 10MG BASE	A077232	001	Oct 31, 2005	May	CAHN
	@	EQ 20MG BASE	A077033	002	Oct 28, 2004	May	CAHN
	@	EQ 20MG BASE	A077213	002	Mar 31, 2006	May	CAHN
AB		EQ 20MG BASE	A077232	002	Oct 31, 2005	May	CAHN
	@	EQ 40MG BASE	A077033	003	Oct 28, 2004	May	CAHN
	@	EQ 40MG BASE	A077213	003	Mar 31, 2006	May	CAHN
AB		EQ 40MG BASE	A077232	003	Oct 31, 2005	May	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

>D>	+ @ FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK ET	N202535	001	Jul 16, 2012	Jun	CMFD
>A>	+!	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK ET	N202535	001	Jul 16, 2012	Jun	CMFD
	+ @	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK ET	N202535	001	Jul 16, 2012	Apr	DISC

CLADRIBINE

TABLET; ORAL

MAVENCLAD

	+! EMD SERONO INC	10MG	N022561	001	Mar 29, 2019	Mar	NEWA
--	-------------------	------	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019	Apr	NEWA
AB		500MG	A206714	002	Apr 25, 2019	Apr	NEWA
AB	STRIDES PHARMA	250MG	A202710	001	Jun 10, 2013	Feb	CAHN
AB		500MG	A202710	002	Jun 10, 2013	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

	@ MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Mar	DISC
--	---------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

BT	+! BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000	May	CAHN
----	-----------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	ENCUBE ETHICALS	EQ 1% BASE	A209914	001	Jan 28, 2019	Jan	NEWA
----	-----------------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOINGEL; TOPICAL
VELTIN

BX	+!	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CAHN
----	----	----------	-------------	---------	-----	--------------	----------

CLOBAZAMSUSPENSION; ORAL
CLOBAZAM

AB		TARO PHARM	2.5MG/ML	A210978	001	Apr 15, 2019	Apr NEWA
>A>	AB	VISTAPHARM	2.5MG/ML	A210746	001	Jul 10, 2019	Jun NEWA

TABLET; ORAL
CLOBAZAM

AB		ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019	May NEWA
AB			20MG	A212398	002	May 23, 2019	May NEWA
AB		MICRO LABS	10MG	A211711	001	Jan 30, 2019	Jan NEWA
AB			20MG	A211711	002	Jan 30, 2019	Jan NEWA

CLOBETASOL PROPIONATEAEROSOL, FOAM; TOPICAL
CLOBETASOL PROPIONATE

AB1		GLENMARK PHARMS LTD	0.05%	A210809	001	Feb 15, 2019	Feb NEWA
AB2		PERRIGO UK FINCO	0.05%	A201402	001	Aug 14, 2012	May CAHN

OINTMENT; TOPICAL

AB		ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb NEWA
AB		@ AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb DISC
AB		TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan NEWA

CLOFARABINESOLUTION; INTRAVENOUS
CLOFARABINE

AP		ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb NEWA
		@ HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb DISC

CLOMIPRAMINE HYDROCHLORIDECAPSULE; ORAL
CLOMIPRAMINE HYDROCHLORIDE

AB		MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Mar NEWA
AB			50MG	A211767	002	Apr 08, 2019	Mar NEWA
AB			75MG	A211767	003	Apr 08, 2019	Mar NEWA

CLONAZEPAMTABLET, ORALLY DISINTEGRATING; ORAL
CLONAZEPAM

>A>	AB	ALEMBIC PHARMS LTD	0.125MG	A211033	001	Jun 28, 2019	Jun NEWA
>A>	AB		0.25MG	A211033	002	Jun 28, 2019	Jun NEWA
>A>	AB		0.5MG	A211033	003	Jun 28, 2019	Jun NEWA
>A>	AB		1MG	A211033	004	Jun 28, 2019	Jun NEWA
>A>	AB		2MG	A211033	005	Jun 28, 2019	Jun NEWA

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

		@ LUITPOLD	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009	Feb DISC
		@	5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009	Feb DISC

TABLET; ORAL

AB		FRONTIDA BIOPHARM	0.1MG	A070923	003	Sep 04, 1987	Apr CMS1
AB			0.2MG	A070923	002	Sep 04, 1987	Apr CMS1

TABLET, EXTENDED RELEASE; ORAL

AB1		NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019	Feb NEWA
		@ UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	May DISC

CLOPIDOGREL BISULFATETABLET; ORAL
CLOPIDOGREL BISULFATE

AB		ANI PHARMS INC	EQ 300MG BASE	A091216	001	May 17, 2012	May CAHN
>D>	AB	CADILA	EQ 75MG BASE	A201686	001	Oct 10, 2012	Jun DISC
>A>		@	EQ 75MG BASE	A201686	001	Oct 10, 2012	Jun DISC
AB			EQ 75MG BASE	A201686	001	Oct 10, 2012	Apr CAHN

TABLET;ORAL

CLOPIDOGREL BISULFATE

@ MYLAN PHARMS INC EQ 300MG BASE

A 077665 002 May 17, 2012 Feb DISC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG

A 072514 002 May 11, 1990 Jan CMS1

@ 7.5MG

A 072514 003 May 11, 1990 Jan CMS1

CLOTTRIMAZOLE

SOLUTION;TOPICAL

CLOTTRIMAZOLE

AT NOVITIUM PHARMA 1%

A 209815 001 Feb 14, 2019 Feb NEWA

CLOZAPINE

TABLET;ORAL

CLOZARIL

AB + HERITAGE LIFE 50MG

N 019758 003 May 20, 2019 May NEWA

AB + 200MG

N 019758 004 May 20, 2019 May NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

>A> AB + JAZZ 12.5MG

N 021590 004 May 30, 2007 Jun CAHN

>A> AB + 25MG

N 021590 001 Feb 10, 2004 Jun CAHN

>A> @ 50MG

N 021590 003 Jun 03, 2005 Jun CAHN

>A> AB +! 100MG

N 021590 002 Feb 10, 2004 Jun CAHN

>A> AB + 150MG

N 021590 005 Jul 09, 2010 Jun CAHN

>A> AB + 200MG

N 021590 006 Jul 09, 2010 Jun CAHN

>D> AB + JAZZ PHARMS III 12.5MG

N 021590 004 May 30, 2007 Jun CAHN

>D> AB + 25MG

N 021590 001 Feb 10, 2004 Jun CAHN

>D> @ 50MG

N 021590 003 Jun 03, 2005 Jun CAHN

>D> AB +! 100MG

N 021590 002 Feb 10, 2004 Jun CAHN

>D> AB + 150MG

N 021590 005 Jul 09, 2010 Jun CAHN

>D> AB + 200MG

N 021590 006 Jul 09, 2010 Jun CAHN

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@ HIKMA 30MG/5ML

N 202245 001 Jun 30, 2011 Mar CAHN

TABLET;ORAL

CODEINE SULFATE

AB + HIKMA 15MG

N 022402 001 Jul 16, 2009 Mar CAHN

AB + 30MG

N 022402 002 Jul 16, 2009 Mar CAHN

AB +! 60MG

N 022402 003 Jul 16, 2009 Mar CAHN

COLCHICINE

CAPSULE;ORAL

COLCHICINE

@ PAR PHARM INC 0.6MG

A 208678 001 Nov 29, 2018 May DISC

MITTIGARE

+! HIKMA INTL PHARMS 0.6MG

N 204820 001 Sep 26, 2014 May CTEC

SOLUTION;ORAL

GLOPERBA

+! ROMEG THERAPS LLC 0.6MG/5ML

N 210942 001 Jan 30, 2019 Jan NEWA

TABLET;ORAL

COLCHICINE

AB ALKEM LABS LTD 0.6MG

A 211250 001 Feb 08, 2019 Feb NEWA

AB AMNEAL PHARMS 0.6MG

A 204711 001 Sep 28, 2016 Jan NEWA

AB ZYDUS PHARMS 0.6MG

A 211519 001 Feb 19, 2019 Feb NEWA

COLCRYS

AB +! TAKEDA PHARMS USA 0.6MG

N 022352 001 Jul 29, 2009 Jan CTEC

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL

WELCHOL

+! DAIICHI SANKYO INC 3.75GM

N 210895 001 Apr 03, 2019 Apr NEWA

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB ALKEM LABS LTD 3.75GM/PACKET

A 210316 001 May 06, 2019 Apr NEWA

GLENMARK PHARMS LTD 1.875GM/PACKET

A 202190 001 Jul 16, 2018 Mar CTEC

FOR SUSPENSION;ORAL
WELCHOL

+ @ DAIICHI SANKYO 1.875GM/PACKET N022362 001 Oct 02, 2009 Mar DISC

CROMOLYN SODIUM

SOLUTION;INHALATION
CROMOLYN SODIUM

>D> @ APOTEX INC 10MG/ML A075333 001 Apr 30, 2002 Jun CAHN
>A> @ HIKMA 10MG/ML A075333 001 Apr 30, 2002 Jun CAHN
@ MYLAN SPECIALITY LP 10MG/ML A074209 001 Apr 26, 1994 Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
AMRIX

AB + TEVA PHARMS INTL 15MG N021777 001 Feb 01, 2007 Mar CTEC
+ 15MG N021777 001 Feb 01, 2007 Jan CTEC
AB +! 30MG N021777 002 Feb 01, 2007 Mar CTEC
+! 30MG N021777 002 Feb 01, 2007 Jan CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

AB APOTEX INC 15MG A206703 001 Jul 24, 2018 Feb CMFD
@ 15MG A206703 001 Jul 24, 2018 Jan DISC
AB 30MG A206703 002 Jul 24, 2018 Feb CMFD
@ 30MG A206703 002 Jul 24, 2018 Jan DISC
AB TWI PHARMS INC 15MG A091281 001 Jan 31, 2013 Mar CMFD
AB 30MG A091281 002 Jan 31, 2013 Mar CMFD

CYCLOPHOSPHAMIDE

CAPSULE;ORAL
CYCLOPHOSPHAMIDE

AB CIPLA 25MG A211608 001 Jan 18, 2019 Jan NEWA
AB 50MG A211608 002 Jan 18, 2019 Jan NEWA

CYCLOSPORINE

CAPSULE;ORAL
CYCLOSPORINE

>A> AB1 APOTEX INC 25MG A210721 001 Jul 10, 2019 Jun NEWA
>A> AB1 50MG A210721 002 Jul 10, 2019 Jun NEWA
>A> AB1 100MG A210721 003 Jul 10, 2019 Jun NEWA
>D> IVAX SUB TEVA PHARMS 50MG A065110 001 Mar 29, 2005 Jun CTEC
>A> AB1 50MG A065110 001 Mar 29, 2005 Jun CTEC

SOLUTION;ORAL
CYCLOSPORINE

@ PD PARTNERS 100MG/ML A065167 001 Jan 05, 2005 May CAHN

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA QUAGEN 2MG/5ML A212423 001 May 22, 2019 May NEWA
AA TORRENT 2MG/5ML A204823 001 Dec 27, 2016 Jan CAHN

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA BEXIMCO PHARMS USA 4MG A206676 001 Apr 12, 2019 Apr NEWA
AA ! HERITAGE PHARMA 4MG A087056 001 Feb CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS
ELCYS

+! EXELA PHARMA SCS LLC 500MG/10ML (50MG/ML) N210660 001 Apr 16, 2019 Apr NEWA

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL
DAKLINZA

>D> + BRISTOL-MYERS SQUIBB EQ 30MG BASE N206843 001 Jul 24, 2015 Jun DISC
>A> + @ EQ 30MG BASE N206843 001 Jul 24, 2015 Jun DISC
>D> + EQ 60MG BASE N206843 002 Jul 24, 2015 Jun DISC
>A> + @ EQ 60MG BASE N206843 002 Jul 24, 2015 Jun DISC
+ @ EQ 90MG BASE N206843 003 Apr 13, 2016 Feb DISC

DACTINOMYCIN

	INJECTABLE; INJECTION						
	DACTINOMYCIN						
	@ LUITPOLD	0.5MG/VIAL	A202562	001	Aug 23, 2013	Mar	DISC
AP	X-GEN PHARMS INC	0.5MG/VIAL	A203999	001	May 20, 2019	May	NEWA

DALFAMPRIDINE

	TABLET, EXTENDED RELEASE; ORAL						
	DALFAMPRIDINE						
AB	MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb	NEWA
AB	SUN PHARM	10MG	A208292	001	May 21, 2019	May	NEWA

DANTROLENE SODIUM

	INJECTABLE; INJECTION						
	DANTROLENE SODIUM						
	@ MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Mar	DISC

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL						
	QTERNMET XR						
+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019	May	NEWA
+		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019	May	NEWA
+		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019	May	NEWA
+	!	10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019	May	NEWA

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

	TABLET; ORAL						
	QTERN						
+	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019	May	NEWA

DAPIPRAZOLE HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC						
	DAPIPRAZOLE HYDROCHLORIDE						
	BARADAINA LLC	0.5%	A204902	001	May 30, 2019	May	NEWA

DAPSONE

	GEL; TOPICAL							
	ACZONE							
>D>	+	ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Jun	CFTG
>A>	AB	+	7.5%	N207154	001	Feb 24, 2016	Jun	CFTG
		+	7.5%	N207154	001	Feb 24, 2016	Feb	CAHN
>A>		DAPSONE						
>A>	AB	TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Jun	NFTG
		TABLET; ORAL						
		DAPSONE						
AB	SAI LIFE SCIENCES	100MG	A207165	001	May 08, 2019	Apr	NEWA	
	@ TARO PHARM	25MG	A209430	001	Mar 01, 2019	May	DISC	
AB		25MG	A209430	001	Mar 01, 2019	Feb	NEWA	
	@	100MG	A209430	002	Mar 01, 2019	May	DISC	
AB		100MG	A209430	002	Mar 01, 2019	Feb	NEWA	

DAPTOMYCIN

	POWDER; INTRAVENOUS							
	DAPTOMYCIN							
>A>	AP	ACCORD HLTHCARE	500MG/VIAL	A211961	001	Jun 24, 2019	Jun	NEWA
>A>	AP	BE PHARMS	500MG/VIAL	A212513	001	Jun 26, 2019	Jun	NEWA
	AP	DR REDDYS	500MG/VIAL	A208375	001	May 01, 2019	Apr	NEWA
	AP	XELLIA PHARMS APS	500MG/VIAL	A206005	001	Jun 15, 2016	Mar	CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

	TABLET, EXTENDED RELEASE; ORAL						
	VIEKIRA XR						
+	@ ABBVIE INC	EQ 200MG BASE; 8.33MG; 50MG; 33.33MG	N208624	001	Jul 22, 2016	Apr	DISC

DAUNORUBICIN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	DAUNORUBICIN HYDROCHLORIDE						
AP	HISUN PHARM HANGZHOU	EQ 5MG BASE/ML	A208759	001	Apr 12, 2019	Apr	NEWA
AP		EQ 20MG BASE/VIAL	A206195	001	Apr 25, 2019	Apr	NEWA

DECITABINE

	INJECTABLE; INTRAVENOUS							
	DECITABINE							
AP	WOCKHARDT BIO AG	50MG/VIAL		A209056	001	Apr 09, 2019	Mar	NEWA

DEFERIPRONE

	TABLET; ORAL							
	DEFERIPRONE							
AB	@ TARO PHARM INDS LTD	500MG		A208800	001	Feb 08, 2019	May	DISC
		500MG		A208800	001	Feb 08, 2019	Feb	NFTG
	FERRIPROX							
AB	+! AOPHARMA INC	500MG		N021825	001	Oct 14, 2011	May	CTEC
	+!	500MG		N021825	001	Oct 14, 2011	Feb	CFTG

DELAVIRDINE MESYLATE

	TABLET; ORAL							
	RESCRIPTOR							
>D>	+ VIIV HLTHCARE	100MG		N020705	001	Apr 04, 1997	Jun	DISC
>A>	+ @	100MG		N020705	001	Apr 04, 1997	Jun	DISC

DESLORATADINE

	TABLET; ORAL							
	DESLORATADINE							
AB	@ MYLAN PHARMS INC	5MG		A078351	001	Feb 10, 2012	May	DISC
	PERRIGO	5MG		A078361	001	Dec 22, 2011	Apr	CAHN

DESMOPRESSIN ACETATE

	INJECTABLE; INJECTION							
	DESMOPRESSIN ACETATE							
AP	LUITPOLD	0.004MG/ML		A091374	001	Feb 14, 2019	Feb	NEWA
AP	TEVA PHARMS USA	0.004MG/ML		A074888	001	Oct 15, 1997	Mar	CMFD
	SPRAY, METERED; NASAL							
	NOCTIVA							
>D>	+ ALYVANT	0.00083MG/SPRAY		N201656	001	Mar 03, 2017	Jun	DISC
>A>	+ @	0.00083MG/SPRAY		N201656	001	Mar 03, 2017	Jun	DISC
	+!	0.00083MG/SPRAY		N201656	001	Mar 03, 2017	Apr	CAHN
>D>	+!	0.00166MG/SPRAY		N201656	002	Mar 03, 2017	Jun	DISC
>A>	+ @	0.00166MG/SPRAY		N201656	002	Mar 03, 2017	Jun	DISC
	+!	0.00166MG/SPRAY		N201656	002	Mar 03, 2017	Apr	CAHN
	TABLET; ORAL							
	DESMOPRESSIN ACETATE							
AB	ABHAI LLC	0.1MG		A210371	001	Jan 28, 2019	Jan	NEWA
AB		0.2MG		A210371	002	Jan 28, 2019	Jan	NEWA
AB	NOVAST LABS	0.1MG		A208357	001	Jun 06, 2019	May	NEWA
AB		0.2MG		A208357	002	Jun 06, 2019	May	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

	TABLET; ORAL-28							
	DESOGEN							
	@ ORGANON USA INC	0.15MG; 0.03MG		N020071	002	Dec 10, 1992	May	DISC
	DESOGESTREL AND ETHINYL ESTRADIOL							
	@ ACCORD HLTHCARE	0.15MG; 0.03MG		A207067	001	Sep 13, 2018	Mar	DISC

DESONIDE

	AEROSOL, FOAM; TOPICAL							
	VERDESO							
	+! ALMIRALL	0.05%		N021978	001	Sep 19, 2006	Feb	CAHN
	OINTMENT; TOPICAL							
	DESONIDE							
AB	ENCUBE ETHICALS	0.05%		A210998	001	Jan 30, 2019	Jan	NEWA
AB	TELISTENT PHARMA INC	0.05%		A212002	001	Mar 12, 2019	Feb	NEWA

DESOXIMETASONE

	CREAM; TOPICAL							
	DESOXIMETASONE							
	@ ZYDUS PHARMS	0.25%		A205620	001	Sep 28, 2018	Feb	DISC

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE

+	!	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	May CTEC
+	!		100MG	N204150	002	Mar 04, 2013	May CTEC
		KHEDEZLA					
	@	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	May DISC
	@		100MG	N204683	002	Jul 10, 2013	May DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

AB		INTELLIPHARMACEUTICS	EQ 50MG BASE	A204805	001	May 07, 2019	Apr NEWA
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Apr NEWA
	@	MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	May DISC
	@		EQ 100MG BASE	A204095	002	Jun 29, 2015	May DISC
	@	YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Mar DISC
	@		EQ 100MG BASE	A210014	002	Oct 01, 2018	Mar DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP		AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019	May NEWA
AP	!	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb CHRS
	@	LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Feb DISC
AP		SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A211036	001	May 10, 2019	Apr NEWA
		SOLUTION/DROPS;OPHTHALMIC, OTIC					
		DEXAMETHASONE SODIUM PHOSPHATE					
	!	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996	May CTEC
	@	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	May DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP		CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan NEWA
	@	LUITPOLD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	Mar DISC
		SOLUTION;INTRAVENOUS					
		DEXMEDETOMIDINE HYDROCHLORIDE					
	+	HQ SPCLT PHARMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar CPOT
	+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar CPOT

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

	@	TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007	May DISC
	@		5MG	A077107	001	Jan 29, 2007	May DISC
	@		10MG	A077107	002	Jan 29, 2007	May DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

>A>	AB	PII	5MG	A205077	001	Jun 21, 2019	Jun NEWA
>A>	AB		10MG	A205077	002	Jun 21, 2019	Jun NEWA
>A>	AB		15MG	A205077	003	Jun 21, 2019	Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE DM

	@	VINTAGE	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	May DISC
--	---	---------	---------------------	---------	-----	--------------	----------

DIAZEPAM

GEL;RECTAL
DIASTAT

+	@	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Feb CAHN
+	@		5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Feb CAHN
+	@		10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Feb CAHN
+	@		15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Feb CAHN
+	@		20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Feb CAHN

	GEL;RECTAL							
	DIASTAT ACUDIAL							
	+	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Feb	CAHN
	+	!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Feb	CAHN
	INJECTABLE; INJECTION							
	DIAZEPAM							
AP		BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Mar	NEWA
AP	!	HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Mar	CTEC
	<u>DICLOFENAC</u>							
	CAPSULE;ORAL							
	ZORVOLEX							
	+	EGALET	18MG	N204592	001	Oct 18, 2013	Feb	CAHN
	+	!	35MG	N204592	002	Oct 18, 2013	Feb	CAHN
	<u>DICLOFENAC EPOLAMINE</u>							
	SYSTEM;TOPICAL							
	LICART							
	+	@ IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb	DISC
	<u>DICLOFENAC POTASSIUM</u>							
	TABLET;ORAL							
	DICLOFENAC POTASSIUM							
AB		AMICI	50MG	A076561	001	Mar 18, 2004	May	CAHN
	<u>DICLOFENAC SODIUM</u>							
	GEL;TOPICAL							
	DICLOFENAC SODIUM							
AB		MYLAN	1%	A204306	001	May 06, 2019	Apr	NEWA
AB		PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	May	NEWA
	SOLUTION;INTRAVENOUS							
	DICLOFENAC SODIUM							
>A>		MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jun	NEWA
	TABLET, EXTENDED RELEASE;ORAL							
	DICLOFENAC SODIUM							
>D>	AB	MYLAN	100MG	A076152	001	Dec 13, 2001	Jun	DISC
>A>		@	100MG	A076152	001	Dec 13, 2001	Jun	DISC
	<u>DICYCLOMINE HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	DICYCLOMINE HYDROCHLORIDE							
	@	APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Feb	DISC
AP		CUSTOPHARM INC	10MG/ML	A210788	001	Feb 11, 2019	Jan	NEWA
AP		FRESENIUS KABI USA	10MG/ML	A210257	001	Jan 25, 2019	Jan	NEWA
AP		NEXUS PHARMS	10MG/ML	A206468	001	Feb 01, 2019	Jan	NEWA
AP		SLATE	10MG/ML	A207076	001	Nov 02, 2018	Feb	CAHN
AP		SUNGEN PHARMA	10MG/ML	A212058	001	Apr 26, 2019	Apr	NEWA
	<u>DIGOXIN</u>							
	ELIXIR;ORAL							
	DIGOXIN							
	+	HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Apr	CAHN
	<u>DIHYDROERGOTAMINE MESYLATE</u>							
	INJECTABLE; INJECTION							
	D.H.E. 45							
AP	+	BAUSCH	1MG/ML	N005929	001		Apr	CAHN
	SPRAY, METERED;NASAL							
	MIGRANAL							
	+	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Apr	CAHN
	+	VALEANT	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Jan	CPOT
	<u>DILTIAZEM HYDROCHLORIDE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	CARDIZEM CD							
AB3	+	BAUSCH	120MG	N020062	001	Aug 10, 1992	Feb	CAHN
AB3	+		180MG	N020062	002	Dec 27, 1991	Feb	CAHN
AB3	+		240MG	N020062	003	Dec 27, 1991	Feb	CAHN
AB3	+		300MG	N020062	004	Dec 27, 1991	Feb	CAHN
AB3	+		360MG	N020062	005	Aug 24, 1999	Feb	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2	!	APOTEX	240MG	A074943	001	Aug 06, 1998	May	CHRS
AB2		MYLAN	240MG	A075124	001	Mar 18, 1998	May	CHRS
>A>	AB3	NOVAST LABS	120MG	A208783	001	Jun 14, 2019	Jun	NEWA
>A>	AB3		180MG	A208783	002	Jun 14, 2019	Jun	NEWA
>A>	AB3		240MG	A208783	003	Jun 14, 2019	Jun	NEWA
>A>	AB3		300MG	A208783	004	Jun 14, 2019	Jun	NEWA
>A>	AB3		360MG	A208783	005	Jun 14, 2019	Jun	NEWA
		@ PAR PHARM	360MG	A209766	001	May 30, 2018	Mar	DISC
		TIAZAC						
AB4	+	BAUSCH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4	+		180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4	+		240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4	+		300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4	+		360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE

@ DR REDDYS 5MG/ML A074894 001 Aug 26, 1997 May CAHN

TABLET; ORAL

CARDIZEM

AB	+	BAUSCH	30MG	N018602	001	Nov 05, 1982	Mar	CAHN
AB	+		60MG	N018602	002	Nov 05, 1982	Mar	CAHN
AB	+		90MG	N018602	003	Dec 08, 1986	Mar	CAHN
AB	+		120MG	N018602	004	Dec 08, 1986	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

AB	+	BAUSCH	120MG	N021392	001	Feb 06, 2003	Mar	CAHN
AB	+		180MG	N021392	002	Feb 06, 2003	Mar	CAHN
AB	+		240MG	N021392	003	Feb 06, 2003	Mar	CAHN
AB	+		300MG	N021392	004	Feb 06, 2003	Mar	CAHN
AB	+		360MG	N021392	005	Feb 06, 2003	Mar	CAHN
AB	+		420MG	N021392	006	Feb 06, 2003	Mar	CAHN

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

@ MYLAN INSTITUTIONAL 50% A076185 001 Nov 29, 2002 Mar DISC

+! MYLAN INSTITUTIONAL 50% N017788 001 Mar CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! HERITAGE PHARMA 50MG A080738 001 May CAHN

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ DR REDDYS 10MG/ML A080873 001 May CAHN

@ 50MG/ML A080873 002 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ DR REDDYS 50MG/ML A080873 003 May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

@ DR REDDYS 5MG/ML A074952 001 Nov 26, 1997 May CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

>A>	AP	ACTAVIS LLC	160MG/8ML (20MG/ML)	N203551	004	Sep 21, 2015	Jun	NEWA
		@ CIPLA	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Mar	DISC
		@	80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Mar	DISC
		@	160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Mar	DISC
AP		MYLAN LABS LTD	160MG/8ML (20MG/ML)	A208137	001	Apr 01, 2019	Mar	NEWA
AP		SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	May	NEWA
AP			80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	May	NEWA
AP			160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	May	NEWA
AP		TEIKOKU PHARMA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Mar	CAHN
AP			80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Mar	CAHN
AP			160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Mar	CAHN

SOLUTION; INTRAVENOUS

DOCETAXEL							
AP	SUN PHARMA GLOBAL	20MG/ML (20MG/ML)	N022534	003	Jan 08, 2019	Jan	NEWA
AP		80MG/4ML (20MG/ML)	N022534	004	Jan 08, 2019	Jan	NEWA
AP		160MG/8ML (20MG/ML)	N022534	005	Jan 08, 2019	Jan	NEWA

DOFETILIDE

CAPSULE; ORAL							
DOFETILDE							
AB	AUROBINDO PHARMA LTD	0.125MG	A210740	001	Jan 22, 2019	Jan	NEWA
AB		0.25MG	A210740	002	Jan 22, 2019	Jan	NEWA
AB		0.5MG	A210740	003	Jan 22, 2019	Jan	NEWA

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET; ORAL							
DOVATO							
+!	VIIV HLTHCARE	EQ 50MG BASE; 300MG	N211994	001	Apr 08, 2019	Apr	NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL							
DONEPEZIL HYDROCHLORIDE							
AB	CADILA	5MG	A090100	001	Oct 24, 2012	Mar	CAHN
AB		10MG	A090100	002	Oct 24, 2012	Mar	CAHN
AB	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	May	CAHN
AB		10MG	A077344	002	May 31, 2011	May	CAHN
AB	@ OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Mar	DISC
AB	STRIDES PHARMA	5MG	A090551	001	May 31, 2011	Apr	CAHN
AB		10MG	A090551	002	May 31, 2011	Apr	CAHN
TABLET, ORALLY DISINTEGRATING; ORAL							
DONEPEZIL HYDROCHLORIDE							
@	HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010	May	CAHN
@		10MG	A078388	001	Nov 26, 2010	May	CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION							
DOPAMINE HYDROCHLORIDE							
@	LUITPOLD	40MG/ML	A070799	001	Feb 11, 1987	Feb	DISC
@		80MG/ML	A070820	001	Feb 11, 1987	Feb	DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
DORZOLAMIDE HYDROCHLORIDE							
AT	FDC LTD	EQ 2% BASE	A205294	001	Jan 24, 2019	Jan	NEWA
@	LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009	Mar	DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC								
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE								
>A>	AT	FDC LTD	EQ 2% BASE; EQ 0.5% BASE	A205295	001	Jun 13, 2019	Jun	NEWA
>A>	AT	SOMERSET THERAPS LLC	EQ 2% BASE; EQ 0.5% BASE	A207523	001	Jun 25, 2019	Jun	NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION								
DOPRAM								
AP	+!	HIKMA	20MG/ML	N014879	001		Mar	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL							
DOXEPIN HYDROCHLORIDE							
AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A211603	001	Mar 27, 2019	Mar	NEWA
AB		EQ 25MG BASE	A211603	002	Mar 27, 2019	Mar	NEWA
AB		EQ 50MG BASE	A211603	003	Mar 27, 2019	Mar	NEWA
AB		EQ 75MG BASE	A211603	004	Mar 27, 2019	Mar	NEWA
AB		EQ 100MG BASE	A211603	005	Mar 27, 2019	Mar	NEWA
AB	PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987	Jan	CMFD
AB		EQ 25MG BASE	A071437	001	Nov 09, 1987	Jan	CMFD
AB		EQ 75MG BASE	A071608	001	Nov 09, 1987	Jan	CMFD
TABLET; ORAL							
SILENOR							
+	CURRAX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN
+!		EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN
+	PERNIX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Feb	CAHN

	TABLET;ORAL								
	SILENOR								
	+!	EQ 6MG BASE		N022036	002	Mar 17, 2010	Feb	CAHN	
	<u>DOXERCALCIFEROL</u>								
	INJECTABLE;INJECTION								
	DOXERCALCIFEROL								
>D>	+!	HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jun	DISC	
>A>	+ @		10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jun	DISC	
	<u>DOXORUBICIN HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	DOXORUBICIN HYDROCHLORIDE								
AP		HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019	Apr	NEWA	
	<u>DOXYCYCLINE</u>								
	CAPSULE;ORAL								
	MONODOX								
AB	+	ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb	CAHN	
AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb	CAHN	
AB	+!		EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb	CAHN	
	TABLET;ORAL								
	DOXYCYCLINE								
	@	MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006	Apr	DISC	
	@		EQ 75MG BASE	A065377	002	Nov 07, 2006	Apr	DISC	
	@		EQ 100MG BASE	A065377	003	Nov 07, 2006	May	DISC	
	@		EQ 150MG BASE	A065427	001	Jun 07, 2007	May	DISC	
	<u>DOXYCYCLINE HYCLATE</u>								
	CAPSULE;ORAL								
	ACTICLATE CAP								
	+ @	ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb	CAHN	
		DOXYCYCLINE HYCLATE							
	@	AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018	Mar	DISC	
	@		EQ 100MG BASE	A211012	002	Sep 24, 2018	Mar	DISC	
	@	MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Apr	DISC	
	@		EQ 100MG BASE	A062337	002	Mar 29, 1982	Apr	DISC	
	TABLET;ORAL								
	ACTICLATE								
AB	+	ALMIRALL	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb	CAHN	
AB	+!		EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb	CAHN	
		DOXYCYCLINE HYCLATE							
AB		APOTEX INC	EQ 75MG BASE	A209243	001	Apr 15, 2019	Apr	NEWA	
AB			EQ 150MG BASE	A209243	002	Apr 15, 2019	Apr	NEWA	
AB		CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb	CAHN	
AB		HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	May	CAHN	
	TABLET, DELAYED RELEASE;ORAL								
	DOXYCYCLINE HYCLATE								
	@	ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018	May	DISC	
	@		EQ 100MG BASE	A206772	002	Dec 21, 2018	May	DISC	
	@		EQ 150MG BASE	A206772	003	Dec 21, 2018	May	DISC	
	<u>DROSPIRENONE</u>								
	TABLET;ORAL								
	SLYND								
	+!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019	May	NEWA	
	<u>DROSPIRENONE; ETHINYL ESTRADIOL</u>								
	TABLET;ORAL								
	DROSPIRENONE AND ETHINYL ESTRADIOL								
AB		HETERO LABS LTD	3MG;0.02MG	A211944	001	Mar 22, 2019	Mar	NEWA	
	TABLET;ORAL-28								
	KEMEYA								
AB		SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Feb	NEWA	
	<u>DULOXETINE HYDROCHLORIDE</u>								
	CAPSULE, DELAYED REL PELLETS;ORAL								
	DULOXETINE HYDROCHLORIDE								
AB		AJANTA PHARMA LTD	EQ 40MG BASE	A208706	004	Mar 11, 2019	Feb	NEWA	
AB		QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	Apr	NEWA	
AB			EQ 30MG BASE	A210599	002	Apr 17, 2019	Apr	NEWA	

CAPSULE, DELAYED REL PELLETS;ORAL
DULOJETINE HYDROCHLORIDE

AB EQ 60MG BASE A210599 003 Apr 17, 2019 Apr NEWA

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

>D> AB BRECKENRIDGE PHARM 0.5MG A204705 001 Nov 20, 2015 Jun DISC
>A> @ 0.5MG A204705 001 Nov 20, 2015 Jun DISC
>D> AB 0.5MG A208227 001 Jun 22, 2018 Jun DISC
>A> @ 0.5MG A208227 001 Jun 22, 2018 Jun DISC
AB CADILA 0.5MG A204373 001 Oct 04, 2017 Feb CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL
ECONAZOLE NITRATE

>D> AB CASI PHARMS INC 1% A076075 001 Nov 26, 2002 Jun DISC
>A> @ 1% A076075 001 Nov 26, 2002 Jun DISC
AB ! PERRIGO ISRAEL 1% A076479 001 Jun 23, 2004 May CAHN

EFAVIRENZ

TABLET;ORAL
EFAVIRENZ

@ AUROBINDO PHARMA LTD 600MG A077673 001 Sep 21, 2018 Feb DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB CIPLA 600MG;200MG;300MG A206894 001 Jun 03, 2019 May NEWA
@ TEVA PHARMS USA 600MG;200MG;300MG A091215 001 Nov 09, 2018 May DISC

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

>D> MACLEODS PHARMS LTD 400MG;300MG;300MG N210649 001 Mar 15, 2019 Jun DISC
>D> @ 400MG;300MG;300MG N210649 001 Mar 15, 2019 Jun DISC
>A> @ 400MG;300MG;300MG N210649 001 Mar 15, 2019 Mar NEWA

EFINACONAZOLE

SOLUTION;TOPICAL
JUBLIA

+! BAUSCH 10% N203567 001 Jun 06, 2014 Feb CAHN

ELTROMBOPAG OLAMINE

TABLET;ORAL
PROMACTA

+ @ NOVARTIS PHARMS CORP EQ 100MG ACID N022291 005 Nov 16, 2012 Feb DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ AMNEAL PHARMS CO 100MG;150MG A209721 001 Aug 22, 2018 Feb DISC
@ 133MG;200MG A209721 002 Aug 22, 2018 Feb DISC
@ 167MG;250MG A209721 003 Aug 22, 2018 Feb DISC
@ 200MG;300MG A209721 004 Aug 22, 2018 Feb DISC
TRUVADA
+ GILEAD 100MG;150MG N021752 002 Mar 10, 2016 Feb CTEC
+ 133MG;200MG N021752 003 Mar 10, 2016 Feb CTEC
+ 167MG;250MG N021752 004 Mar 10, 2016 Feb CTEC

ENALAPRIL MALEATE

FOR SOLUTION;ORAL
EPANED KIT

+ @ SILVERGATE PHARMS 1MG/ML N204308 001 Aug 13, 2013 Mar DISC

TABLET;ORAL

ENALAPRIL MALEATE

@ BEXIMCO PHARMS USA 2.5MG A075621 001 Aug 22, 2000 Feb CAHN
@ 5MG A075621 002 Aug 22, 2000 Feb CAHN
@ 10MG A075621 003 Aug 22, 2000 Feb CAHN
@ 20MG A075621 004 Aug 22, 2000 Feb CAHN
AB HERITAGE PHARMA 2.5MG A075479 001 Aug 22, 2000 Feb CAHN
AB 5MG A075479 002 Aug 22, 2000 Feb CAHN

	TABLET; ORAL								
	ENALAPRIL MALEATE								
	AB	10MG		A075479	003	Aug 22, 2000	Feb	CAHN	
	AB	20MG		A075479	004	Aug 22, 2000	Feb	CAHN	
>D>	AB	MYLAN	5MG	A075480	002	Aug 22, 2000	Jun	DISC	
>A>	@		5MG	A075480	002	Aug 22, 2000	Jun	DISC	
	@		10MG	A075480	003	Aug 22, 2000	Feb	DISC	
	VASOTEC								
	AB	+ BAUSCH	2.5MG	N018998	005	Jul 26, 1988	Mar	CAHN	
	AB	+	5MG	N018998	001	Dec 24, 1985	Mar	CAHN	
	AB	+	10MG	N018998	002	Dec 24, 1985	Mar	CAHN	
	AB	+	20MG	N018998	003	Dec 24, 1985	Mar	CAHN	
	<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>								
	TABLET; ORAL								
	VASERETIC								
	AB	+ BAUSCH	5MG; 12.5MG	N019221	003	Jul 12, 1995	Mar	CAHN	
	AB	+	10MG; 25MG	N019221	001	Oct 31, 1986	Mar	CAHN	
	<u>ENALAPRILAT</u>								
	INJECTABLE; INJECTION								
	ENALAPRILAT								
	AP	DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	May	CAHN	
	<u>ENOXAPARIN SODIUM</u>								
	INJECTABLE; INTRAVENOUS, SUBCUTANEOUS								
	ENOXAPARIN SODIUM								
	AB	AMPHASTAR PHARMS INC	300MG/3ML (100MG/ML)	A208600	001	Mar 14, 2019	Mar	NEWA	
	<u>ENTECAVIR</u>								
	TABLET; ORAL								
	ENTECAVIR								
	AB	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Mar	NEWA	
	AB		1MG	A206226	002	Mar 26, 2019	Mar	NEWA	
	<u>EPINASTINE HYDROCHLORIDE</u>								
	SOLUTION/DROPS; OPHTHALMIC								
	EPINASTINE HYDROCHLORIDE								
>D>	AT	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Jun	DISC	
>A>	@		0.05%	A203384	001	Dec 07, 2016	Jun	DISC	
	<u>EPINEPHRINE</u>								
	INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS								
	EPIPEN JR.								
	+	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar	CTEC	
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS								
	ADRENALIN								
	AP	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan	CDFR
		+		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan	CDFR
	SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS								
	EPINEPHRINE								
	+	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	May	CDFR	
	<u>EPIRUBICIN HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	EPIRUBICIN HYDROCHLORIDE								
		FRESENIUS KABI USA	150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007	Mar	CTEC	
	<u>EPTIFIBATIDE</u>								
	INJECTABLE; INJECTION								
	EPTIFIBATIDE								
	AP	BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan	CAHN	
	AP		75MG/100ML	A208554	002	Nov 23, 2018	Jan	CAHN	
	AP	HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan	NEWA	
	AP		75MG/100ML	A209864	002	Jan 25, 2019	Jan	NEWA	
	AP	USV	2MG/ML	A204361	001	Mar 14, 2019	Mar	NEWA	
	AP		2MG/ML	A204362	001	Mar 11, 2019	Feb	NEWA	
	AP		75MG/100ML	A204361	002	Mar 14, 2019	Mar	NEWA	

ERDAFITINIBTABLET; ORAL
BALVERSA

+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019	Apr	NEWA
+		4MG	N212018	002	Apr 12, 2019	Apr	NEWA
+	!	5MG	N212018	003	Apr 12, 2019	Apr	NEWA

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB	MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb	CMFD
AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb	CMFD
AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb	CMFD
AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar	CMFD
AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar	CMFD
TARCEVA							
AB	+ OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar	CAHN
AB	+	EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb	CTEC
AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar	CAHN
AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb	CTEC
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar	CAHN
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb	CTEC

ERTAPENEM SODIUMINJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

AP	SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A207647	001	Mar 19, 2019	Mar	NEWA
----	---------------------	------------------	---------	-----	--------------	-----	------

ERYTHROMYCINOINTMENT; TOPICAL
AKNE-MYCIN

+	@ BAUSCH	2%	N050584	001	Jan 10, 1985	Apr	CAHN
---	----------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL
ERYTHRA-DERM

@	SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Feb	CAHN
---	-----------------	----	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL
ERY-TAB

>D>	ARBOR PHARMS LLC	250MG	A062298	001		Jun	CTEC
>A>	AB	250MG	A062298	001		Jun	CTEC
>D>		333MG	A062298	003	Mar 29, 1982	Jun	CTEC
>A>	AB	333MG	A062298	003	Mar 29, 1982	Jun	CTEC
>D>	!	500MG	A062298	002		Jun	CTEC
>A>	AB	500MG	A062298	002		Jun	CTEC

ERYTHROMYCIN

>A>	AB	AMNEAL PHARMS CO	250MG	A210954	001	Jul 02, 2019	Jun	NEWA
>A>	AB		333MG	A210954	002	Jul 02, 2019	Jun	NEWA
>A>	AB		500MG	A210954	003	Jul 02, 2019	Jun	NEWA

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	CADILA	EQ 5MG BASE	A077734	001	Sep 11, 2012	Apr	CAHN
AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Apr	CAHN
AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Apr	CAHN

ESKETAMINE HYDROCHLORIDESPRAY; NASAL
SPRAVATO

+	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019	Mar	NEWA
---	----------------	--------------	---------	-----	--------------	-----	------

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

ESMOLOL HYDROCHLORIDE

@	LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Mar	DISC
---	----------	---------	---------	-----	--------------	-----	------

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS; ORAL
ESOMEPRAZOLE MAGNESIUM

>D>	AB	AMNEAL PHARMS NY	EQ 20MG BASE	A209647	001	Apr 10, 2019	Jun	DISC
>A>		@	EQ 20MG BASE	A209647	001	Apr 10, 2019	Jun	DISC
	AB		EQ 20MG BASE	A209647	001	Apr 10, 2019	Mar	NEWA

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

>D>	AB		EQ 40MG BASE	A209647	002	Apr 10, 2019	Jun DISC
>A>		@	EQ 40MG BASE	A209647	002	Apr 10, 2019	Jun DISC
	AB		EQ 40MG BASE	A209647	002	Apr 10, 2019	Mar NEWA
	AB	GLENMARK PHARMS	EQ 20MG BASE	A209495	001	May 10, 2019	Apr NEWA
	AB		EQ 40MG BASE	A209495	002	May 10, 2019	Apr NEWA
		@ HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018	Mar DISC
		@	EQ 40MG BASE	A207265	001	May 18, 2018	Mar DISC
>D>	BX	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Jun CTEC
>A>	AB		EQ 20MG BASE	A202784	001	Sep 21, 2015	Jun CTEC
>D>	BX		EQ 40MG BASE	A202784	002	Sep 21, 2015	Jun CTEC
>A>	AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Jun CTEC
	AB	ZYDUS PHARMS	EQ 20MG BASE	A206296	001	May 22, 2019	May NEWA
	AB		EQ 40MG BASE	A206296	002	May 22, 2019	May NEWA

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL
ESTRADIOL

AB1		AMNEAL PHARMS LLC	0.025MG/24HR	A211293	001	Feb 04, 2019	Jan NEWA
AB1			0.0375MG/24HR	A211293	002	Feb 04, 2019	Jan NEWA
AB1			0.05MG/24HR	A211293	003	Feb 04, 2019	Jan NEWA
AB1			0.075MG/24HR	A211293	004	Feb 04, 2019	Jan NEWA
AB1			0.1MG/24HR	A211293	005	Feb 04, 2019	Jan NEWA
		GEL;TRANSDERMAL					
		DIVIGEL					
		+! VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jan CHRS

ESTRADIOL VALERATE

INJECTABLE;INJECTION
ESTRADIOL VALERATE

		@ DR REDDYS	40MG/ML	A083714	001		May CAHN
--	--	-------------	---------	---------	-----	--	----------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

		@ ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Mar DISC
AB		NOVAST LABS	0.5MG;0.1MG	A210612	001	Apr 03, 2019	Mar NEWA
AB			1MG;0.5MG	A210612	002	Apr 03, 2019	Mar NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL
CENESTIN

		+ @ ASPEN	0.3MG	N020992	001	Jun 21, 2002	Feb CAHN
		+ @	0.45MG	N020992	005	Feb 05, 2004	Feb CAHN
		+ @	0.625MG	N020992	002	Mar 24, 1999	Feb CAHN
		+ @	0.9MG	N020992	003	Mar 24, 1999	Feb CAHN
		+ @	1.25MG	N020992	004	Mar 13, 2000	Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL
ENJUVIA

		@ ASPEN	0.3MG	N021443	001	Dec 20, 2004	Feb CAHN
		@	0.45MG	N021443	002	Dec 20, 2004	Feb CAHN
		@	0.625MG	N021443	003	May 10, 2004	Feb CAHN
		@	0.9MG	N021443	005	Apr 27, 2007	Feb CAHN
		@	1.25MG	N021443	004	May 10, 2004	Feb CAHN

ESZOPICLONE

TABLET;ORAL
ESZOPICLONE

		@ BRECKENRIDGE PHARM	1MG	A203087	001	May 08, 2019	May DISC
AB			1MG	A203087	001	May 08, 2019	Apr NEWA
		@	2MG	A203087	002	May 08, 2019	May DISC
AB			2MG	A203087	002	May 08, 2019	Apr NEWA
		@	3MG	A203087	003	May 08, 2019	May DISC
AB			3MG	A203087	003	May 08, 2019	Apr NEWA

ETHACRYNATE SODIUMINJECTABLE; INJECTION
EDECIN

AP	+	!	BAUSCH	EQ 50MG BASE/VIAL	N016093	001		Mar	CAHN
AP	+	!	VALEANT PHARMS INTL	EQ 50MG BASE/VIAL	N016093	001		Jan	CAHN

ETHACRYNIC ACIDTABLET; ORAL
EDECIN

AB	+	!	BAUSCH	25MG	N016092	001		Mar	CAHN
			@	50MG	N016092	002		Mar	CAHN
AB	+	!	VALEANT PHARMS INTL	25MG	N016092	001		Jan	CAHN
			@	50MG	N016092	002		Jan	CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATETABLET; ORAL-28
LO-MALMOREDE

AB			NOVAST LABS	0.035MG; 1MG	A209548	001	Feb 11, 2019	Jan	NEWA
----	--	--	-------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
SYLEVIA

AB			SUN PHARM	0.03MG; 0.15MG	A202988	001	Feb 06, 2019	Jan	NEWA
----	--	--	-----------	----------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D>	AB2		MYLAN LABS LTD	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Jun	DISC
>A>			@	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Jun	DISC

ETHINYL ESTRADIOL; NORETHINDRONETABLET; ORAL-28
NORTREL 1/35-28

AB	!		BARR	0.035MG; 1MG	A072696	001	Feb 28, 1992	Mar	CHRS
----	---	--	------	--------------	---------	-----	--------------	-----	------

ORTHO-NOVUM 1/35-28

	+	@	JANSSEN PHARMS	0.035MG; 1MG	N017919	002		Mar	DISC
--	---	---	----------------	--------------	---------	-----	--	-----	------

TABLET, CHEWABLE; ORAL
FEMCON FE

	+	@	APIL	0.035MG; 0.4MG	N021490	001	Nov 14, 2003	Mar	DISC
--	---	---	------	----------------	---------	-----	--------------	-----	------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	!		MYLAN LABS LTD	0.035MG; 0.4MG	A202086	001	Apr 01, 2015	Mar	CHRS
----	---	--	----------------	----------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATETABLET; ORAL-21
HAILEY 1.5/30

AB			GLENMARK PHARMS	0.03MG; 1.5MG	A209297	001	Jun 05, 2018	Jan	CDFR
----	--	--	-----------------	---------------	---------	-----	--------------	-----	------

LOESTRIN 21 1.5/30

AB	+		APIL	0.03MG; 1.5MG	N017875	001		Jan	CRLD
----	---	--	------	---------------	---------	-----	--	-----	------

LOESTRIN 21 1/20

AB	+		APIL	0.02MG; 1MG	N017876	001		Jan	CRLD
----	---	--	------	-------------	---------	-----	--	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

	@		MYLAN LABS LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A202132	001	Sep 09, 2015	Jan	DISC
--	---	--	----------------	--	---------	-----	--------------	-----	------

ORTHO CYCLEN-28

	+	@	JANSSEN PHARMS	0.035MG; 0.25MG	N019653	002	Dec 29, 1989	Apr	DISC
--	---	---	----------------	-----------------	---------	-----	--------------	-----	------

SPRINTEC

AB	!		BARR	0.035MG; 0.25MG	A075804	001	Sep 25, 2002	Apr	CHRS
----	---	--	------	-----------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; SEGESTERONE ACETATERING; VAGINAL
ANNOVERA

	+	!	THERAPEUTICSMD INC	0.013MG/24HR; 0.15MG/24HR	N209627	001	Aug 10, 2018	May	CMFD
--	---	---	--------------------	---------------------------	---------	-----	--------------	-----	------

	+	@		0.013MG/24HR; 0.15MG/24HR	N209627	001	Aug 10, 2018	Feb	DISC
--	---	---	--	---------------------------	---------	-----	--------------	-----	------

ETHOSUXIMIDE

	CAPSULE; ORAL						
	ETHOSUXIMIDE						
AB	STRIDES PHARMA	250MG	A211928	001	Feb 19, 2019	Feb	NEWA
	SYRUP; ORAL						
	ETHOSUXIMIDE						
	@ TEVA PHARMS	250MG/5ML	A081306	001	Jul 30, 1993	May	DISC

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

@ LUITPOLD 2MG/ML

A078867 001 Dec 22, 2009 Feb DISC

@ PAR STERILE PRODUCTS 2MG/ML

A091297 001 Jun 20, 2012 Apr DISC

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+! CHEPLAPHARM EQ 100MG BASE/VIAL

N020457 001 May 17, 1996 May CAHN

EVEROLIMUS

TABLET; ORAL

AFINITOR

+! NOVARTIS 5MG

N022334 001 Mar 30, 2009 Apr CHRS

+ 10MG

N022334 002 Mar 30, 2009 Apr CHRS

ZORTRESS

+ NOVARTIS 1MG

N021560 004 Aug 10, 2018 Mar NEWA

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

+ NOVARTIS PHARM 2MG

N203985 001 Aug 29, 2012 Apr CTEC

AB + 2MG

N203985 001 Aug 29, 2012 Apr CFTG

+ 3MG

N203985 002 Aug 29, 2012 Apr CTEC

AB + 3MG

N203985 002 Aug 29, 2012 Apr CFTG

+! 5MG

N203985 003 Aug 29, 2012 Apr CTEC

AB +! 5MG

N203985 003 Aug 29, 2012 Apr CFTG

EVEROLIMUS

@ MYLAN 2MG

A210130 001 Apr 19, 2019 Apr NFTG

@ 3MG

A210130 002 Apr 19, 2019 Apr NFTG

@ 5MG

A210130 003 Apr 19, 2019 Apr NFTG

EXEMESTANE

TABLET; ORAL

EXEMESTANE

@ BRECKENRIDGE PHARM 25MG

A211031 001 Feb 21, 2019 May DISC

AB 25MG

A211031 001 Feb 21, 2019 Feb NEWA

EZETIMIBE

TABLET; ORAL

EZETIMIBE

@ ACCORD HLTHCARE 10MG

A211550 001 Oct 26, 2018 Apr DISC

AB MYLAN 10MG

A201790 001 Apr 26, 2019 Apr NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

>A> AB GLENMARK PHARMS LTD 10MG; 10MG

A208699 001 Jun 27, 2019 Jun NEWA

>A> AB 10MG; 20MG

A208699 002 Jun 27, 2019 Jun NEWA

>A> AB 10MG; 40MG

A208699 003 Jun 27, 2019 Jun NEWA

>A> AB 10MG; 80MG

A208699 004 Jun 27, 2019 Jun NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

@ MYLAN 40MG

A075704 002 Apr 16, 2001 Apr DISC

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

>A> AB ALEMBIC PHARMS LTD 40MG

A205421 001 Jul 01, 2019 Jun NFTG

>A> AB 80MG

A205421 002 Jul 01, 2019 Jun NFTG

>A> AB MYLAN 40MG

A205385 001 Jul 01, 2019 Jun NFTG

>A> AB 80MG

A205385 002 Jul 01, 2019 Jun NFTG

	TABLET;ORAL						
>A>	FEBUXOSTAT						
>A>	AB	SUN PHARM	40MG	A205467	001	Jul 01, 2019	Jun NFTG
>A>	AB		80MG	A205467	002	Jul 01, 2019	Jun NFTG
	ULORIC						
>D>	+	TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Jun CFTG
>A>	AB	+	40MG	N021856	001	Feb 13, 2009	Jun CFTG
>D>		+	80MG	N021856	002	Feb 13, 2009	Jun CFTG
>A>	AB	+	80MG	N021856	002	Feb 13, 2009	Jun CFTG
	<u>FELBAMATE</u>						
	SUSPENSION;ORAL						
	FELBAMATE						
AB		VISTAPHARM	600MG/5ML	A211333	001	May 31, 2019	May NEWA
	<u>FELODIPINE</u>						
	TABLET, EXTENDED RELEASE;ORAL						
	FELODIPINE						
AB		YUNG SHIN PHARM	2.5MG	A204800	001	Apr 29, 2019	Apr NEWA
AB			5MG	A204800	002	Apr 29, 2019	Apr NEWA
AB			10MG	A204800	003	Apr 29, 2019	Apr NEWA
	<u>FENOFIBRATE</u>						
	CAPSULE;ORAL						
	FENOFIBRATE (MICRONIZED)						
AB		AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Jan CAHN
AB			134MG	A207805	002	Nov 16, 2017	Jan CAHN
AB			200MG	A207805	003	Nov 16, 2017	Jan CAHN
AB		INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	Apr NEWA
AB			134MG	A207564	002	Apr 19, 2019	Apr NEWA
AB			200MG	A207564	003	Apr 19, 2019	Apr NEWA
	TABLET;ORAL						
	FENOFIBRATE						
AB		AUSTARPHARMA	54MG	A207803	001	Dec 19, 2017	Jan CAHN
AB			160MG	A207803	002	Dec 19, 2017	Jan CAHN
		@ GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Feb DISC
		@	160MG	A210606	002	Aug 17, 2018	Feb DISC
AB		ORIT LABS LLC	54MG	A209660	001	Feb 11, 2019	Jan NEWA
AB			160MG	A209660	002	Feb 11, 2019	Jan NEWA
	FENOGLIDE						
AB	+	SALIX	40MG	N022118	001	Aug 10, 2007	Mar CAHN
AB		+	120MG	N022118	002	Aug 10, 2007	Mar CAHN
	<u>FENOFIBRIC ACID</u>						
	TABLET;ORAL						
	FIBRICOR						
	+	ATHENA	35MG	N022418	001	Aug 14, 2009	Feb CAHN
		+	105MG	N022418	002	Aug 14, 2009	Feb CAHN
	<u>FENOPROFEN CALCIUM</u>						
	TABLET;ORAL						
	FENOPROFEN CALCIUM						
		@ ANI PHARMS INC	EQ 600MG BASE	A072274	001	May 02, 1988	May CAHN
	<u>FENTANYL CITRATE</u>						
	INJECTABLE;INJECTION						
	FENTANYL CITRATE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762	001	May 03, 2019	Apr NEWA
	<u>FERRIC CARBOXYMALTOSE</u>						
	INJECTABLE;INTRAVENOUS						
	INJECTAFER						
>A>	+	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jun CAHN
>D>	+	LUITPOLD	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jun CAHN
	<u>FINAFLOXACIN</u>						
	SUSPENSION/DROPS;OTIC						
	XTORO						
	+	@ MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014	Apr DISC

FLOXURIDINEINJECTABLE; INJECTION
FLOXURIDINE

@ LUITPOLD 500MG/VIAL A203008 001 Nov 22, 2017 Mar DISC

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

@ DR REDDYS 200MG/100ML (2MG/ML) A076653 001 Jul 29, 2004 May CAHN

@ 400MG/200ML (2MG/ML) A076653 002 Jul 29, 2004 May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ DR REDDYS 200MG/100ML (2MG/ML) A076837 001 Jan 13, 2005 May CAHN

@ 400MG/200ML (2MG/ML) A076837 002 Jan 13, 2005 May CAHN

TABLET; ORAL

FLUCONAZOLE

>D> AB APOTEX 50MG A076665 001 Jul 29, 2004 Jun CAHN

>D> AB 100MG A076665 002 Jul 29, 2004 Jun CAHN

>D> AB 150MG A076665 003 Jul 29, 2004 Jun CAHN

>D> AB 200MG A076665 004 Jul 29, 2004 Jun CAHN

>A> AB CHARTWELL 50MG A076665 001 Jul 29, 2004 Jun CAHN

>A> AB 100MG A076665 002 Jul 29, 2004 Jun CAHN

>A> AB 150MG A076665 003 Jul 29, 2004 Jun CAHN

>A> AB 200MG A076665 004 Jul 29, 2004 Jun CAHN

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

AB + BAUSCH 250MG N017001 001 Feb CAHN

AB +! 500MG N017001 002 Feb CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP DECATUR 20-300mCi/ML A204463 001 Oct 21, 2014 Apr CAHN

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

@ DR REDDYS 0.5MG/5ML (0.1MG/ML) A076589 002 Oct 12, 2004 May CAHN

@ 1MG/10ML (0.1MG/ML) A076589 001 Oct 12, 2004 May CAHN

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

>D> @ APOTEX INC 0.029MG/SPRAY A077436 001 Aug 09, 2007 Jun CMFD

>A> 0.029MG/SPRAY A077436 001 Aug 09, 2007 Jun CMFD

>A> AB 0.029MG/SPRAY A077436 001 Aug 09, 2007 Jun CMFD

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

@ ACTAVIS LABS UT INC 0.01% A208386 001 Oct 21, 2016 Mar DISC

AT ENCUBE ETHICALS 0.01% A209913 001 Feb 13, 2019 Jan NEWA

AT GLASSHOUSE PHARMS 0.01% A209596 001 Dec 26, 2017 Jan CMFD

AT LUPIN 0.01% A206422 001 Sep 02, 2015 Feb CAHN

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

@ AMNEAL PHARMS LLC 0.05% A210554 001 Aug 21, 2018 Feb DISC

AB TELIGENT PHARMA INC 0.1% A211758 001 Apr 03, 2019 Mar NEWA

SOLUTION; TOPICAL

FLUOCINONIDE

AT TELIGENT PHARMA INC 0.05% A207554 001 Mar 18, 2019 Mar NEWA

FLUOROMETHOLONESUSPENSION/DROPS;OPHTHALMIC
FML FORTE

>D>	ALLERGAN	0.25%	N019216	001	Apr 23, 1986	Jun	CRLD
>A>	+!	0.25%	N019216	001	Apr 23, 1986	Jun	CHRS
>A>	+	0.25%	N019216	001	Apr 23, 1986	Jun	CRLD

FLUOROMETHOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
FLAREX

+!	EYEVANCE	0.1%	N019079	001	Feb 11, 1986	Feb	CAHN
----	----------	------	---------	-----	--------------	-----	------

FLUOROMETHOLONE ACETATE; TOBRAMYCINSUSPENSION/DROPS;OPHTHALMIC
TOBRASONE

@	EYEVANCE	0.1%;0.3%	N050628	001	Jul 21, 1989	May	CAHN
---	----------	-----------	---------	-----	--------------	-----	------

FLUOROURACILCREAM;TOPICAL
FLUOROPLEX

+!	ALMIRALL	1%	N016988	001		Feb	CAHN
----	----------	----	---------	-----	--	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

>A>	AB1	APNAR PHARMA LP	EQ 10MG BASE	A075049	001	Aug 02, 2001	Jun	CAHN
>A>	AB1		EQ 20MG BASE	A075049	002	Jan 29, 2002	Jun	CAHN
>A>	AB		EQ 40MG BASE	A075049	003	Jan 29, 2002	Jun	CAHN
		@ BEXIMCO PHARMS USA	EQ 10MG BASE	A075807	001	Jan 29, 2002	Feb	CAHN
		@	EQ 20MG BASE	A075807	002	Jan 29, 2002	Feb	CAHN
	AB1	CADILA PHARMS LTD	EQ 10MG BASE	A206993	001	May 23, 2019	May	NEWA
	AB1		EQ 20MG BASE	A206993	002	May 23, 2019	May	NEWA
	AB		EQ 40MG BASE	A206993	003	May 23, 2019	May	NEWA
		@ PAR PHARM	EQ 40MG BASE	A076922	003	Dec 16, 2004	Mar	DISC
>D>	AB1	SANDOZ	EQ 10MG BASE	A075049	001	Aug 02, 2001	Jun	CAHN
>D>	AB1		EQ 20MG BASE	A075049	002	Jan 29, 2002	Jun	CAHN
>D>	AB		EQ 40MG BASE	A075049	003	Jan 29, 2002	Jun	CAHN

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

		@ BARR	EQ 90MG BASE	A076237	001	Mar 24, 2010	Apr	DISC
		! DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr	CTEC
AB		!	EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr	CHRS
		PROZAC WEEKLY						
		+ @ LILLY	EQ 90MG BASE	N021235	001	Feb 26, 2001	Apr	DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

@	NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	May	CAHN
---	------------------	------------------	---------	-----	--------------	-----	------

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

	AB	APPCO PHARMA LLC	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jan	NEWA
	AB		EQ 20MG BASE	A211696	002	Jan 30, 2019	Jan	NEWA
	AB	DR REDDYS LABS LTD	EQ 60MG BASE	A211721	001	Jan 25, 2019	Jan	NEWA
>A>	AB	G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Jun	NEWA
	AB	LUPIN LTD	EQ 10MG BASE	A211653	001	Apr 15, 2019	Apr	NEWA
	AB		EQ 20MG BASE	A211653	002	Apr 15, 2019	Apr	NEWA
	AB		EQ 60MG BASE	A211632	001	Feb 08, 2019	Feb	NEWA
	AB	SCIEGEN PHARMS INC	EQ 10MG BASE	A210935	001	Mar 20, 2019	Mar	NEWA
	AB		EQ 20MG BASE	A210935	002	Mar 20, 2019	Mar	NEWA
	AB	UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May	CAHN
	AB		EQ 20MG BASE	A211696	002	Jan 30, 2019	May	CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	!	LANNETT CO INC	10MG	A089743	001	Aug 25, 1988	May	CHRS
AB		MYLAN	10MG	A089804	001	Aug 12, 1988	May	CHRS

FLURANDRENOLIDE

	CREAM; TOPICAL							
	CORDRAN SP							
	+! ALMIRALL	0.025%		N012806	003			Feb CAHN
AT	+!	0.05%		N012806	002			Feb CAHN
	LOTION; TOPICAL							
	CORDRAN							
AT	+! ALMIRALL	0.05%		N013790	001			Feb CAHN
	OINTMENT; TOPICAL							
	CORDRAN							
	+ @ ALMIRALL	0.025%		N012806	004			Feb CAHN
AT	+!	0.05%		N012806	001			Feb CAHN
	TAPE; TOPICAL							
	CORDRAN							
	+! ALMIRALL	0.004MG/SQ CM		N016455	001			Feb CAHN

FLUTAMIDE

	CAPSULE; ORAL							
	FLUTAMIDE							
	@ ACTAVIS LABS FL INC	125MG		A075820	001	Sep 18, 2001		Apr DISC

FLUTICASONE PROPIONATE

	CREAM; TOPICAL							
	FLUTICASONE PROPIONATE							
AB	! PERRIGO ISRAEL	0.05%		A076793	001	May 14, 2004		May CAHN

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

	POWDER; INHALATION							
	ADVAIR DISKUS 100/50							
AB	+! GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH		N021077	001	Aug 24, 2000		Jan CFTG
	ADVAIR DISKUS 250/50							
AB	+! GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH		N021077	002	Aug 24, 2000		Jan CFTG
	ADVAIR DISKUS 500/50							
AB	+! GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH		N021077	003	Aug 24, 2000		Jan CFTG
	WIXELA INHUB							
AB	MYLAN	0.1MG/INH;EQ 0.05MG BASE/INH		A208891	001	Jan 30, 2019		Jan NFTG
AB		0.25MG/INH;EQ 0.05MG BASE/INH		A208891	002	Jan 30, 2019		Jan NFTG
AB		0.5MG/INH;EQ 0.05MG BASE/INH		A208891	003	Jan 30, 2019		Jan NFTG

FLUVASTATIN SODIUM

	TABLET, EXTENDED RELEASE; ORAL							
	FLUVASTATIN SODIUM							
>D> AB	MYLAN	EQ 80MG BASE		A202458	001	Sep 11, 2015		Jun DISC
>A>	@	EQ 80MG BASE		A202458	001	Sep 11, 2015		Jun DISC

FLUVOXAMINE MALEATE

	TABLET; ORAL							
	FLUVOXAMINE MALEATE							
	@ MYLAN	25MG		A075889	001	Nov 29, 2000		May DISC
	@	50MG		A075889	002	Nov 29, 2000		May DISC
	@	100MG		A075889	003	Nov 29, 2000		May DISC

FOLIC ACID

	TABLET; ORAL							
	FOLIC ACID							
AA	INVATECH PHARMA	1MG		A211064	001	Mar 08, 2019		Feb NEWA
AA	QINGDAO BAHEAL PHARM	1MG		A091145	001	Jul 12, 2013		May CAHN

FOMEPIZOLE

	INJECTABLE; INJECTION							
	ANTIZOL							
>D> AP	+! PAR PHARM INC	1.5GM/1.5ML (1GM/ML)		N020696	001	Dec 04, 1997		Jun DISC
>A>	+ @	1.5GM/1.5ML (1GM/ML)		N020696	001	Dec 04, 1997		Jun DISC
	FOMEPIZOLE							
>D> AP	MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)		A078639	001	Mar 03, 2008		Jun CHRS
>A> AP	!	1.5GM/1.5ML (1GM/ML)		A078639	001	Mar 03, 2008		Jun CHRS

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC	10MG;12.5MG	A 076608	001	Dec 03, 2004	May	CAHN
@	20MG;12.5MG	A 076608	002	Dec 03, 2004	May	CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A 076886	001	Aug 06, 2007	May	CAHN
@ LUITPOLD	EQ 50MG PHENYTOIN NA/ML	A 078277	001	Aug 06, 2007	Feb	DISC
@	EQ 50MG PHENYTOIN NA/ML	A 090099	001	May 13, 2010	Feb	DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

@ AMNEAL PHARMS CO	EQ 2.5MG BASE	A 211292	001	Nov 06, 2018	May	DISC
--------------------	---------------	----------	-----	--------------	-----	------

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

AO	+	ASTRAZENECA	50MG/ML	N 021344	001	Apr 25, 2002	Apr	CMS1
AP	+		50MG/ML	N 021344	001	Apr 25, 2002	Feb	CFTG

FULVESTRANT

AO		AMNEAL PHARMS CO	50MG/ML	A 210044	001	Mar 04, 2019	Apr	CMS1
AP			50MG/ML	A 210044	001	Mar 04, 2019	Feb	NFTG
AO		SANDOZ INC	50MG/ML	A 205935	001	May 14, 2019	Apr	NEWA

SOLUTION; INTRAMUSCULAR

FULVESTRANT

		FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N 210326	001	May 20, 2019	May	NEWA
--	--	--------------------	---------------------	----------	-----	--------------	-----	------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP		AUROBINDO PHARMA LTD	10MG/ML	A 212174	001	May 03, 2019	Apr	NEWA
----	--	----------------------	---------	----------	-----	--------------	-----	------

TABLET; ORAL

FUROSEMIDE

AB		HERITAGE PHARMA	20MG	N 018413	001	Nov 30, 1983	Feb	CAHN
AB			40MG	N 018413	002	Nov 30, 1983	Feb	CAHN
AB		HIKMA	20MG	N 018823	001	Nov 10, 1983	Apr	CAHN
AB			40MG	N 018823	002	Nov 10, 1983	Apr	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

>D>	AB	APOTEX INC	100MG	A 075360	001	Apr 06, 2005	Jun	CAHN
>D>	AB		300MG	A 075360	002	Apr 06, 2005	Jun	CAHN
>D>	AB		400MG	A 075360	003	Apr 06, 2005	Jun	CAHN
>A>	AB	GRANULES INDIA LTD	100MG	A 075360	001	Apr 06, 2005	Jun	CAHN
>A>	AB		300MG	A 075360	002	Apr 06, 2005	Jun	CAHN
>A>	AB		400MG	A 075360	003	Apr 06, 2005	Jun	CAHN

TABLET; ORAL

GABAPENTIN

@ LUPIN LTD	600MG	A 209306	001	Aug 24, 2018	Mar	DISC
@	800MG	A 209306	002	Aug 24, 2018	Mar	DISC

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

@ HERITAGE PHARMA	EQ 4MG BASE	A 077585	001	Sep 15, 2009	May	CAHN
AB	EQ 4MG BASE	A 077587	001	Jul 09, 2009	May	CAHN
@	EQ 8MG BASE	A 077585	002	Sep 15, 2009	May	CAHN
AB	EQ 8MG BASE	A 077587	002	Jul 09, 2009	May	CAHN
@	EQ 12MG BASE	A 077585	003	Sep 15, 2009	May	CAHN
AB	EQ 12MG BASE	A 077587	003	Jul 09, 2009	May	CAHN

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

BS CURIUM 2mCi/ML N018058 001 Jan CAHN

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
GANCICLOVIR

@ LUITPOLD EQ 500MG BASE/VIAL

A202624 001 Sep 18, 2013 Feb DISC

GANCICLOVIR SODIUM

>A> AP CUSTOPHARM INC EQ 500MG BASE/VIAL

A212001 001 Jun 20, 2019 Jun NEWA

GANIRELIX ACETATE

INJECTABLE; INJECTION
GANIRELIX ACETATE

AP +! ORGANON USA INC 250MCG/0.5ML

N021057 001 Jul 29, 1999 Mar CPOT

AP SUN PHARM 250MCG/0.5ML

A204246 001 Nov 30, 2018 Mar CPOT

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP FRESENIUS KABI USA EQ 200MG BASE/VIAL

A090799 001 Jul 25, 2011 Jan CAHN

AP EQ 1GM BASE/VIAL

A090799 002 Jul 25, 2011 Jan CAHN

AP EQ 2GM BASE/VIAL

A090799 003 May 16, 2011 Jan CAHN

AP INGENUS PHARMS LLC 200MG/5.26ML (38MG/ML)

A210383 001 Feb 14, 2019 Feb NEWA

AP 1GM/26.3ML (38MG/ML)

A210383 002 Feb 14, 2019 Feb NEWA

AP 2GM/52.6ML (38MG/ML)

A210383 003 Feb 14, 2019 Feb NEWA

@ LUITPOLD EQ 200MG BASE/VIAL

A202031 001 May 07, 2013 Feb DISC

@ EQ 1GM BASE/VIAL

A202031 002 May 07, 2013 Feb DISC

AP SHILPA MEDICARE LTD EQ 200MG BASE/VIAL

A207575 001 Feb 22, 2019 Feb NEWA

AP EQ 1GM BASE/VIAL

A207575 002 Feb 22, 2019 Feb NEWA

GLASDEGIB MALEATE

TABLET; ORAL
DAURISMO

+ PFIZER INC EQ 25MG BASE

N210656 001 Nov 21, 2018 Feb CAIN

+! EQ 100MG BASE

N210656 002 Nov 21, 2018 Feb CAIN

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

AB MICRO LABS 1MG

A091220 001 Jun 29, 2012 Mar CAHN

AB 2MG

A091220 002 Jun 29, 2012 Mar CAHN

AB 3MG

A091220 003 Jun 29, 2012 Mar CAHN

AB 4MG

A091220 004 Jun 29, 2012 Mar CAHN

AB 6MG

A091220 005 Jun 29, 2012 Mar CAHN

AB 8MG

A091220 006 Jun 29, 2012 Mar CAHN

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

@ BEXIMCO PHARMS USA 5MG

A074542 001 Jun 20, 1995 Feb CAHN

@ 10MG

A074542 002 Jun 20, 1995 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

@ MYLAN 2.5MG

A202298 001 May 19, 2015 Feb DISC

@ 5MG

A202298 002 May 19, 2015 Feb DISC

@ 10MG

A202298 003 May 19, 2015 Feb DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

@ MYLAN 2.5MG; 250MG

A078083 001 Apr 12, 2007 Apr DISC

GLYBURIDE

TABLET; ORAL
GLYBURIDE

AB1 ORIENT PHARMA CO LTD 1.25MG

A206483 001 Feb 22, 2019 Feb NEWA

AB1 2.5MG

A206483 002 Feb 22, 2019 Feb NEWA

AB1 5MG

A206483 003 Feb 22, 2019 Feb NEWA

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+! HORIZON THERAP 1.1GM/ML N203284 001 Feb 01, 2013 Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP CAPLIN 0.2MG/ML A211705 001 Mar 20, 2019 Mar NEWA
 >D> AP PIRAMAL CRITICAL 0.2MG/ML A210842 001 Oct 25, 2018 Jun CAHN
 >A> AP 0.2MG/ML A210842 001 Oct 25, 2018 Jun CAHN
 AP SANDOZ INC 0.2MG/ML A211334 001 May 14, 2019 Apr NEWA

TABLET; ORAL

GLYCOPYRROLATE

AA AUROLIFE PHARMA LLC 2MG A202675 002 Oct 30, 2018 May NEWA
 AA KENTON 1MG A091182 001 Feb 03, 2014 Mar CAHN
 AA 2MG A091182 002 Feb 03, 2014 Mar CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP BIONPHARMA INC EQ 0.1MG BASE/ML (EQ 0.1MG A078863 001 Jun 30, 2008 Apr CAHN
 BASE/ML)
 AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078880 001 Jun 30, 2008 Apr CAHN
 AP ! DR REDDYS EQ 0.1MG BASE/ML (EQ 0.1MG A078392 001 Dec 31, 2007 May CAHN
 BASE/ML)
 AP ! EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077297 001 Jun 30, 2008 May CAHN
 @ LUITPOLD EQ 1MG BASE/ML (EQ 1MG BASE/ML) A091274 001 Sep 22, 2010 Feb DISC
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE
 AP BIONPHARMA INC EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078863 002 Jun 30, 2008 Apr CAHN
 @ DR REDDYS EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077165 001 Dec 31, 2007 May CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

@ TEVA PHARMS EQ 1MG BASE A078080 001 Dec 31, 2007 Jan DISC
 AB ! WEST-WARD PHARMS INT EQ 1MG BASE A077842 001 Dec 31, 2007 Jan CHRS

GUAIFENESIN; HYDROCODONE BITARTRATE

>D> SOLUTION; ORAL

>D> OBREDON

>D> +! SOVEREIGN PHARMS 200MG/5ML; 2.5MG/5ML N205474 001 Nov 14, 2014 Jun DISC
 >A> + @ 200MG/5ML; 2.5MG/5ML N205474 001 Nov 14, 2014 Jun DISC

>D> TABLET; ORAL

>D> XTRELUS

>D> +! ECI PHARMS LLC 400MG; 5MG N208085 001 Apr 25, 2018 Jun DISC
 >A> + @ 400MG; 5MG N208085 001 Apr 25, 2018 Jun DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB EPIC PHARMA LLC EQ 1MG BASE A074673 001 Feb 28, 1997 Apr CMFD
 AB EQ 2MG BASE A074673 002 Feb 28, 1997 Apr CMFD

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

@ MYLAN EQ 1MG BASE A202578 001 Jun 02, 2015 May DISC
 @ EQ 2MG BASE A202578 002 Jun 02, 2015 May DISC
 @ EQ 3MG BASE A202578 003 Jun 02, 2015 May DISC
 @ EQ 4MG BASE A202578 004 Jun 02, 2015 May DISC

HALOBETASOL PROPIONATE

LOTION; TOPICAL

BRYHALI

+! BAUSCH 0.01% N209355 001 Nov 06, 2018 Apr CAHN
 +! DOW PHARM 0.01% N209355 001 Nov 06, 2018 Jan CHRS
 + 0.01% N209355 001 Nov 06, 2018 Jan CRLD

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION; TOPICAL

DUOBRII

+! BAUSCH 0.01%; 0.045% N209354 001 Apr 25, 2019 Apr NEWA

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL							
	@ INNOGENIX	0.5MG	A 071173	002	Jan 02, 1987	May	CMS1
	@	1MG	A 071173	003	Jan 02, 1987	May	CMS1
	@	2MG	A 071173	004	Jan 02, 1987	May	CMS1
	@	5MG	A 071173	005	Jan 07, 1988	May	CMS1
	@	10MG	A 071173	001	Jan 07, 1988	Mar	CAHN
	@	20MG	A 071173	006	Jan 07, 1988	May	CMS1
	! MYLAN	2MG	A 070278	001	Jun 10, 1986	Jan	CTEC
AB	!	2MG	A 070278	001	Jun 10, 1986	Jan	CHRS
	@ SANDOZ	2MG	A 071208	001	Nov 17, 1986	Jan	DISC

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL							
AA	! PHARM ASSOC	EQ 2MG BASE/ML	A 073037	001	Feb 26, 1993	May	CHRS
	@ TEVA PHARMS	EQ 2MG BASE/ML	A 071617	001	Dec 01, 1988	May	DISC

INJECTABLE; INJECTION

HALOPERIDOL								
>A>	AP	FRESENIUS KABI USA	EQ 5MG BASE/ML	A 210356	001	Jul 01, 2019	Jun	NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM							
AP	+! HIKMA	1,000 UNITS/ML	N 017037	001		Feb	CAHN
AP	+!	5,000 UNITS/ML	N 017037	002		Feb	CAHN
	@	5,000 UNITS/0.5ML	N 017037	013	Apr 07, 1986	Feb	CAHN
AP	+!	10,000 UNITS/ML	N 017037	003		Feb	CAHN
AP	NANJING KING-FRIEND	1,000 UNITS/ML	A 211007	001	May 28, 2019	May	NEWA
AP		5,000 UNITS/ML	A 211007	002	May 28, 2019	May	NEWA
AP		10,000 UNITS/ML	A 211007	003	May 28, 2019	May	NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN							
>D>	+ @ GENUS LIFESCIENCES	1.5MG/5ML; 5MG/5ML	N 005213	002	Jul 26, 1988	Jun	CMFD
>A>	AA	1.5MG/5ML; 5MG/5ML	N 005213	002	Jul 26, 1988	Jun	CMFD
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE							
AA	BRECKENRIDGE PHARM	1.5MG/5ML; 5MG/5ML	A 210663	001	Jun 11, 2019	May	NEWA
AA	TORRENT	1.5MG/5ML; 5MG/5ML	A 204765	001	Mar 06, 2017	May	CMFD
	@	1.5MG/5ML; 5MG/5ML	A 204765	001	Mar 06, 2017	Jan	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

	@ LUITPOLD	20MG/ML	A 040136	001	Jun 30, 1997	Feb	DISC

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AA	APPCO PHARMA LLC	10MG	A 209251	001	Jul 09, 2018	Jun	CAHN
>D>	AA		25MG	A 209251	002	Jul 09, 2018	Jun	CAHN
>D>	AA		50MG	A 209251	003	Jul 09, 2018	Jun	CAHN
>D>	AA		100MG	A 209251	004	Jul 09, 2018	Jun	CAHN
>A>	AA	UPSHER SMITH LABS	10MG	A 209251	001	Jul 09, 2018	Jun	CAHN
>A>	AA		25MG	A 209251	002	Jul 09, 2018	Jun	CAHN
>A>	AA		50MG	A 209251	003	Jul 09, 2018	Jun	CAHN
>A>	AA		100MG	A 209251	004	Jul 09, 2018	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	HERITAGE PHARMA	12.5MG; 10MG	A 075776	001	Jul 01, 2002	Feb	CAHN
AB		12.5MG; 20MG	A 075776	002	Jul 01, 2002	Feb	CAHN
AB		25MG; 20MG	A 075776	003	Jul 01, 2002	Feb	CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ACCORD HLTHCARE	12.5MG; 20MG	A 209281	001	Feb 07, 2019	Jan	NEWA
AB		12.5MG; 40MG	A 209281	002	Feb 07, 2019	Jan	NEWA
AB		25MG; 40MG	A 209281	003	Feb 07, 2019	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

		QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
	@ MYLAN	12.5MG;EQ	10MG BASE	A077093	001	Mar 28,	2005	May	DISC
	@	12.5MG;EQ	20MG BASE	A077093	002	Mar 28,	2005	May	DISC
	@	25MG;EQ	20MG BASE	A077093	003	Mar 28,	2005	May	DISC
		QUINARETIC							
AB	LUPIN	12.5MG;EQ	10MG BASE	A076374	001	Mar 31,	2004	Feb	CAHN
AB		12.5MG;EQ	20MG BASE	A076374	002	Mar 31,	2004	Feb	CAHN
AB		25MG;EQ	20MG BASE	A076374	003	Mar 31,	2004	Feb	CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

		TELMISARTAN AND HYDROCHLOROTHIAZIDE							
AB	GLENMARK PHARMS LTD	12.5MG;	40MG	A202544	001	Mar 04,	2019	Feb	NEWA
AB		12.5MG;	80MG	A202544	002	Mar 04,	2019	Feb	NEWA
AB		25MG;	80MG	A202544	003	Mar 04,	2019	Feb	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

		TRIAMTERENE AND HYDROCHLOROTHIAZIDE							
>D>	AB	ANI PHARMS INC	25MG;50MG	A074259	001	Mar 30,	1995	Jun	DISC
>A>		@	25MG;50MG	A074259	001	Mar 30,	1995	Jun	DISC
>D>	AB	! CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31,	1991	Jun	DISC
>A>		@	25MG;50MG	A073191	001	Jul 31,	1991	Jun	DISC
	AB	ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11,	2019	Jan	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

		VALSARTAN AND HYDROCHLOROTHIAZIDE							
AB	ZYDUS PHARMS	12.5MG;	80MG	A203000	001	Mar 15,	2019	Mar	NEWA
AB		12.5MG;	160MG	A203000	002	Mar 15,	2019	Mar	NEWA
AB		12.5MG;	320MG	A203000	003	Mar 15,	2019	Mar	NEWA
AB		25MG;	160MG	A203000	004	Mar 15,	2019	Mar	NEWA
AB		25MG;	320MG	A203000	005	Mar 15,	2019	Mar	NEWA

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+	!	PERSION	10MG	N202880	001	Oct 25,	2013	Apr	CAHN
+			15MG	N202880	002	Oct 25,	2013	Apr	CAHN
+			20MG	N202880	003	Oct 25,	2013	Apr	CAHN
+			30MG	N202880	004	Oct 25,	2013	Apr	CAHN
+			40MG	N202880	005	Oct 25,	2013	Apr	CAHN
+			50MG	N202880	006	Oct 25,	2013	Apr	CAHN

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

		HYDROCODONE BITARTRATE AND IBUPROFEN							
	@	ANI PHARMS INC	5MG;200MG	A077454	001	Jun 23,	2010	May	CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

		HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
>D>	AA	MAYNE PHARMA INC	5MG/5ML;60MG/5ML	A205658	001	Nov 17,	2015	Jun	DISC
>A>		@	5MG/5ML;60MG/5ML	A205658	001	Nov 17,	2015	Jun	DISC
>D>	AA	PADDOCK LLC	5MG/5ML;60MG/5ML	A204658	001	Apr 29,	2014	Jun	DISC
>A>		@	5MG/5ML;60MG/5ML	A204658	001	Apr 29,	2014	Jun	DISC
		@	5MG/5ML;60MG/5ML	A206661	001	Jan 23,	2019	Feb	DISC
	AA		5MG/5ML;60MG/5ML	A206661	001	Jan 23,	2019	Jan	NEWA
>D>		REZIRA							
>D>	AA	+! PERSION	5MG/5ML;60MG/5ML	N022442	001	Jun 08,	2011	Jun	DISC
>A>		+ @	5MG/5ML;60MG/5ML	N022442	001	Jun 08,	2011	Jun	DISC
	AA	+!	5MG/5ML;60MG/5ML	N022442	001	Jun 08,	2011	Apr	CAHN

HYDROCORTISONE

CREAM; TOPICAL

NUTRACORT

	@	BAUSCH	0.5%	A080442	002			Feb	CAHN
	@		1%	A080442	003			Feb	CAHN

	LOTION;TOPICAL								
	CETACORT								
	@ BAUSCH	0.5%			A080426	002			Feb CAHN
	@	1%			A080426	001			Feb CAHN
	<u>HYDROCORTISONE BUTYRATE</u>								
	CREAM;TOPICAL								
	LOCOID								
AB1	+! BAUSCH	0.1%			N018514	001	Mar 31, 1982		May CAHN
	LOTION;TOPICAL								
	LOCOID								
AB	+! BAUSCH	0.1%			N022076	001	May 18, 2007		May CAHN
	SOLUTION;TOPICAL								
	LOCOID								
AT	+! BAUSCH	0.1%			N019116	001	Feb 25, 1987		May CAHN
	<u>HYDROCORTISONE VALERATE</u>								
	CREAM;TOPICAL								
	HYDROCORTISONE VALERATE								
AB	PERRIGO ISRAEL	0.2%			A075666	001	May 24, 2000		May CAHN
	<u>HYDROMORPHONE HYDROCHLORIDE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	EXALGO								
	+ @ SPECGX LLC	8MG			N021217	001	Mar 01, 2010		Mar DISC
	+ @	12MG			N021217	002	Mar 01, 2010		Mar DISC
	+ @	16MG			N021217	003	Mar 01, 2010		Mar DISC
	+ @	32MG			N021217	004	Aug 24, 2012		Mar DISC
	HYDROMORPHONE HYDROCHLORIDE								
AB	! OSMOTICA	32MG			A205629	004	Jul 07, 2016		Mar CHRS
	<u>HYDROXYCHLOROQUINE SULFATE</u>								
	TABLET;ORAL								
	HYDROXYCHLOROQUINE SULFATE								
AB	LAURUS LABS LTD	200MG			A210959	001	Jan 15, 2019		Jan CAHN
	@ LUPIN LTD	200MG			A210543	001	Jul 06, 2018		Feb DISC
	<u>HYDROXYPROGESTERONE CAPROATE</u>								
	SOLUTION;INTRAMUSCULAR								
	HYDROXYPROGESTERONE CAPROATE								
AP2	! ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)			A200271	001	Aug 24, 2015		Apr CPOT
AP2	!	250MG/ML (250MG/ML)			A200271	001	Aug 24, 2015		Apr CTEC
AP	EUGIA PHARMA	250MG/ML (250MG/ML)			A211071	001	Apr 16, 2019		Apr NEWA
AP1		1250MG/5ML (250MG/ML)			A211070	001	Apr 16, 2019		Apr NEWA
AP2		1250MG/5ML (250MG/ML)			A211142	001	May 09, 2019		Apr NEWA
AP	SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)			A210877	001	Mar 22, 2019		Mar NEWA
AP1		1250MG/5ML (250MG/ML)			A210618	001	Dec 28, 2018		Apr CTEC
AP1	SUN PHARM	1250MG/5ML (250MG/ML)			A208381	001	Apr 09, 2019		Apr CTEC
AP		1250MG/5ML (250MG/ML)			A208381	001	Apr 09, 2019		Mar NEWA
	MAKENA								
AP1	+! AMAG PHARMA USA	1250MG/5ML (250MG/ML)			N021945	001	Feb 03, 2011		Apr CTEC
	<u>HYDROXYPROPYL CELLULOSE</u>								
	INSERT;OPHTHALMIC								
	LACRISERT								
	+! VALEANT PHARMS INTL	5MG			N018771	001			Jan CAHN
	<u>HYDROXYZINE HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	HYDROXYZINE HYDROCHLORIDE								
	! LUITPOLD	50MG/ML			A087408	002			Mar CMFD
	@	50MG/ML			A087408	002			Feb DISC
	SYRUP;ORAL								
	HYDROXYZINE HYDROCHLORIDE								
AA	TORRENT	10MG/5ML			A210634	001	Feb 26, 2019		Feb NEWA
	<u>HYDROXYZINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	HYDROXYZINE HYDROCHLORIDE								
AB	EPIC PHARMA LLC	10MG			A040604	002	Dec 28, 2004		Jan CAHN
AB		25MG			A040604	003	Dec 28, 2004		Jan CAHN
AB		50MG			A040604	001	Dec 28, 2004		Jan CAHN
AB	KVK TECH	25MG			A040786	002	Mar 20, 2007		Feb CMS1

	TABLET;ORAL							
	HYDROXYZINE HYDROCHLORIDE							
AB		50MG	A040786	003	Mar 20, 2007	Feb	CMS1	
	<u>HYDROXYZINE PAMOATE</u>							
	CAPSULE;ORAL							
	HYDROXYZINE PAMOATE							
	@ BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991	Feb	CAHN	
	<u>IBUPROFEN</u>							
	SOLUTION;INTRAVENOUS							
	CALDOLOR							
	+!	CUMBERLAND PHARMS	800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019	Jan	NEWA
	SUSPENSION;ORAL							
	IBUPROFEN							
AB	L PERRIGO CO	100MG/5ML	A076925	001	Sep 23, 2004	May	CAHN	
	TABLET;ORAL							
	IBUPROFEN							
	@ HEC PHARM	400MG	A204062	001	Sep 10, 2018	Mar	DISC	
	@	600MG	A204062	002	Sep 10, 2018	Mar	DISC	
	@	800MG	A204062	003	Sep 10, 2018	Mar	DISC	
AB	PERRIGO PHARMS CO	400MG	A077114	001	Jul 18, 2005	May	CAHN	
AB		600MG	A077114	002	Jul 18, 2005	May	CAHN	
AB		800MG	A077114	003	Jul 18, 2005	May	CAHN	
	<u>IBUTILIDE FUMARATE</u>							
	INJECTABLE;INJECTION							
	IBUTILIDE FUMARATE							
	@ LUITPOLD	0.1MG/ML	A090240	001	Jan 11, 2010	Feb	DISC	
	<u>IMATINIB MESYLATE</u>							
	TABLET;ORAL							
	IMATINIB MESYLATE							
AB	AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019	Feb	NEWA	
AB		EQ 400MG BASE	A207495	002	Feb 08, 2019	Feb	NEWA	
AB	BRECKENRIDGE PHARM	EQ 100MG BASE	A205990	001	Feb 08, 2019	Feb	NEWA	
AB		EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb	NEWA	
AB	NATCO PHARMA LTD	EQ 100MG BASE	A207818	001	Mar 01, 2019	Feb	NEWA	
AB		EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb	NEWA	
AB	SHILPA MEDICARE LTD	EQ 100MG BASE	A208302	001	Jan 17, 2019	Jan	NEWA	
AB		EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan	NEWA	
AB	WOCKHARDT BIO AG	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan	NEWA	
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan	NEWA	
	<u>IMIPRAMINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	IMIPRAMINE HYDROCHLORIDE							
	@ OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar	DISC	
	@	25MG	A040751	002	Feb 28, 2008	Mar	DISC	
	<u>INDIUM IN-111 CHLORIDE</u>							
	INJECTABLE;INJECTION							
>D>	INDICLOR							
>D>	+!	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992	Jun	DISC
>A>	+ @		2mCi/0.2ML	N019862	001	Dec 29, 1992	Jun	DISC
	INDIUM IN 111 CHLORIDE							
	+!	CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan	CAHN
	<u>INDIUM IN-111 PENTETREOTIDE KIT</u>							
	INJECTABLE;INJECTION							
	OCTREOSCAN							
	+!	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jan	CAHN
	<u>INDOMETHACIN</u>							
	CAPSULE;ORAL							
	INDOCIN							
	+ @	EGALET	25MG	N016059	001		Feb	CAHN
	+ @		50MG	N016059	002		Feb	CAHN
	INDOMETHACIN							
	@ ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987	May	CAHN	
	@	50MG	A071149	001	Mar 18, 1987	May	CAHN	
AB	CADILA	25MG	A090403	001	Nov 15, 2010	May	CAHN	

	CAPSULE;ORAL								
	INDOMETHACIN								
AB		50MG	A090403	002	Nov 15, 2010	May	CAHN		
AB	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Feb	CAHN		
AB		50MG	A070756	001	Feb 12, 1986	Feb	CAHN		
	TIVORBEX								
+	EGALET	20MG	N204768	001	Feb 24, 2014	Feb	CAHN		
+	!	40MG	N204768	002	Feb 24, 2014	Feb	CAHN		
	CAPSULE, EXTENDED RELEASE;ORAL								
	INDOCIN SR								
+	@ EGALET	75MG	N018185	001	Feb 23, 1982	Feb	CAHN		
	SUPPOSITORY;RECTAL								
	INDOCIN								
+	@ EGALET	50MG	N017814	001	Aug 13, 1984	Feb	CAHN		
	SUSPENSION;ORAL								
	INDOCIN								
+	!	EGALET	25MG/5ML	N018332	001	Oct 10, 1985	Feb	CAHN	
	<u>INSULIN ASPART</u>								
	SOLUTION;SUBCUTANEOUS								
>A>	FIASP PENFILL								
>A>	+	!	NOVO	300 UNITS/3ML (100 UNITS/ML)	N208751	003	Sep 24, 2018	Jun	NEWA
>D>	<u>INSULIN ASPART; INSULIN DEGLUDEC</u>								
>D>	SOLUTION;SUBCUTANEOUS								
>D>	RYZODEG 70/30								
>D>	+	!	NOVO	90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)	N203313	001	Sep 25, 2015	Jun	DISC
>A>	+	@		90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)	N203313	001	Sep 25, 2015	Jun	DISC
	<u>INSULIN DEGLUDEC</u>								
	SOLUTION;SUBCUTANEOUS								
	TRESIBA								
>A>		NOVO	1000 UNITS/10ML (100 UNITS/ML)	N203314	003	Nov 21, 2018	Jun	NEWA	
	<u>INSULIN HUMAN</u>								
	SOLUTION;INTRAVENOUS								
>A>	MYXREDLIN								
>A>	+	!	CELERITY PHARMS	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019	Jun	NEWA
	<u>IOPROMIDE</u>								
	INJECTABLE;INJECTION								
	ULTRAVIST (PHARMACY BULK)								
+	!	BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004	Apr	CMFD	
+	@		49.9%	N021425	003	Mar 12, 2004	Feb	DISC	
	ULTRAVIST 240								
+	!	BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995	Apr	CMFD	
+	@		49.9%	N020220	003	May 10, 1995	Feb	DISC	
	<u>IOTHALAMATE MEGLUMINE</u>								
	INJECTABLE;INJECTION								
>D>	CONRAY 43								
>D>	+	!	LIEBEL-FLARSHEIM	43%	N013295	002		Jun	DISC
>A>	+	@		43%	N013295	002		Jun	DISC
	<u>IPRATROPIUM BROMIDE</u>								
	SPRAY, METERED;NASAL								
	IPRATROPIUM BROMIDE								
	@	MYLAN SPECIALITY LP	0.021MG/SPRAY	A075552	001	Mar 31, 2003	Mar	DISC	
	@		0.042MG/SPRAY	A075553	001	Mar 31, 2003	Mar	DISC	
	<u>IRINOTECAN HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	IRINOTECAN HYDROCHLORIDE								
AP	FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008	Jan	CAHN		
AP		100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008	Jan	CAHN		

IRON DEXTRANINJECTABLE; INJECTION
DEXFERRUM

@ LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	Mar DISC
PROFERDEX					
@ NEW RIVER	EQ 50MG IRON/ML	N017807	001		Mar DISC

IRON SUCROSEINJECTABLE; INTRAVENOUS
VENOFER

+ AM REGENT	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr CAHN
@	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Apr CAHN
@	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005	Apr CAHN
+!	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000	Apr CAHN
+	EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007	Apr CAHN

ISOPROPYL ALCOHOLSOLUTION; TOPICAL
ZURAGARD

+! ZUREX PHARMA	70% (10.5ML)	N210872	001	Apr 26, 2019	Apr NEWA
-----------------	--------------	---------	-----	--------------	----------

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

>A> AP	CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019	Jun NEWA
AP	+! BAUSCH	0.2MG/ML	N010515	001		Mar CAHN

ISOSORBIDE DINITRATETABLET; ORAL
ISORDIL

AB	+ BAUSCH	5MG	N012093	007	Jul 29, 1988	Mar CAHN
	+ @	10MG	N012093	002	Jul 29, 1988	Mar CAHN
	+ @	20MG	N012093	006	Jul 29, 1988	Mar CAHN
	+ @	30MG	N012093	005	Jul 29, 1988	Mar CAHN
	+!	40MG	N012093	001	Jul 29, 1988	Mar CAHN

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

AB	HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Mar CAHN
AB		60MG	A076813	001	Jan 07, 2005	Mar CAHN

ITRACONAZOLECAPSULE; ORAL
ITRACONAZOLE

>A> AB	PII	100MG	A206410	001	Jul 02, 2019	Jun NEWA
--------	-----	-------	---------	-----	--------------	----------

IVABRADINESOLUTION; ORAL
CORLANOR

+! AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Apr NEWA
--------------	------------------	---------	-----	--------------	----------

IVACAFTORGRANULE; ORAL
KALYDECO

+ VERTEX PHARMS INC	25MG/PACKET	N207925	003	Apr 29, 2019	May NEWA
+ VERTEX PHARMS	75MG	N203188	002	May 20, 2019	May NEWA

KETOCONAZOLE

	GEL;TOPICAL								
	XOLEGEL								
	+! ALMIRALL	2%		N021946	001	Jul 28, 2006	Feb	CAHN	
	SHAMPOO;TOPICAL								
	KETOCONAZOLE								
AB	PERRIGO ISRAEL	2%		A076419	001	Jan 07, 2004	May	CAHN	
	TABLET;ORAL								
	KETOCONAZOLE								
	@ HERITAGE PHARMA	200MG		A074971	001	Jun 15, 1999	May	CAHN	
	@	200MG		A075362	001	Jun 15, 1999	May	CAHN	
AB	! TARO	200MG		A075319	001	Jun 15, 1999	Apr	CHRS	
	@ TEVA	200MG		A075273	001	Jun 15, 1999	Apr	DISC	

KETOROLAC TROMETHAMINE

	INJECTABLE;INJECTION								
	KETOROLAC TROMETHAMINE								
AP	WEST-WARD PHARMS INT	15MG/ML		A075772	001	Jul 21, 2004	Feb	CMFD	
AP		30MG/ML		A075772	002	Jul 21, 2004	Feb	CMFD	
	SOLUTION/DROPS;OPHTHALMIC								
	KETOROLAC TROMETHAMINE								
	@ AUROBINDO PHARMA LTD	0.4%		A205191	001	Nov 15, 2018	May	DISC	
AT	MICRO LABS LTD INDIA	0.5%		A203410	001	Apr 05, 2019	Mar	NEWA	
	@ SANDOZ INC	0.4%		A078721	001	Nov 05, 2009	May	DISC	

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION;IRRIGATION								
>A>	KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE								
>A> AT	LUPIN LTD	EQ 0.3% BASE;EQ 1% BASE		A210183	001	Jul 01, 2019	Jun	NFTG	
	OMIDRIA								
>D>	+! OMEROS	EQ 0.3% BASE;EQ 1% BASE		N205388	001	May 30, 2014	Jun	CFTG	
>A> AT	+!	EQ 0.3% BASE;EQ 1% BASE		N205388	001	May 30, 2014	Jun	CFTG	

L-GLUTAMINE

	FOR SOLUTION;ORAL								
	NUTRESTORE								
>D>	+! EMMAUS MEDCL	5GM/PACKET		N021667	001	Jun 10, 2004	Jun	DISC	
>A>	+ @	5GM/PACKET		N021667	001	Jun 10, 2004	Jun	DISC	

LABETALOL HYDROCHLORIDE

	TABLET;ORAL								
	LABETALOL HYDROCHLORIDE								
AB	CADILA PHARMS LTD	100MG		A211325	001	May 13, 2019	Apr	NEWA	
AB		200MG		A211325	002	May 13, 2019	Apr	NEWA	
AB		300MG		A211325	003	May 13, 2019	Apr	NEWA	
AB	HERITAGE PHARMA	100MG		A074787	001	Aug 03, 1998	Feb	CAHN	
AB		200MG		A074787	002	Aug 03, 1998	Feb	CAHN	
AB		300MG		A074787	003	Aug 03, 1998	Feb	CAHN	
AB	INVATECH PHARMA	100MG		A207863	001	Feb 04, 2019	Jan	NEWA	
AB		200MG		A207863	002	Feb 04, 2019	Jan	NEWA	
AB		300MG		A207863	003	Feb 04, 2019	Jan	NEWA	
	TRANDATE								
AB	+ CNTY LINE PHARMS	100MG		N018716	001	May 24, 1985	Jan	CRLD	
AB	+	200MG		N018716	002	Aug 01, 1984	Jan	CRLD	
AB	+	300MG		N018716	003	Aug 01, 1984	Jan	CRLD	

LACTULOSE

	SOLUTION;ORAL								
	LACTULOSE								
	@ BAJAJ	10GM/15ML		A075911	001	Feb 21, 2002	Jan	CAHN	
AA	TORRENT	10GM/15ML		A207786	001	Jun 11, 2018	Jan	CAHN	
	@ XTTRIUM LABS INC	10GM/15ML		A075911	001	Feb 21, 2002	Mar	CAHN	
	SOLUTION;ORAL, RECTAL								
	LACTULOSE								
	@ BAJAJ	10GM/15ML		A076645	001	Jul 28, 2003	Jan	CAHN	
AA	TORRENT	10GM/15ML		A203762	001	Mar 27, 2015	Jan	CAHN	

LAMIVUDINE

TABLET;ORAL		LAMIVUDINE							
AB	ANNORA	100MG		A211306	001	Mar 21, 2019	Mar	NEWA	
AB	MACLEODS PHARMS LTD	150MG		A090198	001	May 01, 2019	Apr	NEWA	
AB		300MG		A090198	002	May 01, 2019	Apr	NEWA	
	@ MYLAN	150MG		A204528	001	Mar 04, 2016	Apr	DISC	
	@	300MG		A204528	002	Mar 04, 2016	Apr	DISC	
AB	MYLAN LABS LTD	150MG		A078545	001	Mar 05, 2019	Feb	NEWA	
AB		300MG		A078545	002	Mar 05, 2019	Feb	NEWA	

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL		LAMIVUDINE AND ZIDOVUDINE							
	@ MYLAN	150MG;300MG		A204005	001	Aug 28, 2014	Jan	DISC	

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL		LAMOTRIGINE							
	@ RUBICON	25MG		A202887	001	Jun 17, 2013	Mar	CAHN	
	@	50MG		A202887	002	Jun 17, 2013	Mar	CAHN	
AB		100MG		A202887	003	Jun 17, 2013	Mar	CAHN	
AB		200MG		A202887	004	Jun 17, 2013	Mar	CAHN	

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL		LANSOPRAZOLE							
AB	ALKEM LABS LTD	15MG		A207394	001	Jan 18, 2019	Jan	NEWA	
AB		30MG		A207394	002	Jan 18, 2019	Jan	NEWA	
	@ BRECKENRIDGE PHARM	15MG		A203964	001	Oct 17, 2018	May	DISC	
	@	30MG		A203964	002	Oct 17, 2018	May	DISC	
	@ KRKA TOVARNA ZDRAVIL	15MG		A091212	001	Sep 16, 2013	Feb	DISC	
	@	30MG		A091212	002	Sep 16, 2013	Feb	DISC	

>D>		<u>LAROTRECTINIB</u>							
>D>		CAPSULE;ORAL							
>D>		VITRAKVI							
>D>	+	BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Jun	CPOT	
	+		25MG	N210861	001	Nov 26, 2018	Feb	CAHN	
>D>	+	!	100MG	N210861	002	Nov 26, 2018	Jun	CPOT	
	+	!	100MG	N210861	002	Nov 26, 2018	Feb	CAHN	
>D>		SOLUTION;ORAL							
>D>		VITRAKVI							
>D>	+	BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Jun	CPOT	
	+		20MG/ML	N211710	001	Nov 26, 2018	Feb	CAHN	

>A>		<u>LAROTRECTINIB SULFATE</u>							
>A>		CAPSULE;ORAL							
>A>		VITRAKVI							
>A>	+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun	CAIN	
>A>	+		EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun	CPOT	
>A>	+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun	CAIN	
>A>	+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun	CPOT	
>A>		SOLUTION;ORAL							
>A>		VITRAKVI							
>A>	+	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun	CAIN	
>A>	+	!	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun	CPOT	

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC		ROCKLATAN							
+	!	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar	NEWA	

LEFLUNOMIDE

TABLET;ORAL		LEFLUNOMIDE							
AB	ABHAI LLC	10MG		A212453	001	Jun 03, 2019	May	NEWA	
AB		20MG		A212453	002	Jun 03, 2019	May	NEWA	
AB	ZYDUS	10MG		A212308	001	Apr 24, 2019	Apr	NEWA	
AB		20MG		A212308	002	Apr 24, 2019	Apr	NEWA	

LESINURADTABLET;ORAL
ZURAMPIC

+ @ IRONWOOD PHARMS INC 200MG N207988 001 Dec 22, 2015 Apr DISC

LETROZOLETABLET;ORAL
LETROZOLE

AB FRESENIUS KABI USA 2.5MG A090491 001 Jun 03, 2011 Feb CAHN

LEUCOVORIN CALCIUMINJECTABLE;INJECTION
LEUCOVORIN CALCIUM

AP INGENUS PHARMS LLC EQ 10MG BASE/ML A210917 001 Nov 23, 2018 Feb CPOT

LEUPROLIDE ACETATE

>D> FOR SUSPENSION;INTRAMUSCULAR

>D> LUTRATE DEPOT KIT

>D> +! GP-PHARM SA 22.5MG/VIAL N205054 001 Aug 28, 2018 Jun DISC

>A> + @ 22.5MG/VIAL N205054 001 Aug 28, 2018 Jun DISC

LEVETIRACETAM

>A> INJECTABLE;INTRAVENOUS

>A> KEPPRA

>A> AP +! UCB INC 500MG/5ML (100MG/ML) N021872 001 Jul 31, 2006 Jun CDFR

>A> LEVETIRACETAM

>A> AP AKORN 500MG/5ML (100MG/ML) A209934 001 May 04, 2018 Jun CDFR

>A> AP AUROBINDO PHARMA LTD 500MG/5ML (100MG/ML) A204312 001 Feb 01, 2016 Jun CDFR

>A> AP FRESENIUS KABI USA 500MG/5ML (100MG/ML) A090813 001 May 26, 2010 Jun CDFR

>A> AP 500MG/5ML (100MG/ML) A090876 001 Aug 13, 2015 Jun CDFR

>A> AP HAINAN POLY PHARM 500MG/5ML (100MG/ML) A209781 001 Mar 20, 2018 Jun CDFR

>A> AP HIKMA FARMACEUTICA 500MG/5ML (100MG/ML) A090981 001 Oct 13, 2011 Jun CDFR

>A> AP HOSPIRA INC 500MG/5ML (100MG/ML) A202869 001 Apr 06, 2012 Jun CDFR

>A> AP JUBILANT GENERICS 500MG/5ML (100MG/ML) A206838 001 Jun 02, 2016 Jun CDFR

>A> @ LUITPOLD 500MG/5ML (100MG/ML) A202143 001 Jan 31, 2012 Jun CDFR

>A> AP MYLAN LABS LTD 500MG/5ML (100MG/ML) A203308 001 Sep 16, 2016 Jun CDFR

>A> AP SAGENT PHARMS 500MG/5ML (100MG/ML) A091627 001 Jun 26, 2013 Jun CDFR

>A> AP SUN PHARM INDS LTD 500MG/5ML (100MG/ML) A090754 001 Jun 16, 2010 Jun CDFR

>A> AP X GEN PHARMS 500MG/5ML (100MG/ML) A091485 001 Aug 05, 2011 Jun CDFR

>A> LEVETIRACETAM IN SODIUM CHLORIDE

>A> AP AUROBINDO PHARMA LTD 500MG/100ML (5MG/ML) A207160 001 Jan 04, 2017 Jun CDFR

>A> AP 1000MG/100ML (10MG/ML) A207160 002 Jan 04, 2017 Jun CDFR

>A> AP 1500MG/100ML (15MG/ML) A207160 003 Jan 04, 2017 Jun CDFR

>A> AP GLAND PHARMA LTD 500MG/100ML (5MG/ML) A206880 001 Oct 25, 2017 Jun CDFR

>A> AP 1000MG/100ML (10MG/ML) A206880 002 Oct 25, 2017 Jun CDFR

>A> AP 1500MG/100ML (15MG/ML) A206880 003 Oct 25, 2017 Jun CDFR

>A> AP +! HQ SPECIALITY PHARMA 500MG/100ML (5MG/ML) N202543 001 Nov 09, 2011 Jun CDFR

>A> AP +! 1000MG/100ML (10MG/ML) N202543 002 Nov 09, 2011 Jun CDFR

>A> AP +! 1500MG/100ML (15MG/ML) N202543 003 Nov 09, 2011 Jun CDFR

>D> INJECTABLE;IV (INFUSION)

>D> KEPPRA

>D> AP +! UCB INC 500MG/5ML (100MG/ML) N021872 001 Jul 31, 2006 Jun CDFR

>D> LEVETIRACETAM

>D> AP AKORN 500MG/5ML (100MG/ML) A209934 001 May 04, 2018 Jun CDFR

>D> AP AUROBINDO PHARMA LTD 500MG/5ML (100MG/ML) A204312 001 Feb 01, 2016 Jun CDFR

>D> AP FRESENIUS KABI USA 500MG/5ML (100MG/ML) A090813 001 May 26, 2010 Jun CDFR

>D> AP 500MG/5ML (100MG/ML) A090876 001 Aug 13, 2015 Jun CDFR

>D> AP HAINAN POLY PHARM 500MG/5ML (100MG/ML) A209781 001 Mar 20, 2018 Jun CDFR

>D> AP HIKMA FARMACEUTICA 500MG/5ML (100MG/ML) A090981 001 Oct 13, 2011 Jun CDFR

>D> AP HOSPIRA INC 500MG/5ML (100MG/ML) A202869 001 Apr 06, 2012 Jun CDFR

>D> AP JUBILANT GENERICS 500MG/5ML (100MG/ML) A206838 001 Jun 02, 2016 Jun CDFR

>D> @ LUITPOLD 500MG/5ML (100MG/ML) A202143 001 Jan 31, 2012 Jun CDFR

>D> @ 500MG/5ML (100MG/ML) A202143 001 Jan 31, 2012 Mar DISC

>D> AP MYLAN LABS LTD 500MG/5ML (100MG/ML) A203308 001 Sep 16, 2016 Jun CDFR

>D> AP SAGENT PHARMS 500MG/5ML (100MG/ML) A091627 001 Jun 26, 2013 Jun CDFR

>D> AP SUN PHARM INDS LTD 500MG/5ML (100MG/ML) A090754 001 Jun 16, 2010 Jun CDFR

>D> AP X GEN PHARMS 500MG/5ML (100MG/ML) A091485 001 Aug 05, 2011 Jun CDFR

>D> LEVETIRACETAM IN SODIUM CHLORIDE

>D> AP AUROBINDO PHARMA LTD 500MG/100ML (5MG/ML) A207160 001 Jan 04, 2017 Jun CDFR

>D> AP 1000MG/100ML (10MG/ML) A207160 002 Jan 04, 2017 Jun CDFR

>D> AP 1500MG/100ML (15MG/ML) A207160 003 Jan 04, 2017 Jun CDFR

>D>	INJECTABLE;IV (INFUSION)								
>D>	LEVETIRACETAM IN SODIUM CHLORIDE								
>D> AP	GLAND PHARMA LTD	500MG/100ML (5MG/ML)	A206880	001	Oct 25, 2017	Jun	CDFR		
>D> AP		1000MG/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Jun	CDFR		
>D> AP		1500MG/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Jun	CDFR		
>D> AP	+! HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011	Jun	CDFR		
>D> AP	+!	1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Jun	CDFR		
>D> AP	+!	1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Jun	CDFR		
<u>LEVOBUNOLOL HYDROCHLORIDE</u>									
	SOLUTION/DROPS;OPHTHALMIC								
	LEVOBUNOLOL HYDROCHLORIDE								
	@ SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	May	DISC		
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>									
	SOLUTION;ORAL								
	LEVOCETIRIZINE HYDROCHLORIDE								
AA	HETERO LABS LTD III	2.5MG/5ML	A210914	001	Apr 01, 2019	Mar	NEWA		
<u>LEVOFLOXACIN</u>									
	SOLUTION/DROPS;OPHTHALMIC								
	LEVOFLOXACIN								
	MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019	Feb	NEWA		
	TABLET;ORAL								
	LEVOFLOXACIN								
AB	HEC PHARM	250MG	A204968	001	Feb 05, 2019	Jan	NEWA		
AB		500MG	A204968	002	Feb 05, 2019	Jan	NEWA		
AB		750MG	A204968	003	Feb 05, 2019	Jan	NEWA		
<u>LEVOLEUCOVORIN</u>									
	POWDER;INTRAVENOUS								
	KHAPZORY								
	+! ACROTECH	175MG/VIAL	N211226	001	Oct 19, 2018	Mar	CAHN		
	+!	300MG/VIAL	N211226	002	Oct 19, 2018	Mar	CAHN		
<u>LEVOLEUCOVORIN CALCIUM</u>									
	POWDER;INTRAVENOUS								
	FUSILEV								
AP	+! ACROTECH	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CAHN		
	LEVOLEUCOVORIN CALCIUM								
>D>	+! ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	Jun	DISC		
>A>	+ @	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	Jun	DISC		
	SOLUTION;INTRAVENOUS								
	FUSILEV								
	+ @ ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Mar	CAHN		
	+ @	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Mar	CAHN		
<u>LEVOMILNACIPRAN HYDROCHLORIDE</u>									
	CAPSULE, EXTENDED RELEASE;ORAL								
	FETZIMA								
>D> AB	+ ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jun	CTEC		
>A>	+	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jun	CTEC		
AB	+	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan	CFTG		
>D> AB	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Jun	CTEC		
>A>	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Jun	CTEC		
AB	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan	CFTG		
>D> AB	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jun	CTEC		
>A>	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jun	CTEC		
AB	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan	CFTG		
>D> AB	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jun	CTEC		
>A>	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jun	CTEC		
AB	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan	CFTG		
>D>	LEVOMILNACIPRAN HYDROCHLORIDE								
>D> AB	AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jun	DISC		
>A>	@	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jun	DISC		
AB		EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan	NFTG		
>D> AB		EQ 40MG BASE	A210790	002	Feb 04, 2019	Jun	DISC		
>A>	@	EQ 40MG BASE	A210790	002	Feb 04, 2019	Jun	DISC		
AB		EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan	NFTG		
>D> AB		EQ 80MG BASE	A210790	003	Feb 04, 2019	Jun	DISC		

CAPSULE, EXTENDED RELEASE;ORAL
LEVOMILNACIPRAN HYDROCHLORIDE

>A>	@	EQ 80MG BASE	A210790	003	Feb 04, 2019	Jun	DISC
AB		EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan	NFTG
>D>	AB	EQ 120MG BASE	A210790	004	Feb 04, 2019	Jun	DISC
>A>	@	EQ 120MG BASE	A210790	004	Feb 04, 2019	Jun	DISC
AB		EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan	NFTG

LEVONORGESTRELTABLET;ORAL
LEVONORGESTREL

AB	!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May	CAHN
----	---	--------------	--------	---------	-----	--------------	-----	------

LEVORPHANOL TARTRATETABLET;ORAL
LEVORPHANOL TARTRATE

@	SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Feb	DISC
!		3MG	A074278	003	Jun 18, 2018	May	CMFD
@		3MG	A074278	003	Jun 18, 2018	Feb	DISC

LEVOTHYROXINE SODIUMPOWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

@	PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015	Apr	DISC
---	----------------------	-------------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS
LEVOTHYROXINE SODIUM

+	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019	Apr	NEWA
+		200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019	Apr	NEWA
+		500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019	Apr	NEWA

SOLUTION;ORAL

TIROSINT-SOL

+	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jan	CMFD
+		25MCG/ML	N206977	002	Dec 15, 2016	Jan	CMFD
+		50MCG/ML	N206977	003	Dec 15, 2016	Jan	CMFD
+		75MCG/ML	N206977	004	Dec 15, 2016	Jan	CMFD
+		88MCG/ML	N206977	005	Dec 15, 2016	Jan	CMFD
+		100MCG/ML	N206977	006	Dec 15, 2016	Jan	CMFD
+		112MCG/ML	N206977	007	Dec 15, 2016	Jan	CMFD
+		125MCG/ML	N206977	008	Dec 15, 2016	Jan	CMFD
+		137MCG/ML	N206977	009	Dec 15, 2016	Jan	CMFD
+		150MCG/ML	N206977	010	Dec 15, 2016	Jan	CMFD
+		175MCG/ML	N206977	011	Dec 15, 2016	Jan	CMFD
+		200MCG/ML	N206977	012	Dec 15, 2016	Jan	CMFD

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

>D>	AB2	AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019	Jun	DISC
>A>	@		0.025MG	A210831	001	Feb 19, 2019	Jun	DISC
	AB2		0.025MG	A210831	001	Feb 19, 2019	May	CTEC
	AB1,		0.025MG	A210831	001	Feb 19, 2019	Feb	NEWA
	AB2							
>D>	AB2		0.05MG	A210831	002	Feb 19, 2019	Jun	DISC
>A>	@		0.05MG	A210831	002	Feb 19, 2019	Jun	DISC
	AB2		0.05MG	A210831	002	Feb 19, 2019	May	CTEC
	AB1,		0.05MG	A210831	002	Feb 19, 2019	Feb	NEWA
	AB2							
>D>	AB2		0.075MG	A210831	003	Feb 19, 2019	Jun	DISC
>A>	@		0.075MG	A210831	003	Feb 19, 2019	Jun	DISC
	AB2		0.075MG	A210831	003	Feb 19, 2019	May	CTEC
	AB1,		0.075MG	A210831	003	Feb 19, 2019	Feb	NEWA
	AB2							
>D>	AB2		0.088MG	A210831	004	Feb 19, 2019	Jun	DISC
>A>	@		0.088MG	A210831	004	Feb 19, 2019	Jun	DISC
	AB2		0.088MG	A210831	004	Feb 19, 2019	May	CTEC
	AB1,		0.088MG	A210831	004	Feb 19, 2019	Feb	NEWA
	AB2							
>D>	AB2		0.1MG	A210831	005	Feb 19, 2019	Jun	DISC
>A>	@		0.1MG	A210831	005	Feb 19, 2019	Jun	DISC
	AB2		0.1MG	A210831	005	Feb 19, 2019	May	CTEC
	AB1,		0.1MG	A210831	005	Feb 19, 2019	Feb	NEWA
	AB2							
>D>	AB2		0.112MG	A210831	006	Feb 19, 2019	Jun	DISC

TABLET;ORAL
LEVOTHYROXINE SODIUM

>A>	@	0.112MG	A210831	006	Feb 19, 2019	Jun	DISC
AB2		0.112MG	A210831	006	Feb 19, 2019	May	CTEC
AB1, AB2		0.112MG	A210831	006	Feb 19, 2019	Feb	NEWA
>D>		0.125MG	A210831	007	Feb 19, 2019	Jun	DISC
>A>	@	0.125MG	A210831	007	Feb 19, 2019	Jun	DISC
AB2		0.125MG	A210831	007	Feb 19, 2019	May	CTEC
AB1, AB2		0.125MG	A210831	007	Feb 19, 2019	Feb	NEWA
>D>		0.137MG	A210831	008	Feb 19, 2019	Jun	DISC
>A>	@	0.137MG	A210831	008	Feb 19, 2019	Jun	DISC
AB2		0.137MG	A210831	008	Feb 19, 2019	May	CTEC
AB1, AB2		0.137MG	A210831	008	Feb 19, 2019	Feb	NEWA
>D>		0.15MG	A210831	009	Feb 19, 2019	Jun	DISC
>A>	@	0.15MG	A210831	009	Feb 19, 2019	Jun	DISC
AB2		0.15MG	A210831	009	Feb 19, 2019	May	CTEC
AB1, AB2		0.15MG	A210831	009	Feb 19, 2019	Feb	NEWA
>D>		0.175MG	A210831	010	Feb 19, 2019	Jun	DISC
>A>	@	0.175MG	A210831	010	Feb 19, 2019	Jun	DISC
AB2		0.175MG	A210831	010	Feb 19, 2019	May	CTEC
AB1, AB2		0.175MG	A210831	010	Feb 19, 2019	Feb	NEWA
>D>		0.2MG	A210831	011	Feb 19, 2019	Jun	DISC
>A>	@	0.2MG	A210831	011	Feb 19, 2019	Jun	DISC
AB2		0.2MG	A210831	011	Feb 19, 2019	May	CTEC
AB1, AB2		0.2MG	A210831	011	Feb 19, 2019	Feb	NEWA
>D>		0.3MG	A210831	012	Feb 19, 2019	Jun	DISC
>A>	@	0.3MG	A210831	012	Feb 19, 2019	Jun	DISC
AB2		0.3MG	A210831	012	Feb 19, 2019	May	CTEC
AB1, AB2		0.3MG	A210831	012	Feb 19, 2019	Feb	NEWA
AB2	LUPIN ATLANTIS	0.025MG	A209713	001	Jan 18, 2019	Jan	NEWA
AB2		0.05MG	A209713	002	Jan 18, 2019	Jan	NEWA
AB2		0.075MG	A209713	003	Jan 18, 2019	Jan	NEWA
AB2		0.088MG	A209713	004	Jan 18, 2019	Jan	NEWA
AB2		0.1MG	A209713	005	Jan 18, 2019	Jan	NEWA
AB2		0.112MG	A209713	006	Jan 18, 2019	Jan	NEWA
AB2		0.125MG	A209713	007	Jan 18, 2019	Jan	NEWA
AB2		0.137MG	A209713	008	Jan 18, 2019	Jan	NEWA
AB2		0.15MG	A209713	009	Jan 18, 2019	Jan	NEWA
AB2		0.175MG	A209713	010	Jan 18, 2019	Jan	NEWA
AB2		0.2MG	A209713	011	Jan 18, 2019	Jan	NEWA
AB2		0.3MG	A209713	012	Jan 18, 2019	Jan	NEWA
	THYRO-TABS						
AB2, +	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.05MG	N021116	002	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.075MG	N021116	003	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.088MG	N021116	010	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.1MG	N021116	004	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.112MG	N021116	011	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.125MG	N021116	005	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.137MG	N021116	012	Dec 07, 2004	Mar	CAHN
AB4							
AB2, +		0.15MG	N021116	006	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.175MG	N021116	007	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +		0.2MG	N021116	008	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +!		0.3MG	N021116	009	Oct 24, 2002	Mar	CAHN
AB4							
AB2, +	LLOYD	0.025MG	N021116	001	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.05MG	N021116	002	Oct 24, 2002	Feb	CMFD
AB4							
AB2, +		0.075MG	N021116	003	Oct 24, 2002	Feb	CMFD

TABLET; ORAL
THYRO-TABS

AB4								
AB2, +		0.088MG		N021116	010	Oct 24, 2002	Feb	CMFD
AB4								
AB2, +		0.1MG		N021116	004	Oct 24, 2002	Feb	CMFD
AB4								
AB2, +		0.112MG		N021116	011	Oct 24, 2002	Feb	CMFD
AB4								
AB2, +		0.125MG		N021116	005	Oct 24, 2002	Feb	CMFD
AB4								
AB2, +		0.137MG		N021116	012	Dec 07, 2004	Feb	CMFD
AB4								
AB2, +		0.15MG		N021116	006	Oct 24, 2002	Feb	CMFD
AB4								
AB2, +		0.175MG		N021116	007	Oct 24, 2002	Feb	CMFD
AB4								
AB2, +		0.2MG		N021116	008	Oct 24, 2002	Feb	CMFD
AB4								
AB2, +!		0.3MG		N021116	009	Oct 24, 2002	Feb	CMFD
AB4								

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

>A>	LIDOCAINE HYDROCHLORIDE							
>A>	AP	FRESENIUS KABI USA	1%	A080404	002		Jun	CTNA
>A>	AP		2%	A080404	003		Jun	CTNA
	@	LUITPOLD	1%	A080850	001		Mar	DISC
	@		1%	A091564	001	Aug 14, 2015	Feb	DISC
>D>		LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE					
>D>	AP	FRESENIUS KABI USA	1%	A080404	002		Jun	CTNA
>D>	AP		2%	A080404	003		Jun	CTNA

JELLY; TOPICAL

ANESTACON

@	BIONPHARMA INC	2%		A080429	001		Apr	CAHN
---	----------------	----	--	---------	-----	--	-----	------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB	+!	TEVA BRANDED PHARM	2.5%; 2.5%	N019941	001	Dec 30, 1992	Apr	CAHN
----	----	--------------------	------------	---------	-----	--------------	-----	------

LINEZOLID

TABLET; ORAL

LINEZOLID

AB		CELLTRION	600MG	A210702	001	Apr 25, 2019	Apr	NEWA
>D>	AB	MYLAN	600MG	A078845	001	Dec 21, 2015	Jun	DISC
>A>	@		600MG	A078845	001	Dec 21, 2015	Jun	DISC

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

>D>	AB	+!	KING PHARMS	EQ 0.05MG BASE	N010379	003		Jun	CHRS
>A>	AB	+		EQ 0.05MG BASE	N010379	003		Jun	CHRS
			LIOTHYRONINE SODIUM						
		@	MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Mar	DISC
		@		EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Mar	DISC
		@		EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Mar	DISC
>D>	AB		SIGMAPHARM LABS LLC	EQ 0.05MG BASE	A200295	003	Nov 29, 2012	Jun	CHRS
>A>	AB	!		EQ 0.05MG BASE	A200295	003	Nov 29, 2012	Jun	CHRS
>D>	AB		SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jun	DISC
>A>		@		EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jun	DISC
>D>	AB			EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jun	DISC
>A>		@		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jun	DISC
>D>	AB			EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jun	DISC
>A>		@		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jun	DISC
		@	TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Apr	DISC
		@		EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Apr	DISC
		@		EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Apr	DISC

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	HERITAGE PHARMA	2.5MG	A 075752	001	Jul 01, 2002	Feb	CAHN
AB		5MG	A 075752	002	Jul 01, 2002	Feb	CAHN
AB		10MG	A 075752	003	Jul 01, 2002	Feb	CAHN
AB		20MG	A 075752	004	Jul 01, 2002	Feb	CAHN
AB		30MG	A 075752	005	Jul 01, 2002	Feb	CAHN
AB		40MG	A 075752	006	Jul 01, 2002	Feb	CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB	+	HIKMA	150MG	N 017812	002	Jan 28, 1987	Apr	CAHN
AB	+		300MG	N 017812	001		Apr	CAHN
AB	+	!	600MG	N 017812	003	Jan 28, 1987	Apr	CAHN
>D>	AB	MYLAN	600MG	A 078763	001	Apr 15, 2008	Jun	DISC
>A>		@	600MG	A 078763	001	Apr 15, 2008	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

@ HERITAGE PHARMA

@

300MG

450MG

A 076170	001	Jun 10, 2002	May	CAHN
A 076366	001	Aug 21, 2003	May	CAHN

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	+	!	HIKMA	EQ 300MG CARBONATE/5ML	N 018421	001		Apr	CAHN
----	---	---	-------	------------------------	----------	-----	--	-----	------

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

AA		SAPTALIS PHARMS	2MG/ML	A 079244	001	Apr 28, 2009	Feb	CAHN
----	--	-----------------	--------	----------	-----	--------------	-----	------

INJECTABLE;INJECTION

ATIVAN

AP	+	!	HIKMA	2MG/ML	N 018140	001		Mar	CAHN
AP	+	!		4MG/ML	N 018140	002		Mar	CAHN

TABLET;ORAL

ATIVAN

AB	+		BAUSCH	0.5MG	N 017794	001		Feb	CAHN
AB	+			1MG	N 017794	002		Feb	CAHN
AB	+	!		2MG	N 017794	003		Feb	CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB		HISUN PHARM HANGZHOU	25MG	A 204795	001	Apr 04, 2019	Mar	NEWA
AB			50MG	A 204795	002	Apr 04, 2019	Mar	NEWA
AB			100MG	A 204795	003	Apr 04, 2019	Mar	NEWA
AB		MICRO LABS	25MG	A 091541	001	Sep 24, 2012	Mar	CAHN
AB			50MG	A 091541	002	Sep 24, 2012	Mar	CAHN
AB			100MG	A 091541	003	Sep 24, 2012	Mar	CAHN
AB		STRIDES PHARMA	25MG	A 090382	001	Oct 06, 2010	Apr	CAHN
AB			50MG	A 090382	002	Oct 06, 2010	Apr	CAHN
AB			100MG	A 090382	003	Oct 06, 2010	Apr	CAHN

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX SM

+! BAUSCH AND LOMB INC 0.38%

SUSPENSION/DROPS;OPHTHALMIC

LOTEMAX

AB	+	!	BAUSCH AND LOMB	0.5%	N 020583	001	Mar 09, 1998	Apr	CFTG
AB			HI TECH	0.5%	A 207609	001	Apr 17, 2019	Apr	NFTG

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	BEXIMCO PHARMS USA	10MG	A075300	001	Dec 17, 2001	Feb	CAHN
AB		20MG	A075300	002	Dec 17, 2001	Feb	CAHN
AB		40MG	A075300	003	Dec 17, 2001	Feb	CAHN
	@ MYLAN	10MG	A075451	001	Dec 17, 2001	Feb	DISC
	@	20MG	A075451	002	Dec 17, 2001	Feb	DISC
	@	40MG	A075451	003	Dec 17, 2001	Feb	DISC

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

@ TEVA BRANDED PHARM

EQ 25MG BASE/ML

N017658 001

Feb CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

+ @	TEVA BRANDED PHARM	EQ 5MG BASE	N017525	001		Feb	CAHN
+ @		EQ 10MG BASE	N017525	002		Feb	CAHN
+ @		EQ 25MG BASE	N017525	003		Feb	CAHN
+ @		EQ 50MG BASE	N017525	004		Feb	CAHN

TABLET; ORAL

LOXITANE

+ @	TEVA BRANDED PHARM	EQ 10MG BASE	N017525	006		Feb	CAHN
+ @		EQ 25MG BASE	N017525	007		Feb	CAHN
+ @		EQ 50MG BASE	N017525	008		Feb	CAHN
+ @		EQ 50MG BASE	N017525	008		Feb	CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

>D>	AB	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Jun	DISC
>A>		@	20MG	A208002	001	Jan 03, 2019	Jun	DISC
>D>	AB		40MG	A208002	002	Jan 03, 2019	Jun	DISC
>A>		@	40MG	A208002	002	Jan 03, 2019	Jun	DISC
>D>	AB		60MG	A208002	003	Jan 03, 2019	Jun	DISC
>A>		@	60MG	A208002	003	Jan 03, 2019	Jun	DISC
>D>	AB		80MG	A208002	004	Jan 03, 2019	Jun	DISC
>A>		@	80MG	A208002	004	Jan 03, 2019	Jun	DISC
>D>	AB		120MG	A208002	005	Jan 03, 2019	Jun	DISC
>A>		@	120MG	A208002	005	Jan 03, 2019	Jun	DISC
	AB	TEVA PHARMS USA	20MG	A208060	001	May 17, 2019	May	NEWA
	AB		40MG	A208060	002	May 17, 2019	May	NEWA
	AB		60MG	A208060	003	May 17, 2019	May	NEWA
	AB		80MG	A208060	004	May 17, 2019	May	NEWA
	AB		120MG	A208060	005	May 17, 2019	May	NEWA
		@ TORRENT	20MG	A208055	001	Jan 03, 2019	Feb	DISC
		@	40MG	A208055	002	Jan 03, 2019	Feb	DISC
		@	80MG	A208055	003	Jan 03, 2019	Feb	DISC
		@	120MG	A208055	004	Jan 03, 2019	Feb	DISC
	AB	ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019	Mar	NEWA
	AB		40MG	A208052	002	Mar 19, 2019	Mar	NEWA
	AB		60MG	A208052	003	Mar 19, 2019	Mar	NEWA
	AB		80MG	A208052	004	Mar 19, 2019	Mar	NEWA
	AB		120MG	A208052	005	Mar 19, 2019	Mar	NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	+!	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan	CTEC
AP		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Jan	CTEC

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER; ORAL

COLPREP KIT

+ @	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553	001	Dec 27, 2016	Mar	DISC
-----	--------------	---------------------------------	---------	-----	--------------	-----	------

MANNITOL

INJECTABLE; INJECTION
MANNITOL 25%

@ LUITPOLD 12.5GM/50ML A087409 001 Jan 21, 1982 Mar DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
ANTIVERT

AA + CASPER PHARMA LLC 12.5MG N010721 006 Feb CMFD
+ @ 12.5MG N010721 006 Jan CRLD
AA + 25MG N010721 004 Feb CMFD
+ @ 25MG N010721 004 Jan CRLD
AA + 50MG N010721 001 Jan 20, 1982 Feb CMFD
+ @ 50MG N010721 001 Jan 20, 1982 Jan CRLD

MECLIZINE HYDROCHLORIDE

AA ! AMNEAL PHARMS 12.5MG A201451 001 Feb 23, 2011 Jan CHRS
AA ! 25MG A201451 002 Feb 23, 2011 Jan CHRS
@ ANI PHARMS INC 12.5MG A088732 001 Dec 11, 1985 May CAHN
AA INDICUS PHARMA 12.5MG A205136 001 Feb 22, 2019 Feb NEWA
AA 25MG A205136 002 Feb 22, 2019 Feb NEWA
AA 50MG A205136 003 Feb 22, 2019 Feb NEWA

TABLET, CHEWABLE; ORAL
ANTIVERT

AA + CASPER PHARMA LLC 25MG N010721 005 Feb CMFD
+ @ 25MG N010721 005 Jan CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
MEDROXYPROGESTERONE ACETATE

AB CIPLA 150MG/ML A210335 001 Jan 25, 2019 Jan NEWA
AB SUN PHARM 150MG/ML A210760 001 May 01, 2019 Apr NEWA
AB 150MG/ML A210761 001 Apr 24, 2019 Apr NEWA

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID

@ BRECKENRIDGE PHARM 250MG A090359 001 Feb 05, 2013 Feb DISC

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE

@ PD PARTNERS 40MG/ML A077404 001 Feb 16, 2006 May CAHN

MELOXICAM

CAPSULE; ORAL
VIVLODEX

+ EGALET 5MG N207233 001 Oct 22, 2015 Feb CAHN
+! 10MG N207233 002 Oct 22, 2015 Feb CAHN

SUSPENSION; ORAL
MOBIC

>A> + @ AVONDALE PHARMS 7.5MG/5ML N021530 001 Jun 01, 2004 Jun CAHN
>D> + @ BOEHRINGER INGELHEIM 7.5MG/5ML N021530 001 Jun 01, 2004 Jun CAHN

TABLET; ORAL
MELOXICAM

AB HERITAGE PHARMA 7.5MG A077936 001 Jul 19, 2006 Feb CAHN
AB 15MG A077936 002 Jul 19, 2006 Feb CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
ALKERAN

AP + APOTEX INC EQ 50MG BASE/VIAL N020207 001 Nov 18, 1992 Feb CMFD
MELPHALAN HYDROCHLORIDE
AP ALVOGEN INC EQ 50MG BASE/VIAL A204817 001 May 17, 2019 May NEWA
AP GLAND PHARMA LTD EQ 50MG BASE/VIAL A209826 001 May 28, 2019 May NEWA
AP US WORLDMEDS LLC EQ 50MG BASE/VIAL A207032 001 May 03, 2019 Apr NEWA

POWDER; INTRAVENOUS
EVOVELA

+! ACROTECH EQ 50MG BASE/VIAL N207155 001 Mar 10, 2016 Mar CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL		MEMANTINE HYDROCHLORIDE							
AA	!	TORRENT	2MG/ML	A205446	001	Dec 07, 2015	Jan	CAHN	
TABLET; ORAL		MEMANTINE HYDROCHLORIDE							
	@	APOTEX INC	5MG	A090244	001	Jul 11, 2018	Jan	DISC	
	@		10MG	A090244	002	Jul 11, 2018	Jan	DISC	
AB		CADILA	5MG	A090961	001	Jul 10, 2017	Feb	CAHN	
AB			10MG	A090961	002	Jul 10, 2017	Feb	CAHN	

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		MEPERGAN							
>A>	@	HIKMA	25MG/ML; 25MG/ML	N011730	001		Jun	CAHN	
>D>	@	WEST-WARD PHARMS INT	25MG/ML; 25MG/ML	N011730	001		Jun	CAHN	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL		SOLAGE							
	@	ALMIRALL	2%; 0.01%	N020922	001	Dec 10, 1999	Feb	CAHN	

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL		DELZICOL							
AB	+	APIL	400MG	N204412	001	Feb 01, 2013	Apr	CFTG	
SUPPOSITORY; RECTAL		MESALAMINE							
AB		TEVA PHARMS USA	400MG	A207873	001	May 09, 2019	Apr	NFTG	
TABLET, DELAYED RELEASE; ORAL		MESALAMINE							
>A>	AB	AMRING PHARMS	1GM	A208362	001	Jun 21, 2019	Jun	NEWA	
	AB	PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Apr	NEWA	
	AB	SANDOZ INC	1GM	A202065	001	Jun 12, 2019	May	NEWA	
AB		SUN PHARM	1.2GM	A211858	001	Jan 25, 2019	Jan	NEWA	

METAPROTERENOL SULFATE

TABLET; ORAL		METAPROTERENOL SULFATE							
	@	HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990	May	CAHN	
	@		20MG	A072520	001	Mar 30, 1990	May	CAHN	

METAXALONE

TABLET; ORAL		METAXALONE							
AB		APPCO PHARMA LLC	800MG	A208774	001	Sep 24, 2018	Feb	CAHN	

METFORMIN HYDROCHLORIDE

TABLET; ORAL		GLUCOPHAGE							
>D>	AB	+	BRISTOL MYERS SQUIBB	500MG	N020357	001	Mar 03, 1995	Jun	DISC
>A>		+	@	500MG	N020357	001	Mar 03, 1995	Jun	DISC
>D>	AB	+		850MG	N020357	002	Mar 03, 1995	Jun	DISC
>A>		+	@	850MG	N020357	002	Mar 03, 1995	Jun	DISC
>D>	AB	+	!	1GM	N020357	005	Nov 05, 1998	Jun	DISC
>A>		+	@	1GM	N020357	005	Nov 05, 1998	Jun	DISC
TABLET, EXTENDED RELEASE; ORAL		FORTAMET							
>D>	AB		GRANULES INDIA	1GM	A090564	003	Apr 22, 2010	Jun	CHRS
>A>	AB	!		1GM	A090564	003	Apr 22, 2010	Jun	CHRS
	AB		HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Feb	CAHN
	AB			850MG	A075978	002	Jan 25, 2002	Feb	CAHN
	AB			1GM	A075978	003	Nov 05, 2002	Feb	CAHN
		@	SUNSHINE LAKE	500MG	A208999	001	Oct 12, 2018	Apr	DISC
		@		850MG	A208999	002	Oct 12, 2018	Apr	DISC
		@		1GM	A208999	003	Oct 12, 2018	Apr	DISC
TABLET, EXTENDED RELEASE; ORAL		FORTAMET							
	+	@	ANDRX LABS LLC	500MG	N021574	001	Apr 27, 2004	Apr	DISC
	+	@		1GM	N021574	002	Apr 27, 2004	Apr	DISC

<u>TABLET, EXTENDED RELEASE;ORAL</u>										
<u>GLUCOPHAGE XR</u>										
>D>	AB1	+	BRISTOL MYERS SQUIBB	500MG	N021202	001	Oct 13, 2000	Jun	DISC	
>A>		+	@	500MG	N021202	001	Oct 13, 2000	Jun	DISC	
>D>	AB	+	!	750MG	N021202	004	Apr 11, 2003	Jun	DISC	
>A>		+	@	750MG	N021202	004	Apr 11, 2003	Jun	DISC	
<u>METFORMIN HYDROCHLORIDE</u>										
>D>	AB		AMNEAL PHARMS NY	750MG	A078596	002	Jan 03, 2008	Jun	CHRS	
>A>	AB		!	750MG	A078596	002	Jan 03, 2008	Jun	CHRS	
	AB1		CADILA	500MG	A077060	001	Apr 20, 2005	Feb	CAHN	
	AB			750MG	A077078	001	Apr 21, 2005	Feb	CAHN	
	AB2		!	LUPIN LTD	1GM	A090692	002	Jun 29, 2011	Apr	CHRS
>D>	AB1		SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Jun	CHRS	
>A>	AB1		!	500MG	A077336	001	Feb 09, 2006	Jun	CHRS	
			@	YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Mar	DISC
			@		750MG	A211052	002	Sep 24, 2018	Mar	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+	@	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009	Mar	DISC
+	@		1GM;EQ 30MG BASE	N022024	002	May 12, 2009	Mar	DISC

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

@	MICRO LABS	25MG	A207438	001	Oct 05, 2018	Mar	DISC
@		50MG	A207438	002	Oct 05, 2018	Mar	DISC

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP		SLATE	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Feb	CAHN	
AP	+	!	ROBAXIN						
			HIKMA	1GM/10ML (100MG/ML)	N011790	001		Feb	CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS

RASUVO

+	!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr	CAHN
+	!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr	CAHN
+	!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr	CAHN
+	!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr	CAHN
+	!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr	CAHN
+	!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr	CAHN
+	!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr	CAHN
+	!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr	CAHN
+	@		27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Apr	CAHN
+	!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr	CAHN

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

>D>	AA		BRACKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Jun	DISC
>A>			@	2.5MG	A040642	001	Dec 06, 2011	Jun	DISC
>D>	AA			5MG	A040642	002	Dec 06, 2011	Jun	DISC
>A>			@	5MG	A040642	002	Dec 06, 2011	Jun	DISC

METHYLDOPA

TABLET;ORAL

METHYLDOPA

AB		HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Feb	CAHN
AB			500MG	A070343	001	Feb 20, 1986	Feb	CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

METHYLDOPATE HYDROCHLORIDE

@	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Mar	DISC
---	----------	---------	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB	TEVA PHARMS USA	0.2MG	A211455	001	Mar 20, 2019	Mar	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

ADHANSIA XR

+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Mar	CRLD
		25MG	N212038	001	Feb 27, 2019	Feb	NEWA
+		35MG	N212038	002	Feb 27, 2019	Feb	NEWA
+		45MG	N212038	003	Feb 27, 2019	Feb	NEWA
+		55MG	N212038	004	Feb 27, 2019	Feb	NEWA
+		70MG	N212038	005	Feb 27, 2019	Feb	NEWA
+		85MG	N212038	006	Feb 27, 2019	Feb	NEWA

METHYLPHENIDATE HYDROCHLORIDE

AB1	GRANULES PHARMS	10MG	A211796	001	May 23, 2019	May	NEWA
AB1		20MG	A211796	002	May 23, 2019	May	NEWA
AB1		30MG	A211796	003	May 23, 2019	May	NEWA
AB1		40MG	A211796	004	May 23, 2019	May	NEWA
AB1		60MG	A211796	005	May 23, 2019	May	NEWA
AB1	! MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	May	CTEC

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS LABS FL INC 5MG/ML

QUILLIVANT XR

+	NEXTWAVE	5MG/ML	N202100	001	Sep 27, 2012	Feb	CAHN
+	NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Jan	CTEC

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 5MG

@ 10MG

@ 20MG

AB	CEDIPROF INC	5MG	A209276	001	Oct 25, 2018	Apr	DISC
			A209276	002	Oct 25, 2018	Apr	DISC
			A209276	003	Oct 25, 2018	Apr	DISC
AB		5MG	A208737	001	Feb 01, 2019	Jan	NEWA
AB		10MG	A208737	002	Feb 01, 2019	Jan	NEWA
AB		20MG	A208737	003	Feb 01, 2019	Jan	NEWA
	@ LANNETT CO INC	5MG	A086429	001		Jan	DISC
	@	10MG	A085799	001		Jan	DISC
	@	20MG	A086428	001		Jan	DISC

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

@ LANNETT CO INC 20MG

METHYLPHENIDATE HYDROCHLORIDE

AB	! ABHAI LLC	20MG	A207488	002	Jun 09, 2015	Jan	NEWA
AB	ANDOR PHARMS	18MG	A211918	001	Apr 24, 2019	Apr	NEWA
AB		27MG	A211918	002	Apr 24, 2019	Apr	NEWA
AB		36MG	A211918	003	Apr 24, 2019	Apr	NEWA
AB		54MG	A211918	004	Apr 24, 2019	Apr	NEWA
	@ HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001	May	CAHN

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	+ PHARMACIA AND UPJOHN	2MG	N011153	002		Mar	CFTG
----	------------------------	-----	---------	-----	--	-----	------

METHYLPREDNISOLONE

AB	LUPIN LTD	2MG	A209097	001	Feb 22, 2019	Mar	NFTG
AB		2MG	A209097	001	Feb 22, 2019	Feb	NEWA
AB		4MG	A209097	002	Feb 22, 2019	Feb	NEWA
AB		8MG	A209097	003	Feb 22, 2019	Feb	NEWA
AB		16MG	A209097	004	Feb 22, 2019	Feb	NEWA
AB		32MG	A209097	005	Feb 22, 2019	Feb	NEWA
>A>	AB SUNGEN PHARMA	4MG	A212262	001	Jun 27, 2019	Jun	NEWA
AB	TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr	CMFD

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	AMNEAL PHARMS CO	40MG/ML	A210043	001	May 20, 2019	May	NEWA
AB		80MG/ML	A210043	002	May 20, 2019	May	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

@ HOSPIRA

EQ 40MG BASE/VIAL

A 040664 001 Dec 20, 2005 Mar DISC

@

EQ 125MG BASE/VIAL

A 040665 001 Dec 20, 2005 Mar DISC

METHYLTESTOSTERONE

CAPSULE; ORAL

VIRILON

>A> @ CHARTWELL

10MG

A 087750 001 Nov 24, 1982 Jun CAHN

>D> @ STAR PHARMS FL

10MG

A 087750 001 Nov 24, 1982 Jun CAHN

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

@ SANDOZ INC

0.3%

A 075720 001 Aug 06, 2001 May DISC

OPTIPRANOLOL

+! BAUSCH AND LOMB

0.3%

N 019907 001 Dec 29, 1989 May CTEC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

TOPROL-XL

AB + TOPROL

EQ 25MG TARTRATE

N 019962 004 Feb 05, 2001 Mar CAHN

AB +!

EQ 50MG TARTRATE

N 019962 001 Jan 10, 1992 Mar CAHN

AB +

EQ 100MG TARTRATE

N 019962 002 Jan 10, 1992 Mar CAHN

AB +!

EQ 200MG TARTRATE

N 019962 003 Jan 10, 1992 Mar CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

>D> AP +! NOVARTIS

1MG/ML

N 018704 001 Mar 30, 1984 Jun DISC

>A> + @

1MG/ML

N 018704 001 Mar 30, 1984 Jun DISC

METOPROLOL TARTRATE

>D> AP HOSPIRA

1MG/ML

A 078085 001 Apr 29, 2008 Jun CHRS

>A> AP !

1MG/ML

A 078085 001 Apr 29, 2008 Jun CHRS

@ LUITPOLD

1MG/ML

A 090386 001 Sep 30, 2009 Mar DISC

@

1MG/ML

A 091307 001 Dec 29, 2010 Feb DISC

TABLET; ORAL

METOPROLOL TARTRATE

AB HERITAGE PHARMA

50MG

A 074141 001 Jan 31, 1995 Apr CAHN

AB

100MG

A 074141 002 Jan 31, 1995 Apr CAHN

METRONIDAZOLE

GEL; VAGINAL

METROGEL-VAGINAL

AB +! BAUSCH

0.75%

N 020208 001 Aug 17, 1992 Mar CAHN

METRONIDAZOLE

>A> AB GAGE DEVELOPMENT

0.75%

A 211786 001 Jul 02, 2019 Jun NEWA

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP INFORLIFE

500MG/100ML

A 206191 001 Feb 25, 2019 Feb NEWA

TABLET; ORAL

METRONIDAZOLE

AB CADILA

250MG

A 206560 001 Nov 16, 2016 Mar CAHN

AB

500MG

A 206560 002 Nov 16, 2016 Mar CAHN

AB STRIDES PHARMA

250MG

A 070040 001 Jan 29, 1985 Apr CAHN

AB

500MG

A 070039 001 Jan 29, 1985 Apr CAHN

METYROSINE

CAPSULE; ORAL

DEMSEER

+! BAUSCH

250MG

N 017871 001 Mar CAHN

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

AP FRESENIUS KABI USA

EQ 50MG BASE/VIAL

A 207344 001 May 17, 2019 May NFTG

AP

EQ 100MG BASE/VIAL

A 207344 002 May 17, 2019 May NFTG

MYCAMINE

AP +! ASTELLAS

EQ 50MG BASE/VIAL

N 021506 002 Mar 16, 2005 May CFTG

	INJECTABLE; INTRAVENOUS						
	MYCAMINE						
AP	+	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May	CDFR
	<u>MIDAZOLAM</u>						
	SPRAY; NASAL						
	NAYZILAM						
	+	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019	May NEWA
	<u>MIDAZOLAM HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	MIDAZOLAM HYDROCHLORIDE						
AP		MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr CAHN
AP			EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr CAHN
	SYRUP; ORAL						
	MIDAZOLAM HYDROCHLORIDE						
	@	PD PARTNERS	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	May CAHN
	<u>MIDODRINE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	MIDODRINE HYDROCHLORIDE						
	@	CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	May DISC
	@		5MG	A076514	002	Sep 11, 2003	May DISC
	@		10MG	A076514	003	Jul 02, 2004	May DISC
AB		MYLAN PHARMS INC	5MG	A076577	002	Sep 10, 2003	May CHRS
	ORVATEN						
AB	!	UPSHER SMITH LABS	5MG	A076725	002	Nov 03, 2004	May CHRS
	<u>MIFEPRISTONE</u>						
	TABLET; ORAL						
	MIFEPREX						
AB	+	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000	Mar CFTG
	MIFEPRISTONE						
AB		GENBIOPRO	200MG	A091178	001	Apr 11, 2019	Mar NFTG
	<u>MINOCYCLINE HYDROCHLORIDE</u>						
	CAPSULE; ORAL						
	MINOCIN						
AB	+	BAUSCH	EQ 50MG BASE	N050649	001	May 31, 1990	May CAHN
	+	@	EQ 75MG BASE	N050649	003	Feb 12, 2001	May CAHN
AB	+		EQ 100MG BASE	N050649	002	May 31, 1990	May CAHN
	SUSPENSION; ORAL						
	MINOCIN						
	@	BAUSCH	EQ 50MG BASE/5ML	N050445	001		May CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	MINOCYCLINE HYDROCHLORIDE						
AB		BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Jan CMFD
AB			EQ 105MG BASE	A065485	008	Apr 26, 2017	Jan CMFD
	<u>MIRTAZAPINE</u>						
	TABLET; ORAL						
	MIRTAZAPINE						
	@	WATSON LABS	15MG	A076312	001	Jun 19, 2003	May DISC
	@		30MG	A076312	002	Jun 19, 2003	May DISC
	@		45MG	A076312	003	Jun 19, 2003	May DISC
	<u>MISOPROSTOL</u>						
	TABLET; ORAL						
	MISOPROSTOL						
>A>	AB	ZYDUS PHARMS	0.1MG	A210201	001	Jul 02, 2019	Jun NEWA
>A>	AB		0.2MG	A210201	002	Jul 02, 2019	Jun NEWA
	<u>MITOMYCIN</u>						
	INJECTABLE; INJECTION						
	MITOMYCIN						
AP		WEST-WARD PHARMS INT	20MG/VIAL	A064117	002	Apr 19, 1995	Jan CMFD
AP			40MG/VIAL	A064117	003	Jun 02, 1999	Jan CMFD

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@ MYLAN INSTITUTIONAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A 078980	001	Apr 13, 2009	Mar	DISC
@	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A 078980	002	Apr 13, 2009	Mar	DISC

MODAFINIL

TABLET; ORAL

MODAFINIL

@ CADILA	100MG	A 209966	001	Sep 14, 2017	May	CAHN
@	200MG	A 209966	002	Sep 14, 2017	May	CAHN
@ ZYDUS PHARMS	100MG	A 209966	001	Sep 14, 2017	Apr	DISC
@	200MG	A 209966	002	Sep 14, 2017	Apr	DISC

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB @ MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A 202776	001	Dec 18, 2012	Feb	DISC
TORRENT	EQ 4MG BASE/PACKET	A 210431	001	Jul 31, 2018	Mar	CAHN

TABLET; ORAL

MONTELUKAST SODIUM

AB L PERRIGO CO	EQ 10MG BASE	A 206112	001	Apr 26, 2017	May	CAHN
@ VINTAGE PHARMS LLC	EQ 10MG BASE	A 091576	001	Aug 03, 2012	Feb	DISC

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

@ MYLAN PHARMS INC	EQ 4MG BASE	A 079142	001	Aug 03, 2012	Apr	DISC
@	EQ 5MG BASE	A 079142	002	Aug 03, 2012	Apr	DISC
@ VINTAGE PHARMS LLC	EQ 4MG BASE	A 091588	001	Aug 03, 2012	Feb	DISC
@	EQ 5MG BASE	A 091588	002	Aug 03, 2012	Feb	DISC

MORPHINE SULFATE

INJECTABLE; INJECTION

ASTRAMORPH PF

@ FRESENIUS KABI USA	0.5MG/ML	A 071050	001	Oct 07, 1986	Mar	DISC
@	0.5MG/ML	A 071051	001	Oct 07, 1986	Mar	DISC
@	1MG/ML	A 071052	001	Oct 07, 1986	Mar	DISC
@	1MG/ML	A 071053	001	Oct 07, 1986	Mar	DISC

SOLUTION; ORAL

MORPHINE SULFATE

@ LANNETT CO INC	10MG/5ML	A 202309	001	Nov 25, 2015	Feb	DISC
@	20MG/5ML	A 202310	001	Oct 30, 2015	Jan	DISC
@	100MG/5ML	N 201517	001	Jun 23, 2011	Jan	DISC

TABLET; ORAL

MORPHINE SULFATE

>A> + HIKMA	15MG	N 022207	001	Mar 17, 2008	Jun	CAHN
>A> +!	30MG	N 022207	002	Mar 17, 2008	Jun	CAHN
>D> + WEST-WARD PHARMS INT	15MG	N 022207	001	Mar 17, 2008	Jun	CAHN
>D> +!	30MG	N 022207	002	Mar 17, 2008	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

ARYMO ER

+ @ EGALET	15MG	N 208603	001	Jan 09, 2017	Mar	CAHN
+ @	30MG	N 208603	002	Jan 09, 2017	Mar	CAHN
+ @	60MG	N 208603	003	Jan 09, 2017	Mar	CAHN

MORPHINE SULFATE

@ MYLAN PHARMS INC	200MG	A 200824	005	Oct 18, 2011	Feb	DISC
--------------------	-------	----------	-----	--------------	-----	------

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1 ALEMBIC PHARMS LTD	EQ 0.5% BASE	A 209469	001	Feb 13, 2019	Jan	NEWA
------------------------	--------------	----------	-----	--------------	-----	------

TABLET; ORAL

MOXIFLOXACIN HYDROCHLORIDE

@ SUNSHINE LAKE	EQ 400MG BASE	A 206295	001	Sep 28, 2018	Mar	DISC
-----------------	---------------	----------	-----	--------------	-----	------

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB ! PERRIGO ISRAEL	2%	A 065123	001	Nov 07, 2003	May	CAHN
---------------------	----	----------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

	SUSPENSION;ORAL						
	MYCOPHENOLATE MOFETIL						
AB	VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Jan	NEWA

NADOLOL

	TABLET;ORAL						
	NADOLOL						
AB	HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Apr	CAHN
AB		40MG	A074229	002	Aug 30, 1996	Apr	CAHN
AB		80MG	A074255	001	Jan 24, 1996	Apr	CAHN
	@	120MG	A074255	002	Jan 24, 1996	Apr	CAHN
	@	160MG	A074255	003	Jan 24, 1996	Apr	CAHN

NAFTIFINE HYDROCHLORIDE

	GEL;TOPICAL						
	NAFTIFINE HYDROCHLORIDE						
	@ TARO	2%	A208201	001	Apr 10, 2019	May	DISC
AB		2%	A208201	001	Apr 10, 2019	Mar	NFTG
AB	TOLMAR	1%	A206165	001	Mar 20, 2019	Mar	NFTG
	NAFTIN						
AB	+! SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Mar	CFTG
AB	+!	2%	N204286	001	Jun 27, 2013	Mar	CFTG

NALBUPHINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	NALBUPHINE HYDROCHLORIDE						
	@ DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	May	CAHN
	@	20MG/ML	A074471	002	Mar 19, 1998	May	CAHN
AP	MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan	NEWA
AP		20MG/ML	A206506	002	Feb 06, 2019	Jan	NEWA

NALDEMEDINE TOSYLATE

	TABLET;ORAL						
	SYMPROIC						
	+! BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Apr	CAHN

NALOXONE HYDROCHLORIDE

	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS						
	EVZIO (AUTOINJECTOR)						
	+! KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb	CTNA
	SPRAY, METERED;NASAL						
	NALOXONE HYDROCHLORIDE						
	@ TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	May	DISC
AB		4MG/SPRAY	A209522	001	Apr 19, 2019	Apr	NFTG
	NARCAN						
	+! ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015	May	CTEC
AB	+!	4MG/SPRAY	N208411	001	Nov 18, 2015	Apr	CFTG

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

	TABLET;ORAL						
	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE						
AB	LUPIN	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Feb	CAHN

NANDROLONE DECANOATE

	INJECTABLE;INJECTION						
	NANDROLONE DECANOATE						
	@ LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010	Feb	DISC

NAPROXEN

	SUSPENSION;ORAL							
	NAPROSYN							
>D>	AB	+! ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun	CHRS
>A>	AB	+	25MG/ML	N018965	001	Mar 23, 1987	Jun	CHRS
	NAPROXEN							
>D>	AB	ROXANE	25MG/ML	A074190	001	Mar 30, 1994	Jun	CHRS
>A>	AB	! WEST-WARD PHARMS INT	25MG/ML	A074190	001	Mar 30, 1994	Jun	CHRS
	TABLET;ORAL							
	NAPROXEN							
AB	PERRIGO PHARMS CO	250MG	A077339	001	Apr 27, 2005	Apr	CAHN	
AB		375MG	A077339	002	Apr 27, 2005	Apr	CAHN	

	TABLET;ORAL						
	NAPROXEN						
AB		500MG	A077339	003	Apr 27, 2005	Apr	CAHN
	<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE</u>						
	TABLET;ORAL						
	TREMIMET						
	+ @ CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Apr	CAHN
AB	+!	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Apr	CAHN
	<u>NARATRIPTAN HYDROCHLORIDE</u>						
	TABLET;ORAL						
	NARATRIPTAN						
>D>	AB	CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Jun DISC
>A>		@	EQ 1MG BASE	A090288	001	Jul 07, 2010	Jun DISC
>D>	AB		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Jun DISC
>A>		@	EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Jun DISC
	<u>NATEGLINIDE</u>						
	TABLET;ORAL						
	NATEGLINIDE						
AB		CADILA PHARMS LTD	60MG	A206432	001	Apr 19, 2019	Apr NEWA
AB			120MG	A206432	002	Apr 19, 2019	Apr NEWA
	<u>NEOMYCIN SULFATE</u>						
	TABLET;ORAL						
	NEOMYCIN SULFATE						
>D>	AA	LANNETT CO INC	500MG	A204435	001	Jun 10, 2016	Jun DISC
>A>		@	500MG	A204435	001	Jun 10, 2016	Jun DISC
	<u>NEOSTIGMINE METHYLSULFATE</u>						
	SOLUTION;INTRAVENOUS						
	NEOSTIGMINE METHYLSULFATE						
AP		AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jan CAHN
AP			10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jan CAHN
AP		BE PHARMS	5MG/10ML (0.5MG/ML)	A212512	001	May 13, 2019	Apr NEWA
AP			10MG/10ML (1MG/ML)	A212512	002	May 13, 2019	Apr NEWA
	<u>NIACIN</u>						
	TABLET, EXTENDED RELEASE;ORAL						
	NIACIN						
		@ JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Apr DISC
		@	750MG	A209156	002	May 14, 2018	Apr DISC
		@	1GM	A209156	003	May 14, 2018	Apr DISC
AB		MYLAN	500MG	A203742	001	Feb 22, 2019	Feb NEWA
AB			750MG	A203742	002	Feb 22, 2019	Feb NEWA
AB			1GM	A203742	003	Feb 22, 2019	Feb NEWA
AB		YICHANG HUMANWELL	500MG	A212017	001	Jun 10, 2019	May NEWA
AB			750MG	A212017	002	Jun 10, 2019	May NEWA
AB			1GM	A212017	003	Jun 10, 2019	May NEWA
	<u>NIFEDIPINE</u>						
	TABLET, EXTENDED RELEASE;ORAL						
	NIFEDIPINE						
AB2		NOVAST LABS	30MG	A210614	001	Mar 12, 2019	Feb NEWA
AB2			60MG	A210614	002	Mar 12, 2019	Feb NEWA
AB2			90MG	A210614	003	Mar 12, 2019	Feb NEWA
AB2		OSMOTICA PHARM US	90MG	A077127	003	Oct 03, 2007	Apr CMS1
AB2		SPIL	30MG	A210838	001	Apr 16, 2019	Apr NEWA
AB2			60MG	A210838	002	Apr 16, 2019	Apr NEWA
AB2			90MG	A210838	003	Apr 16, 2019	Apr NEWA
	<u>NITROGLYCERIN</u>						
	AEROSOL, METERED;SUBLINGUAL						
	NITROMIST						
	+!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006	May CAHN
	FILM, EXTENDED RELEASE;TRANSDERMAL						
	MINITRAN						
		@ MEDICIS	0.4MG/HR	A089773	001	Aug 30, 1996	May DISC
		@ VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996	May DISC
>D>	AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Jun DISC
>A>		@	0.6MG/HR	A089774	001	Aug 30, 1996	Jun DISC

	FILM, EXTENDED RELEASE;TRANSDERMAL								
	MINITRAN								
	@ VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May	DISC		
	NITRO-DUR								
	+! USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	May	CTEC		
	+!	0.2MG/HR	N020145	002	Apr 04, 1995	May	CTEC		
	+!	0.4MG/HR	N020145	004	Apr 04, 1995	May	CTEC		
>D>	AB1 +!	0.6MG/HR	N020145	005	Apr 04, 1995	Jun	CTEC		
>A>	+!	0.6MG/HR	N020145	005	Apr 04, 1995	Jun	CTEC		
	NITROGLYCERIN								
AB2	HERCON PHARM	0.1MG/HR	A089885	002	Oct 30, 2017	Feb	NEWA		
AB2	! MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Feb	CTEC		
	TABLET;SUBLINGUAL								
	NITROGLYCERIN								
AB	ALVOGEN MALTA	0.3MG	A211604	001	Apr 30, 2019	Apr	NEWA		
AB		0.4MG	A211604	002	Apr 30, 2019	Apr	NEWA		
AB		0.6MG	A211604	003	Apr 30, 2019	Apr	NEWA		
	<u>NORETHINDRONE</u>								
	TABLET;ORAL-28								
	MICRONOR								
	+ @ JANSSEN PHARMS	0.35MG	N016954	001		Mar	DISC		
	NORETHINDRONE								
AB2	! MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013	Mar	CHRS		
	<u>NORETHINDRONE ACETATE</u>								
	TABLET;ORAL								
	NORETHINDRONE ACETATE								
AB	RISING	5MG	A206490	001	Nov 05, 2018	May	CAHN		
	<u>NYSTATIN</u>								
	OINTMENT;TOPICAL								
	NYSTATIN								
AT	TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Jan	NEWA		
	POWDER;TOPICAL								
	NYSTATIN								
AT	LUPIN	100,000 UNITS/GM	A065138	001	Jul 23, 2004	Feb	CAHN		
	<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>								
	OINTMENT;TOPICAL								
	NYSTATIN AND TRIAMCINOLONE ACETONIDE								
	@ ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	DISC		
	<u>OCTREOTIDE ACETATE</u>								
	INJECTABLE;INJECTION								
	OCTREOTIDE ACETATE								
AP	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr	CAHN		
AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr	CAHN		
	@	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Mar	DISC		
AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Jan	CAHN		
AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr	CAHN		
	@	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Mar	DISC		
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Jan	CAHN		
	<u>OFLOXACIN</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	OFLOXACIN								
AT	APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb	CMFD		
	@ SANDOZ INC	0.3%	A076231	001	May 14, 2004	Mar	DISC		
	SOLUTION/DROPS;OTIC								
	OFLOXACIN								
	@ SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Mar	DISC		
	<u>OLANZAPINE</u>								
	TABLET;ORAL								
	OLANZAPINE								
	@ SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018	Apr	DISC		
	@	5MG	A206238	002	Nov 19, 2018	Apr	DISC		
	@	7.5MG	A206238	003	Nov 19, 2018	Apr	DISC		
	@	10MG	A206238	004	Nov 19, 2018	Apr	DISC		
	@	15MG	A206238	005	Nov 19, 2018	Apr	DISC		
	@	20MG	A206238	006	Nov 19, 2018	Apr	DISC		

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

	@ HEC PHARM	5MG	A208146	001	Jul 02, 2018	Feb	DISC
	@	10MG	A208146	002	Jul 02, 2018	Feb	DISC
	@	15MG	A208146	003	Jul 02, 2018	Feb	DISC
	@	20MG	A208146	004	Jul 02, 2018	Feb	DISC

OLIVE OIL; SOYBEAN OIL

>A>	EMULSION;INTRAVENOUS						
>A>	CLINOLIPID 20%						
>A>	+ @ BAXTER HLTHCARE CORP	16% (160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun	CDFR
>D>	INJECTABLE;INJECTION						
>D>	CLINOLIPID 20%						
>D>	+ @ BAXTER HLTHCARE CORP	16% (160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun	CDFR

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb	NEWA
AB		20MG	A211049	002	Feb 22, 2019	Feb	NEWA
AB		40MG	A211049	003	Feb 22, 2019	Feb	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 0.2% BASE	A209420	001	Apr 29, 2019	Apr	NEWA
AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE	A209995	001	Apr 04, 2019	Mar	NEWA
>A> AT	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Jun	CAHN
>D> AT	USV NORTH AMERICA	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Jun	CAHN

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL

TECHNIVIE

	+ @ ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Apr	DISC
--	----------------	------------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb	NEWA
>D> AB	PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun	DISC
>A>	@	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun	DISC
>A> AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Jun	NEWA
>A> AB	ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019	Jun	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

>D> AB	MYLAN	10MG	A075876	001	May 29, 2003	Jun	DISC
>A>	@	10MG	A075876	001	May 29, 2003	Jun	DISC

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

ZEGERID

AB	+ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr	CAHN
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

	@ LUITPOLD	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008	Feb	DISC
--	------------	----------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@ HIKMA FARMACEUTICA EQ 2MG BASE/ML

A076780 001 Dec 26, 2006 Feb DISC

@ LUITPOLD EQ 2MG BASE/ML

A079032 001 Nov 18, 2008 Feb DISC

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA PD PARTNERS EQ 4MG BASE/5ML

A078127 001 Jun 25, 2007 May CAHN

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ MYLAN EQ 24MG BASE

A076930 004 Jun 25, 2007 Feb DISC

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

+ @ TELIGENT 30MG/ML

N013055 001 Jan CRLD

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB LUPIN 100MG

A040284 001 Jun 19, 1998 Feb CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

>A> AB ALEMBIC PHARMS LTD EQ 30MG BASE

A211823 001 Jun 24, 2019 Jun NEWA

>A> AB EQ 45MG BASE

A211823 002 Jun 24, 2019 Jun NEWA

>A> AB EQ 75MG BASE

A211823 003 Jun 24, 2019 Jun NEWA

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

AB TEVA PHARMS USA EQ 6MG BASE/ML

A211125 001 Feb 27, 2019 Feb NEWA

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

+ @ SANOFI AVENTIS US 50MG/VIAL

N021492 001 Aug 09, 2002 Feb CDFR

AP +! 50MG/10ML (5MG/ML)

N021759 001 Jan 31, 2005 Feb CDFR

+ @ 100MG/VIAL

N021492 002 Aug 09, 2002 Feb CDFR

AP +! 100MG/20ML (5MG/ML)

N021759 002 Jan 31, 2005 Feb CDFR

+ @ 200MG/40ML (5MG/ML)

N021759 003 Nov 17, 2006 Feb CDFR

OXALIPLATIN

AP ACCORD HLTHCARE 50MG/10ML (5MG/ML)

A207474 001 Mar 21, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML)

A207474 002 Mar 21, 2017 Feb CDFR

AP 200MG/40ML (5MG/ML)

A207474 003 Mar 21, 2017 Feb CDFR

AP ACTAVIS LLC 50MG/10ML (5MG/ML)

A204880 001 Mar 05, 2018 Feb CDFR

AP 100MG/20ML (5MG/ML)

A204880 002 Mar 05, 2018 Feb CDFR

AP ACTAVIS TOTOWA 50MG/VIAL

A078803 001 Aug 08, 2012 Feb CDFR

AP 100MG/VIAL

A078803 002 Aug 08, 2012 Feb CDFR

AP CIPLA 50MG/10ML (5MG/ML)

A208523 001 Feb 10, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML)

A208523 002 Feb 10, 2017 Feb CDFR

AP EUGIA PHARMA 50MG/10ML (5MG/ML)

A205529 001 Sep 06, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML)

A205529 002 Sep 06, 2017 Feb CDFR

AP FRESENIUS KABI USA 50MG/10ML (5MG/ML)

A078811 001 Jun 10, 2010 Feb CDFR

AP 100MG/20ML (5MG/ML)

A078811 002 Jun 10, 2010 Feb CDFR

AP 50MG/VIAL

A078819 001 Jun 02, 2010 Feb CDFR

AP 50MG/10ML (5MG/ML)

A090030 001 Jan 31, 2017 Feb CDFR

AP 100MG/VIAL

A078819 002 Jun 02, 2010 Feb CDFR

AP 100MG/20ML (5MG/ML)

A090030 002 Jan 31, 2017 Feb CDFR

AP 200MG/40ML (5MG/ML)

A090030 003 Jan 31, 2017 Feb CDFR

AP GLAND PHARMA LTD 50MG/10ML (5MG/ML)

A207325 001 Feb 10, 2017 Feb CDFR

AP 50MG/VIAL

A207385 001 May 23, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML)

A207325 002 Feb 10, 2017 Feb CDFR

AP 100MG/VIAL

A207385 002 May 23, 2017 Feb CDFR

AP 200MG/40ML (5MG/ML)

A207325 003 Oct 18, 2017 Feb CDFR

@ HOSPIRA INC 50MG/VIAL

A078815 001 Sep 30, 2009 Apr DISC

AP 50MG/VIAL

A078815 001 Sep 30, 2009 Feb CDFR

@ 100MG/VIAL

A078815 002 Sep 30, 2009 Apr DISC

AP 100MG/VIAL

A078815 002 Sep 30, 2009 Feb CDFR

AP HOSPIRA WORLDWIDE 50MG/10ML (5MG/ML)

A078813 001 Aug 07, 2009 Feb CDFR

AP 100MG/20ML (5MG/ML)

A078813 002 Aug 07, 2009 Feb CDFR

AP INGENUS PHARMS LLC 50MG/10ML (5MG/ML)

A207562 001 Oct 16, 2018 Feb CDFR

AP 100MG/20ML (5MG/ML)

A207562 002 Oct 16, 2018 Feb CDFR

AP JIANGSU HENGRUI MED 50MG/10ML (5MG/ML)

A203869 001 Jun 18, 2014 Feb CDFR

AP 100MG/20ML (5MG/ML)

A203869 002 Jun 18, 2014 Feb CDFR

@ LUITPOLD 50MG/10ML (5MG/ML)

A204378 001 May 12, 2017 Feb DISC

INJECTABLE; INTRAVENOUS							
OXALIPLATIN							
AP		50MG/10ML (5MG/ML)		A204378	001	May 12, 2017	Feb CDFR
	@	100MG/20ML (5MG/ML)		A204378	002	May 12, 2017	Feb DISC
AP		100MG/20ML (5MG/ML)		A204378	002	May 12, 2017	Feb CDFR
AP	MYLAN LABS LTD	50MG/10ML (5MG/ML)		A091358	001	Aug 07, 2012	Feb CDFR
AP		50MG/VIAL		A200979	001	Aug 08, 2012	Feb CDFR
AP		100MG/20ML (5MG/ML)		A091358	002	Aug 07, 2012	Feb CDFR
AP		100MG/VIAL		A200979	002	Aug 08, 2012	Feb CDFR
AP		200MG/40ML (5MG/ML)		A091358	003	Nov 14, 2017	Feb CDFR
AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)		A204368	001	Jun 07, 2016	Feb CDFR
AP		50MG/VIAL		A204616	001	May 11, 2016	Feb CDFR
AP		100MG/20ML (5MG/ML)		A204368	002	Jun 07, 2016	Feb CDFR
AP		100MG/VIAL		A204616	002	May 11, 2016	Feb CDFR
AP	!	200MG/40ML (5MG/ML)		A204368	003	Jun 07, 2016	Feb CDFR
AP	SANDOZ	50MG/10ML (5MG/ML)		A078817	001	Jan 24, 2011	Feb CDFR
	@	50MG/VIAL		A090849	001	Apr 28, 2011	Feb CDFR
AP		100MG/20ML (5MG/ML)		A078817	002	Jan 24, 2011	Feb CDFR
	@	100MG/VIAL		A090849	002	Apr 28, 2011	Feb CDFR
	@ SANDOZ INC	50MG/10ML (5MG/ML)		A078812	001	Aug 07, 2009	Feb CDFR
	@	100MG/20ML (5MG/ML)		A078812	002	Aug 07, 2009	Feb CDFR
AP	SUN PHARM	200MG/40ML (5MG/ML)		A202922	003	Feb 15, 2019	Apr CDFR
AP	+! TEVA PHARMS	50MG/10ML (5MG/ML)		N022160	001	Aug 07, 2009	Feb CDFR
AP	+!	100MG/20ML (5MG/ML)		N022160	002	Aug 07, 2009	Feb CDFR
INJECTABLE; IV (INFUSION)							
OXALIPLATIN							
AP	SUN PHARMA GLOBAL	200MG/40ML (5MG/ML)		A202922	003	Feb 15, 2019	Feb NEWA
<u>OXAPROZIN</u>							
TABLET; ORAL							
OXAPROZIN							
	@ BEXIMCO PHARMS USA	600MG		A075842	001	Apr 12, 2001	Mar CAHN
<u>OXYBUTYNIN CHLORIDE</u>							
SYRUP; ORAL							
OXYBUTYNIN CHLORIDE							
	@ PD PARTNERS	5MG/5ML		A074997	001	Oct 15, 1997	May CAHN
TABLET; ORAL							
OXYBUTYNIN CHLORIDE							
AB	EMCURE PHARMS LTD	5MG		A211682	001	May 10, 2019	Apr NEWA
AB	INVATECH PHARMA	5MG		A211062	001	Feb 06, 2019	Jan NEWA
TABLET, EXTENDED RELEASE; ORAL							
OXYBUTYNIN CHLORIDE							
AB	AJANTA PHARMA LTD	5MG		A211655	001	Feb 28, 2019	Feb NEWA
AB		10MG		A211655	002	Feb 28, 2019	Feb NEWA
AB		15MG		A211655	003	Feb 28, 2019	Feb NEWA
<u>OXYCODONE HYDROCHLORIDE</u>							
SOLUTION; ORAL							
OXYCODONE HYDROCHLORIDE							
AA	ALKEM LABS LTD	5MG/5ML		A211748	001	Feb 07, 2019	Feb NEWA
AA		100MG/5ML		A211749	001	Feb 04, 2019	Jan NEWA
	@ LANNETT CO INC	100MG/5ML		A204085	001	Sep 09, 2014	Jan DISC
AA	PHARM ASSOC	5MG/5ML		A206914	001	Feb 01, 2019	May CPOT
AA		5MG/ML		A206914	001	Feb 01, 2019	Jan NEWA
TABLET; ORAL							
OXYCODONE HYDROCHLORIDE							
	@ VINTAGE PHARMS	5MG		A077712	003	Mar 02, 2009	Apr DISC
	@	10MG		A077712	004	Apr 13, 2015	Apr DISC
	@	15MG		A077712	001	Jan 31, 2007	Apr DISC
	@	20MG		A077712	005	Apr 13, 2015	Apr DISC
	@	30MG		A077712	002	Jan 31, 2007	Apr DISC
<u>OXYTOCIN</u>							
INJECTABLE; INJECTION							
OXYTOCIN							
	@ DR REDDYS	10USP UNITS/ML (10USP UNITS/ML)		A077453	001	Jan 24, 2008	May CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)		A077453	002	Jan 24, 2008	May CAHN

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

	@	ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	Mar	DISC
>D>	AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jun	DISC
>A>		@	6MG/ML	A078167	001	Dec 26, 2007	Jun	DISC

PALIPERIDONETABLET, EXTENDED RELEASE; ORAL
PALIPERIDONE

AB		INVENTIA HLTHCARE	1.5MG	A204452	001	Jun 12, 2019	May	NEWA
AB			3MG	A204452	002	Jun 12, 2019	May	NEWA
AB			6MG	A204452	003	Jun 12, 2019	May	NEWA
AB			9MG	A204452	004	Jun 12, 2019	May	NEWA

PALONOSETRON HYDROCHLORIDEINJECTABLE; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

	@	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Mar	DISC
--	---	--------------------	---	---------	-----	--------------	-----	------

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP		DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May	CAHN
AP			60MG/10ML (6MG/ML)	A078156	002	Aug 19, 2008	May	CAHN
AP			90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May	CAHN
	@	LUITPOLD	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008	Mar	DISC
	@		90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008	Mar	DISC

PANCURONIUM BROMIDEINJECTABLE; INJECTION
PANCURONIUM BROMIDE

AP	!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May	CAHN
	!		2MG/ML	A072760	001	Jul 31, 1990	May	CAHN

PANOBINOSTAT LACTATECAPSULE; ORAL
FARYDAK

>D>	+	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Jun	CAHN
>D>	+		EQ 15MG BASE	N205353	002	Feb 23, 2015	Jun	CAHN
>D>	+!		EQ 20MG BASE	N205353	003	Feb 23, 2015	Jun	CAHN
>A>	+	SECURA	EQ 10MG BASE	N205353	001	Feb 23, 2015	Jun	CAHN
>A>	+		EQ 15MG BASE	N205353	002	Feb 23, 2015	Jun	CAHN
>A>	+!		EQ 20MG BASE	N205353	003	Feb 23, 2015	Jun	CAHN

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB		INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Feb	NEWA
AB		L PERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014	May	CAHN

PENICILLAMINECAPSULE; ORAL
CUPRIMINE

	@	VALEANT PHARMS INTL	125MG	N019853	002		Jan	CAHN
AB	+		250MG	N019853	001		Apr	CFTG
	+		250MG	N019853	001		Jan	CAHN
AB		AMERIGEN PHARMS LTD	250MG	A209921	001	May 07, 2019	Apr	NFTG
>A>	AB	WATSON LABS INC	250MG	A210976	001	Jun 24, 2019	Jun	NEWA

PENTAMIDINE ISETHIONATEFOR SOLUTION; INHALATION
NEBUPENT

AN	+	FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989	Apr	CFTG
AN		SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr	NFTG

PENTOSTATININJECTABLE; INJECTION
PENTOSTATIN

@ MYLAN INSTITUTIONAL 10MG/VIAL A203554 001 Sep 19, 2014 Mar DISC

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

	@ ANI PHARMS INC	400MG	A074878	001	Jul 09, 1997	May	CAHN
>D>	AB MYLAN	400MG	A074425	001	Jul 08, 1997	Jun	DISC
>A>	@	400MG	A074425	001	Jul 08, 1997	Jun	DISC

PERMETHRINCREAM; TOPICAL
PERMETHRIN

AB	ENCUBE ETHICALS	5%	A211303	001	Apr 03, 2019	Mar	NEWA
AB	PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	May	CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>D>	AP CIPLA	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun	CAHN
>D>	AP	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun	CAHN
>D>	AP	100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun	CAHN
	AP FRESENIUS KABI USA	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019	Jan	NEWA
	AP	50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Jan	NEWA
	AP	100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Jan	NEWA
>A>	AP MEITHEAL	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun	CAHN
>A>	AP	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun	CAHN
>A>	AP	100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun	CAHN
	AP SANDOZ INC	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Jan	NEWA
	AP	50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Jan	NEWA
	AP	100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Jan	NEWA

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	+! AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan	CTEC
AT	+!	10%	N207926	002	Jan 15, 2015	Jan	CTEC
AT	+! PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Jan	CTEC
AT	+!	10%	N203510	002	Mar 21, 2013	Jan	CTEC

PHENYTOIN SODIUMINJECTABLE; INJECTION
PHENYTOIN SODIUM

@ LUITPOLD 50MG/ML A040781 001 Dec 04, 2007 Feb DISC

PHYTONADIONEINJECTABLE; INJECTION
PHYTONADIONE

AB	DR REDDYS LABS LTD	10MG/ML	A207719	001	May 22, 2019	May	NEWA
AB	! HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	May	CTEC
	TABLET; ORAL						
	MEPHYTON						
AB	+! BAUSCH	5MG	N010104	003		Feb	CAHN
AB	+! VALEANT PHARMS INTL	5MG	N010104	003		Jan	CAHN
	PHYTONADIONE						
AB	ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb	NEWA

PIMAVANSERIN TARTRATETABLET; ORAL
NUPLAZID

+ @ ACADIA PHARMS INC EQ 17MG BASE N207318 001 Apr 29, 2016 Jan DISC

PINDOLOLTABLET; ORAL
PINDOLOL

>D>	AB ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017	Jun	DISC
>A>	@	5MG	A209866	001	Aug 18, 2017	Jun	DISC
>D>	AB	10MG	A209866	002	Aug 18, 2017	Jun	DISC
>A>	@	10MG	A209866	002	Aug 18, 2017	Jun	DISC

PIROXICAMCAPSULE;ORAL
PIROXICAM

AB	CADILA	10MG	A205585	001	Jul 17, 2018	Feb	CAHN
AB		20MG	A205585	002	Jul 17, 2018	Feb	CAHN

PITAVASTATIN CALCIUMTABLET;ORAL
PITAVASTATIN CALCIUM

	@ MYLAN	EQ 1MG BASE	A206070	001	Apr 04, 2019	Apr	DISC
	@	EQ 2MG BASE	A206070	002	Apr 04, 2019	Apr	DISC
	@	EQ 4MG BASE	A206070	003	Apr 04, 2019	Apr	DISC
AB	MYLAN PHARMS INC	EQ 1MG BASE	A206070	001	Apr 04, 2019	Mar	NEWA
AB		EQ 2MG BASE	A206070	002	Apr 04, 2019	Mar	NEWA
AB		EQ 4MG BASE	A206070	003	Apr 04, 2019	Mar	NEWA

PLECANATIDETABLET;ORAL
TRULANCE

+!	BAUSCH	3MG	N208745	001	Jan 19, 2017	Mar	CAHN
+!	SALIX	3MG	N208745	001	Jan 19, 2017	Apr	CAHN

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
GLYCOLAX

	@ LANNETT CO INC	17GM/SCOOPFUL	A076652	001	Jul 02, 2004	May	DISC
	@ NEXGEN PHARMA INC	17GM/SCOOPFUL	A077706	001	Sep 27, 2006	May	DISC
	@ PADDOCK LLC	17GM/SCOOPFUL	A077893	001	May 26, 2006	May	DISC

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB	PRINSTON INC	8MEQ	A209026	001	Jun 11, 2019	May	NEWA
AB		10MEQ	A209026	002	Jun 11, 2019	May	NEWA
AB	ZYDUS PHARMS	8MEQ	A208445	001	Mar 11, 2019	Feb	NEWA
AB		10MEQ	A208445	002	Mar 11, 2019	Feb	NEWA

FOR SOLUTION;ORAL
POTASSIUM CHLORIDE

AA	AMNEAL PHARMS LLC	20MEQ	A210902	001	May 23, 2019	May	NEWA
AA	BELCHER PHARMS LLC	20MEQ	A212183	001	May 06, 2019	Apr	NEWA

SOLUTION;ORAL
POTASSIUM CHLORIDE

AA	PHARM ASSOC	20MEQ/15ML	A210766	001	Mar 29, 2019	Mar	NEWA
AA		40MEQ/15ML	A210766	002	Mar 29, 2019	Mar	NEWA

TABLET, EXTENDED RELEASE;ORAL
KLOR-CON M15

AB1	UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Mar	CTEC
>A>	ADARE PHARMS INC	10MEQ	A076368	002	Jun 05, 2019	Jun	NEWA
AB2	PII	8MEQ	A206881	001	Jan 22, 2019	Jan	NEWA
AB1		10MEQ	A206630	001	Mar 29, 2019	Mar	NEWA
AB2		10MEQ	A206881	002	Jan 22, 2019	Jan	NEWA
>A>	AB3	10MEQ	A210097	001	Jun 17, 2019	Jun	NEWA
AB1		15MEQ	A206630	002	Mar 29, 2019	Mar	NEWA
AB1		20MEQ	A206630	003	Mar 29, 2019	Mar	NEWA
AB2		20MEQ	A210098	001	Apr 26, 2019	Apr	NEWA
AB1	PRINSTON INC	10MEQ	A209922	001	Apr 30, 2019	Apr	NEWA
AB1		15MEQ	A209922	002	Apr 30, 2019	Apr	NEWA
AB1		20MEQ	A209922	003	Apr 30, 2019	Apr	NEWA

PRALATREXATESOLUTION;INTRAVENOUS
FOLOTYN

+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Mar	CAHN
+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Mar	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	HERITAGE PHARMA	0.125MG	A 077724	001	Feb 19, 2008	May	CAHN
	@	0.125MG	A 091254	001	Nov 30, 2010	May	CAHN
AB		0.25MG	A 077724	002	Feb 19, 2008	May	CAHN
	@	0.25MG	A 091254	002	Nov 30, 2010	May	CAHN
AB		0.5MG	A 077724	003	Feb 19, 2008	May	CAHN
	@	0.5MG	A 091254	003	Nov 30, 2010	May	CAHN
	@	0.75MG	A 091254	004	Nov 30, 2010	May	CAHN
AB		1MG	A 077724	004	Feb 19, 2008	May	CAHN
	@	1MG	A 091254	005	Nov 30, 2010	May	CAHN
AB		1.5MG	A 077724	005	Feb 19, 2008	May	CAHN
	@	1.5MG	A 091254	006	Nov 30, 2010	May	CAHN

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

>A>	AB	APNAR PHARMA LP	10MG	A 076397	003	Oct 23, 2006	Jun	CAHN
>A>	AB		20MG	A 076397	002	Oct 23, 2006	Jun	CAHN
>A>	AB		40MG	A 076397	001	Oct 23, 2006	Jun	CAHN
>A>	AB		80MG	A 077491	001	Feb 11, 2008	Jun	CAHN
>D>	AB	SANDOZ	10MG	A 076397	003	Oct 23, 2006	Jun	CAHN
>D>	AB		20MG	A 076397	002	Oct 23, 2006	Jun	CAHN
>D>	AB		40MG	A 076397	001	Oct 23, 2006	Jun	CAHN
>D>	AB		80MG	A 077491	001	Feb 11, 2008	Jun	CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

	@	PD PARTNERS	5MG/5ML	A 040570	001	Aug 25, 2005	May	CAHN
	@		15MG/5ML	A 040571	001	Aug 25, 2005	May	CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

	@	EYEVANCE	0.125%	N 017468	001		May	CAHN
--	---	----------	--------	----------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A 074449	001	Dec 29, 1995	May	CTEC	
	@	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A 073630	001	May 27, 1993	May	DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

	@	GENEYORK PHARMS	1MG	A 211496	001	Dec 28, 2018	May	DISC
	@		2.5MG	A 211495	001	Dec 07, 2018	May	DISC
	@		5MG	A 211495	002	Dec 07, 2018	May	DISC
	@		10MG	A 210525	001	Dec 04, 2018	May	DISC
	@		20MG	A 210525	002	Dec 04, 2018	May	DISC
	@		50MG	A 210525	003	Dec 04, 2018	May	DISC
AB		SUN PHARM INDUSTRIES	5MG	A 089247	002	Dec 04, 1985	Jan	CMS1
AB			10MG	A 089247	003	Dec 04, 1985	Jan	CMS1

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	NEXUS PHARMS	EQ 5MG BASE/ML	A 204860	001	Feb 15, 2019	Feb	NEWA
----	--------------	----------------	----------	-----	--------------	-----	------

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

	@	LUITPOLD	50MG/ML	A 090845	001	Jun 22, 2009	Mar	DISC
--	---	----------	---------	----------	-----	--------------	-----	------

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL		PROMETHAZINE HYDROCHLORIDE					
AB	PERRIGO ISRAEL	12.5MG	A 040500	001	Jun 30, 2003	May	CAHN
AB		25MG	A 040500	002	Jun 30, 2003	May	CAHN
TABLET;ORAL		PROMETHAZINE HYDROCHLORIDE					
	@ IMPAX LABS	12.5MG	A 040791	002	Feb 12, 2008	Mar	DISC
	@	25MG	A 040791	003	Feb 12, 2008	Mar	DISC

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL		PROPRANOLOL HYDROCHLORIDE					
	@ INNOGENIX	10MG	A 070322	002	Oct 22, 1985	May	CMS1
	@	20MG	A 070322	003	Oct 22, 1985	May	CMS1
	@	40MG	A 070322	004	Oct 22, 1985	May	CMS1
	@	60MG	A 070322	005	Sep 24, 1986	May	CMS1
	@	80MG	A 070322	001	Aug 04, 1986	Mar	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL		VIVACTIL					
AB	HERITAGE PHARMA	5MG	A 073644	001	Aug 24, 1995	May	CAHN
AB	!	10MG	A 073645	001	Aug 24, 1995	May	CAHN

PYRIDOSTIGMINE BROMIDE

INJECTABLE;INJECTION		MESTINON					
AP	+! BAUSCH	5MG/ML	N 009830	001		Feb	CAHN
SYRUP;ORAL		MESTINON					
AA	+! BAUSCH	60MG/5ML	N 015193	001		Feb	CFTG
	+!	60MG/5ML	N 015193	001		Feb	CAHN
TABLET;ORAL		MESTINON					
AA	NOVITIUM PHARMA	60MG/5ML	A 211694	001	Mar 08, 2019	Feb	NFTG
TABLET;ORAL		MESTINON					
AB	+! BAUSCH	60MG	N 009829	002		Feb	CAHN
TABLET, EXTENDED RELEASE;ORAL		MESTINON					
AB	+! BAUSCH	180MG	N 011665	001		Feb	CAHN

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION		PYRIDOXINE HYDROCHLORIDE					
	@ DR REDDYS	100MG/ML	A 080572	001		May	CAHN

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL		QUETIAPINE FUMARATE					
	@ AMNEAL PHARMS	EQ 400MG BASE	A 211405	001	Oct 26, 2018	Apr	DISC

QUININE SULFATE

CAPSULE;ORAL		QUININE SULFATE					
	@ MYLAN PHARMS INC	324MG	A 202581	001	Dec 14, 2012	Mar	DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL		RABEPRAZOLE SODIUM					
AB	RUBICON	20MG	A 204237	001	Nov 18, 2015	Feb	CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL		RANITIDINE HYDROCHLORIDE					
AB	APPCO PHARMA LLC	EQ 150MG BASE	A 211893	001	Apr 05, 2019	Mar	NEWA
AB		EQ 300MG BASE	A 211893	002	Apr 05, 2019	Mar	NEWA

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA	TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Jan	CAHN
TABLET;ORAL							
RANITIDINE HYDROCHLORIDE							
AB	HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Feb	CAHN
AB		EQ 300MG BASE	A075165	002	Sep 30, 1998	Feb	CAHN
AB	STRIDES PHARMA	EQ 150MG BASE	A210010	001	Aug 01, 2018	Apr	CAHN
AB		EQ 300MG BASE	A210010	002	Aug 01, 2018	Apr	CAHN
AB	VKT PHARMA PVT LTD	EQ 150MG BASE	A211289	001	Jan 31, 2019	Jan	NEWA
AB		EQ 300MG BASE	A211289	002	Jan 31, 2019	Jan	NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

AB	+ GILEAD	500MG	N021526	002	Jan 27, 2006	Feb	CTEC
AB	+!	1GM	N021526	001	Feb 12, 2007	Feb	CTEC

RANOLAZINE

AB	ACTAVIS ELIZABETH	500MG	A208862	001	May 28, 2019	May	NEWA
AB		1GM	A208862	002	May 28, 2019	May	NEWA
AB	AJANTA PHARMA LTD	500MG	A210054	001	May 28, 2019	May	NEWA
AB		1GM	A210054	002	May 28, 2019	May	NEWA
AB	CIPLA	500MG	A211291	001	May 28, 2019	May	NEWA
AB		1GM	A211291	002	May 28, 2019	May	NEWA
>A>	GLENMARK PHARMS LTD	500MG	A211082	001	Jul 05, 2019	Jun	NEWA
>A>		1GM	A211082	002	Jul 05, 2019	Jun	NEWA
AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb	CMFD
AB		1GM	A201046	002	Jul 29, 2013	Feb	CMFD
AB	SCIEGEN PHARMS INC	500MG	A211829	001	Jun 04, 2019	May	NEWA
AB		1GM	A211829	002	Jun 04, 2019	May	NEWA
AB	SUN PHARM	500MG	A211707	001	May 28, 2019	May	NEWA
AB		1GM	A211707	002	May 28, 2019	May	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB	MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar	NEWA
AB		EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar	NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

	+ @ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar	DISC
	+ @	1MG	N020741	002	Dec 22, 1997	Mar	DISC
	+ @	2MG	N020741	003	Dec 22, 1997	Mar	DISC
REPAGLINIDE							
AB	! AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar	CHRS
	@ MYLAN	0.5MG	A090252	001	Aug 23, 2013	Feb	DISC

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

	+! ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar	CAHN
--	-------------	----	---------	-----	--------------	-----	------

RIBAVIRIN

CAPSULE;ORAL

RIBAVIRIN

>D>	AB	CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Jun	DISC
>A>		@	200MG	A076192	001	Apr 06, 2004	Jun	DISC
>D>	SOLUTION;ORAL							
>D>	REBETOL							
>D>	+!	SCHERING	40MG/ML	N021546	001	Jul 29, 2003	Jun	DISC
>A>	+ @		40MG/ML	N021546	001	Jul 29, 2003	Jun	DISC

TABLET;ORAL

RIBAVIRIN

AB	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb	CAHN
AB		400MG	A202546	002	Aug 12, 2014	Feb	CAHN
AB		500MG	A202546	003	Aug 12, 2014	Feb	CAHN
AB		600MG	A202546	004	Aug 12, 2014	Feb	CAHN
AB	HERITAGE PHARMA	200MG	A077053	001	Dec 05, 2005	May	CAHN

RILUZOLE

TABLET;ORAL

RILUZOLE

@ DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar DISC
-----------------------	------	---------	-----	--------------	----------

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

@ HERITAGE PHARMA	100MG	A076375	001	Jan 14, 2003	May CAHN
-------------------	-------	---------	-----	--------------	----------

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

@ EYEVANCE	1%	N020474	001	Dec 30, 1994	May CAHN
------------	----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

AB	HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Feb NEWA
----	-------------------	------	---------	-----	--------------	----------

@ MYLAN	5MG	A200477	001	Nov 30, 2015	May DISC
---------	-----	---------	-----	--------------	----------

@	30MG	A200477	002	Nov 30, 2015	May DISC
---	------	---------	-----	--------------	----------

@	35MG	A200477	003	Nov 30, 2015	May DISC
---	------	---------	-----	--------------	----------

@	75MG	A200477	004	Jun 10, 2014	May DISC
---	------	---------	-----	--------------	----------

@	150MG	A200477	005	Jun 10, 2014	May DISC
---	-------	---------	-----	--------------	----------

AB	ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019	Apr NEWA
----	-----------------	------	---------	-----	--------------	----------

AB		35MG	A205280	002	May 13, 2019	Apr NEWA
----	--	------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

>A> AB	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Jun NEWA
--------	-----------	------	---------	-----	--------------	----------

@ ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb DISC
----------------	------	---------	-----	--------------	----------

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA	TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Jan CAHN
----	---------	--------	---------	-----	--------------	----------

TABLET;ORAL

RISPERIDONE

AB	HERITAGE PHARMA	0.25MG	A076228	001	Jun 30, 2008	May CAHN
----	-----------------	--------	---------	-----	--------------	----------

AB		0.25MG	A077769	001	Oct 16, 2008	May CAHN
----	--	--------	---------	-----	--------------	----------

AB		0.5MG	A076228	002	Jun 30, 2008	May CAHN
----	--	-------	---------	-----	--------------	----------

AB		0.5MG	A077769	002	Oct 16, 2008	May CAHN
----	--	-------	---------	-----	--------------	----------

AB		1MG	A076228	003	Jun 30, 2008	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		1MG	A077769	003	Oct 16, 2008	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		2MG	A076228	004	Jun 30, 2008	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		2MG	A077769	004	Oct 16, 2008	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		3MG	A076228	005	Jun 30, 2008	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		3MG	A077769	005	Oct 16, 2008	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		4MG	A076228	006	Jun 30, 2008	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		4MG	A077769	006	Oct 16, 2008	May CAHN
----	--	-----	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB	HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	May CAHN
----	-----------------	-------	---------	-----	--------------	----------

AB		1MG	A076908	002	Mar 12, 2012	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		2MG	A076908	003	Mar 12, 2012	May CAHN
----	--	-----	---------	-----	--------------	----------

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb NEWA
----	---------------------	------------	---------	-----	--------------	----------

AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb NEWA
----	--	------------	---------	-----	--------------	----------

AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb NEWA
----	--	-------------	---------	-----	--------------	----------

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Mar NEWA
----	------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb	CAHN
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb	CAHN
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb	CAHN
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb	CAHN
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb	CAHN
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb	CAHN
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb	CAHN
AB	LAX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Mar	CAHN
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Mar	CAHN
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Mar	CAHN
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Mar	CAHN
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Mar	CAHN
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Mar	CAHN
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Mar	CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

	@ AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018	Apr	DISC
	@	10MG	A208850	002	Oct 16, 2018	Apr	DISC
	@	20MG	A208850	003	Oct 16, 2018	Apr	DISC
	@	40MG	A208850	004	Oct 16, 2018	Apr	DISC
AB	SCIEGEN PHARMS INC	5MG	A206381	001	Apr 24, 2019	Apr	NEWA
AB		10MG	A206381	002	Apr 24, 2019	Apr	NEWA
AB		20MG	A206381	003	Apr 24, 2019	Apr	NEWA
AB		40MG	A206381	004	Apr 24, 2019	Apr	NEWA
AB	SHANDONG	5MG	A207375	001	May 07, 2019	Apr	NEWA
AB		10MG	A207375	002	May 07, 2019	Apr	NEWA
AB		20MG	A207375	003	May 07, 2019	Apr	NEWA
AB		40MG	A207375	004	May 07, 2019	Apr	NEWA
AB	UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019	Mar	NEWA
AB		10MG	A207626	002	Apr 09, 2019	Mar	NEWA
AB		20MG	A207626	003	Apr 09, 2019	Mar	NEWA
AB		40MG	A207626	004	Apr 09, 2019	Mar	NEWA
AB	ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019	Feb	NEWA
AB		10MG	A206513	002	Mar 01, 2019	Feb	NEWA
AB		20MG	A206513	003	Mar 01, 2019	Feb	NEWA
AB		40MG	A206513	004	Mar 01, 2019	Feb	NEWA

RUFINAMIDE

SUSPENSION;ORAL

BANZEL

AB	+! EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Apr	CFTG
	RUFINAMIDE						
AB	BIONPHARMA INC	40MG/ML	A211388	001	Apr 23, 2019	Apr	NFTG
AB	HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Apr	NFTG

TABLET;ORAL

RUFINAMIDE

	@ MYLAN	200MG	A205095	001	May 16, 2016	Feb	DISC
	@	400MG	A205095	002	May 16, 2016	Feb	DISC

SAPROPTERIN DIHYDROCHLORIDE

TABLET;ORAL

KUVAN

AB	+! BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	May	CTEC
AB	+!	100MG	N022181	001	Dec 13, 2007	Apr	CFTG
	SAPROPTERIN DIHYDROCHLORIDE						
	@ PAR PHARM INC	100MG	A207200	001	May 10, 2019	May	DISC
AB		100MG	A207200	001	May 10, 2019	Apr	NFTG

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

>A>	AB	MYLAN TECHNOLOGIES	1MG/72HR	A203753	001	Jun 19, 2019	Jun	NEWA
-----	----	--------------------	----------	---------	-----	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

>A>	AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Jun	CAHN
>D>	AB	KENTON	5MG	A074912	001	Apr 30, 1998	Jun	CAHN
	AB		5MG	A074912	001	Apr 30, 1998	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

+!	BAUSCH	1.25MG	N021479	001	Jun 14, 2006	Mar	CAHN
----	--------	--------	---------	-----	--------------	-----	------

SELENIOS ACID

SOLUTION; INTRAVENOUS

SELENIOS ACID

+!	AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019	Apr	NEWA
----	-----------	--	---------	-----	--------------	-----	------

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

>A>	+!	BAUSCH	2%	N021385	001	Dec 10, 2003	Jun	CAHN
>D>	+!	VALEANT LUXEMBOURG	2%	N021385	001	Dec 10, 2003	Jun	CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Jun	DISC
>A>	@		EQ 25MG BASE	A077106	001	Feb 06, 2007	Jun	DISC
	AB		EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb	CAHN
>D>	AB		EQ 50MG BASE	A077106	002	Feb 06, 2007	Jun	DISC
>A>	@		EQ 50MG BASE	A077106	002	Feb 06, 2007	Jun	DISC
	AB		EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb	CAHN
>D>	AB		EQ 100MG BASE	A077106	003	Feb 06, 2007	Jun	DISC
>A>	@		EQ 100MG BASE	A077106	003	Feb 06, 2007	Jun	DISC
	AB		EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb	CAHN
	AB	HERITAGE PHARMA	EQ 25MG BASE	A076465	001	Aug 11, 2006	May	CAHN
	@		EQ 25MG BASE	A077299	001	Feb 06, 2007	May	CAHN
	@		EQ 25MG BASE	A077345	001	Feb 06, 2007	May	CAHN
	AB		EQ 50MG BASE	A076465	002	Aug 11, 2006	May	CAHN
	@		EQ 50MG BASE	A077299	002	Feb 06, 2007	May	CAHN
	@		EQ 50MG BASE	A077345	002	Feb 06, 2007	May	CAHN
	AB		EQ 100MG BASE	A076465	003	Aug 11, 2006	May	CAHN
	@		EQ 100MG BASE	A077299	003	Feb 06, 2007	May	CAHN
	@		EQ 100MG BASE	A077345	003	Feb 06, 2007	May	CAHN
	@	MYLAN PHARMS INC	EQ 25MG BASE	A078626	001	Jan 31, 2008	May	DISC
	@		EQ 50MG BASE	A078626	002	Jan 31, 2008	May	DISC

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

AB	+	GENZYME	400MG	N021179	001	Jul 12, 2000	Feb	CFTG
AB	+!		800MG	N021179	002	Jul 12, 2000	Feb	CFTG

SEVELAMER HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	400MG	A204724	001	Feb 08, 2019	Feb	NFTG
AB			800MG	A204724	002	Feb 08, 2019	Feb	NFTG

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

AB	+!	PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	May	CFTG
AB		NOVITIUM PHARMA	EQ 10MG BASE/ML	A212260	001	May 31, 2019	May	NFTG

TABLET; ORAL

SILDENAFIL CITRATE

AB		LUPIN LTD	EQ 25MG BASE	A212051	001	Mar 22, 2019	Mar	NEWA
AB			EQ 50MG BASE	A212051	002	Mar 22, 2019	Mar	NEWA
AB			EQ 100MG BASE	A212051	003	Mar 22, 2019	Mar	NEWA
AB		MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Mar	NEWA
AB			EQ 50MG BASE	A201171	002	Mar 25, 2019	Mar	NEWA
AB			EQ 100MG BASE	A201171	003	Mar 25, 2019	Mar	NEWA

SIMVASTATINTABLET;ORAL
SIMVASTATIN

AB	MICRO LABS	5MG	A090383	001	Sep 16, 2011	Mar	CAHN
AB		10MG	A090383	002	Sep 16, 2011	Mar	CAHN
AB		20MG	A090383	003	Sep 16, 2011	Mar	CAHN
AB		40MG	A090383	004	Sep 16, 2011	Mar	CAHN
AB		80MG	A090383	005	Sep 16, 2011	Mar	CAHN

SIPONIMODTABLET;ORAL
MAYZENT

+	NOVARTIS PHARMS CORP	0.25MG	N209884	001	Mar 26, 2019	Mar	NEWA
+	!	2MG	N209884	002	Mar 26, 2019	Mar	NEWA

SIPONIMOD FUMARIC ACIDTABLET;ORAL
MAYZENT

+	NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr	CAIN
+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr	CAIN

SIROLIMUSSOLUTION;ORAL
RAPAMUNE

AA	+	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Jan	CFTG
AA		NOVITIUM PHARMA	1MG/ML	A211040	001	Jan 28, 2019	Jan	NFTG

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

>A>		EXELA PHARMA SCS LLC	0.5MEQ/ML	A211091	001	Jun 20, 2019	Jun	NEWA
>A>	AP		0.9MEQ/ML	A211091	002	Jun 20, 2019	Jun	NEWA
>A>	AP		1MEQ/ML	A211091	003	Jun 20, 2019	Jun	NEWA

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	3GM/100ML	A209476	001	Mar 13, 2019	Feb	NEWA
----	--	--------------------	-----------	---------	-----	--------------	-----	------

SODIUM CHROMATE CR-51INJECTABLE;INJECTION
SODIUM CHROMATE CR 51
@ CURIUM

100uCi/ML	N016708	001		Jan	CAHN
-----------	---------	-----	--	-----	------

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP		DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014	Apr	CAHN
----	--	---------	--------------	---------	-----	--------------	-----	------

SODIUM IODIDE I-131CAPSULE;ORAL
SODIUM IODIDE I 131

@	CURIUM	0.8-100mCi	N016515	002		Jan	CAHN
+	@	0.8-100mCi	N016517	001		Jan	CAHN
@		15-100uCi	N016517	002		Jan	CAHN

SOLUTION;ORAL
SODIUM IODIDE I 131

+	@	CURIUM	3.5-150mCi/VIAL	N016515	001		Jan	CAHN
---	---	--------	-----------------	---------	-----	--	-----	------

SODIUM NITROPRUSSIDEINJECTABLE;INJECTION
SODIUM NITROPRUSSIDE

AP		DR REDDYS LABS LTD	25MG/ML	A210114	001	Apr 10, 2019	Mar	NEWA
----	--	--------------------	---------	---------	-----	--------------	-----	------

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB +! HORIZON THERAP 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Feb CAHN

TABLET;ORAL

BUPHENYL

AB +! HORIZON THERAP 500MG N020572 001 May 13, 1996 Feb CAHN

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	May	NEWA
AB		10MG	A205483	002	May 20, 2019	May	NEWA
AB	ALEMBIC PHARMS LTD	5MG	A205575	001	May 20, 2019	May	NEWA
AB		10MG	A205575	002	May 20, 2019	May	NEWA
AB	ALKEM LABS LTD	5MG	A210224	001	May 20, 2019	May	NEWA
AB		10MG	A210224	002	May 20, 2019	May	NEWA
AB	AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	May	NEWA
AB		10MG	A209719	002	May 20, 2019	May	NEWA
AB	BRECKENRIDGE PHARM	5MG	A209818	001	May 20, 2019	May	NEWA
AB		10MG	A209818	002	May 20, 2019	May	NEWA
AB	CELLTRION	5MG	A210582	001	May 20, 2019	May	NEWA
AB		10MG	A210582	002	May 20, 2019	May	NEWA
AB	CIPLA	5MG	A209839	001	May 20, 2019	May	NEWA
AB		10MG	A209839	002	May 20, 2019	May	NEWA
AB	GLENMARK PHARMS INC	5MG	A209239	001	May 20, 2019	May	NEWA
AB		10MG	A209239	002	May 20, 2019	May	NEWA
AB	JIANGXI BOYA SEEHOT	5MG	A210281	001	May 20, 2019	May	NEWA
AB		10MG	A210281	002	May 20, 2019	May	NEWA
AB	MSN LABS PVT LTD	5MG	A210688	001	May 20, 2019	May	NEWA
AB		10MG	A210688	002	May 20, 2019	May	NEWA
AB	QILU PHARM CO LTD	5MG	A209333	001	May 20, 2019	May	NEWA
AB		10MG	A209333	002	May 20, 2019	May	NEWA
AB	SCIEGEN PHARMS INC	5MG	A211657	001	May 20, 2019	May	NEWA
AB		10MG	A211657	002	May 20, 2019	May	NEWA
AB	WATSON LABS INC	5MG	A202551	001	May 20, 2019	May	NEWA
AB		10MG	A202551	002	May 20, 2019	May	NEWA

>A> SOLRIAMFETOL

>A> TABLET;ORAL

>A> SUNOSI

>A> + JAZZ 75MG N211230 001 Jun 17, 2019 Jun NEWA

>A> + 150MG N211230 002 Jun 17, 2019 Jun NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL

BETAPACE

AB	+ COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May	CTEC
AB	+	120MG	N019865	005	Apr 20, 1994	May	CTEC
AB	+!	160MG	N019865	002	Oct 30, 1992	May	CTEC
AB	+	240MG	N019865	003	Oct 30, 1992	May	CTEC

BETAPACE AF

AB	+ COVIS PHARMA BV	80MG	N021151	001	Feb 22, 2000	May	CTEC
AB	+	120MG	N021151	002	Feb 22, 2000	May	CTEC
AB	+!	160MG	N021151	003	Feb 22, 2000	May	CTEC

SORINE

AB	UPSHER SMITH LABS	80MG	A075500	001	Apr 27, 2001	May	CTEC
AB		120MG	A075500	004	Apr 27, 2001	May	CTEC
AB		160MG	A075500	002	Apr 27, 2001	May	CTEC
AB		240MG	A075500	003	Apr 27, 2001	May	CTEC

SOTALOL HYDROCHLORIDE

AB	APOTEX	80MG	A076214	001	Aug 27, 2003	May	CTEC
AB		120MG	A076214	002	Aug 27, 2003	May	CTEC
AB		160MG	A076214	003	Aug 27, 2003	May	CTEC
AB	APOTEX INC	80MG	A076140	001	Sep 26, 2002	May	CTEC
AB		120MG	A076140	002	Sep 26, 2002	May	CTEC
AB		160MG	A076140	003	Sep 26, 2002	May	CTEC
AB		240MG	A076140	004	Sep 26, 2002	May	CTEC
AB	BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016	May	CTEC
AB		80MG	A207429	001	Nov 02, 2018	May	CTEC
AB		120MG	A207428	002	Oct 21, 2016	May	CTEC
AB		120MG	A207429	002	Nov 02, 2018	May	CTEC

TABLET;ORAL

SOTALOL HYDROCHLORIDE

AB		160MG	A207428	003	Oct 21, 2016	May	CTEC	
AB		160MG	A207429	003	Nov 02, 2018	May	CTEC	
AB	EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	May	CTEC	
AB		120MG	A077070	002	Nov 04, 2005	May	CTEC	
AB		160MG	A077070	003	Nov 04, 2005	May	CTEC	
AB	MYLAN	80MG	A077616	001	Feb 07, 2007	May	CTEC	
AB		120MG	A077616	002	Feb 07, 2007	May	CTEC	
AB		160MG	A077616	003	Feb 07, 2007	May	CTEC	
AB	OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	May	CTEC	
AB		120MG	A075563	002	Nov 07, 2003	May	CTEC	
AB		160MG	A075563	003	Nov 07, 2003	May	CTEC	
AB		240MG	A075563	004	Nov 07, 2003	May	CTEC	
AB	TEVA	80MG	A075429	001	May 01, 2000	May	CTEC	
AB		120MG	A075429	002	May 01, 2000	May	CTEC	
AB		160MG	A075429	003	May 01, 2000	May	CTEC	
AB		240MG	A075429	004	May 01, 2000	May	CTEC	
>D>	AB	UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000	Jun	DISC
>A>	@		80MG	A075366	001	May 01, 2000	Jun	DISC
AB		80MG	A075366	001	May 01, 2000	May	CTEC	
>D>	AB	120MG	A075366	002	May 01, 2000	Jun	DISC	
>A>	@		120MG	A075366	002	May 01, 2000	Jun	DISC
AB		120MG	A075366	002	May 01, 2000	May	CTEC	
>D>	AB	160MG	A075366	003	May 01, 2000	Jun	DISC	
>A>	@		160MG	A075366	003	May 01, 2000	Jun	DISC
AB		160MG	A075366	003	May 01, 2000	May	CTEC	
>D>	AB	240MG	A075366	004	May 01, 2000	Jun	DISC	
>A>	@		240MG	A075366	004	May 01, 2000	Jun	DISC
AB		240MG	A075366	004	May 01, 2000	May	CTEC	

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

>D>	AB	ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006	Jun	DISC
>A>	@		25MG	A040353	003	Mar 15, 2006	Jun	DISC
>D>	AB		50MG	A040353	001	Jul 29, 1999	Jun	DISC
>A>	@		50MG	A040353	001	Jul 29, 1999	Jun	DISC
>D>	AB		100MG	A040353	002	Jul 29, 1999	Jun	DISC
>A>	@		100MG	A040353	002	Jul 29, 1999	Jun	DISC
>D>	AB	CASI PHARMS INC	25MG	A086809	001		Jun	DISC
>A>	@		25MG	A086809	001		Jun	DISC

STAVUDINE

FOR SOLUTION;ORAL

ZERIT

+	@	BRISTOL-MYERS SQUIBB	1MG/ML	N020413	001	Sep 06, 1996	Mar	DISC
---	---	----------------------	--------	---------	-----	--------------	-----	------

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON

AP	+	Q BIOMED	1mCi/ML	N020134	001	Jun 18, 1993	Jan	CAHN
----	---	----------	---------	---------	-----	--------------	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

AP		AMRING PHARMS	20MG/ML	A210231	001	Jun 04, 2018	Jan	CAHN
----	--	---------------	---------	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	AP	SOMERSET THERAPS LLC	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Jun	NEWA
-----	----	----------------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB		HERITAGE PHARMA	800MG;160MG	A070037	001	Jun 02, 1987	May	CAHN
----	--	-----------------	-------------	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

AB		HERITAGE PHARMA	400MG;80MG	A070030	001	Jun 02, 1987	May	CAHN
----	--	-----------------	------------	---------	-----	--------------	-----	------

SUMATRIPTAN

SPRAY;NASAL
TOSYMRA

+! DR REDDYS LABS LTD 10MG/SPRAY N210884 001 Jan 25, 2019 Jan NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

@ PAR STERILE PRODUCTS EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A 077871 001 Jul 09, 2009 Apr DISC
@ ZYDUS EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A 090310 001 Aug 11, 2010 Apr CAHN

TACROLIMUS

OINTMENT;TOPICAL
TACROLIMUS

AB ACCORD HLTHCARE 0.03% A211688 001 Jan 31, 2019 Jan NEWA
AB 0.1% A211688 002 Jan 31, 2019 Jan NEWA

TADALAFIL

TABLET;ORAL
ALYQ

AB2 TEVA PHARMS USA 20MG A209942 001 Feb 05, 2019 Jan NEWA
TADALAFIL
AB ACCORD HLTHCARE 2.5MG A209167 001 Mar 26, 2019 Mar NEWA
AB 5MG A209167 002 Mar 26, 2019 Mar NEWA
AB1 20MG A209167 004 Mar 26, 2019 Mar NEWA
AB AJANTA PHARMA LTD 2.5MG A209654 001 Mar 26, 2019 Mar NEWA
AB 5MG A209654 002 Mar 26, 2019 Mar NEWA
AB 10MG A209654 003 Mar 26, 2019 Mar NEWA
AB1 20MG A209654 004 Mar 26, 2019 Mar NEWA
AB2 20MG A210392 001 Feb 05, 2019 Jan NEWA
AB ALEMBIC PHARMS LTD 2.5MG A204809 001 Mar 26, 2019 Mar NEWA
AB 5MG A204809 002 Mar 26, 2019 Mar NEWA
AB 10MG A204809 003 Mar 26, 2019 Mar NEWA
AB1 20MG A204809 004 Mar 26, 2019 Mar NEWA
AB AMNEAL PHARMS CO 2.5MG A209744 001 Mar 26, 2019 Mar NEWA
AB 5MG A209744 002 Mar 26, 2019 Mar NEWA
AB 10MG A209744 003 Mar 26, 2019 Mar NEWA
AB1 20MG A209744 004 Mar 26, 2019 Mar NEWA
AB AUROBINDO PHARMA LTD 2.5MG A206285 001 Mar 26, 2019 Mar NEWA
AB 5MG A206285 002 Mar 26, 2019 Mar NEWA
AB 10MG A206285 003 Mar 26, 2019 Mar NEWA
AB1 20MG A206285 004 Mar 26, 2019 Mar NEWA
AB2 20MG A206286 001 Feb 05, 2019 Jan NEWA
AB CIPLA 2.5MG A209539 001 Mar 26, 2019 Mar NEWA
AB 5MG A209539 002 Mar 26, 2019 Mar NEWA
AB 10MG A209539 003 Mar 26, 2019 Mar NEWA
AB1 20MG A209539 004 Mar 26, 2019 Mar NEWA
AB2 20MG A210255 001 Feb 05, 2019 Jan NEWA
AB DR REDDYS LABS LTD 2.5MG A210069 001 Mar 26, 2019 Mar NEWA
AB 5MG A210069 002 Mar 26, 2019 Mar NEWA
AB 10MG A210069 003 Mar 26, 2019 Mar NEWA
AB1 20MG A210069 004 Mar 26, 2019 Mar NEWA
AB2 20MG A210145 001 Feb 05, 2019 Jan NEWA
AB HETERO LABS LTD III 2.5MG A209908 001 Mar 26, 2019 Mar NEWA
AB 5MG A209908 002 Mar 26, 2019 Mar NEWA
AB 10MG A209908 003 Mar 26, 2019 Mar NEWA
AB2 20MG A209907 001 Feb 05, 2019 Jan NEWA
AB1 20MG A209908 004 Mar 26, 2019 Mar NEWA
AB LUPIN LTD 2.5MG A210567 001 Mar 26, 2019 Mar NEWA
AB 5MG A210567 002 Mar 26, 2019 Mar NEWA
AB 10MG A210567 003 Mar 26, 2019 Mar NEWA
AB1 20MG A210567 004 Mar 26, 2019 Mar NEWA
AB2 20MG A210572 001 Feb 05, 2019 Jan NEWA
AB MYLAN 2.5MG A206956 001 Apr 29, 2019 Apr NEWA
AB 5MG A206957 001 Apr 29, 2019 Apr NEWA
AB 10MG A206956 002 Apr 29, 2019 Apr NEWA
AB1 20MG A206956 003 Apr 29, 2019 Apr NEWA
AB QILU PHARM CO LTD 2.5MG A210420 001 Mar 26, 2019 Mar NEWA
AB 5MG A210420 002 Mar 26, 2019 Mar NEWA
AB 10MG A210420 003 Mar 26, 2019 Mar NEWA
AB1 20MG A210420 004 Mar 26, 2019 Mar NEWA

<u>TABLET;ORAL</u>						
<u>TADALAFIL</u>						
AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar NEWA
AB		5MG	A208934	002	Mar 26, 2019	Mar NEWA
AB		10MG	A208934	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A208934	004	Mar 26, 2019	Mar NEWA
AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211335	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211335	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211335	004	Mar 26, 2019	Mar NEWA
AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211839	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211839	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211839	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A212062	001	Mar 26, 2019	Mar NEWA
AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209250	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209250	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209250	004	Mar 26, 2019	Mar NEWA
AB	WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Mar NEWA
AB		5MG	A205885	002	Mar 29, 2019	Mar NEWA
AB		10MG	A205885	003	Mar 29, 2019	Mar NEWA
AB1		20MG	A205885	004	Mar 29, 2019	Mar NEWA
AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar NEWA
AB		5MG	A206693	002	Mar 26, 2019	Mar NEWA
AB		10MG	A206693	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A206693	004	Mar 26, 2019	Mar NEWA
<u>TAFAMIDIS</u>						
<u>CAPSULE;ORAL</u>						
<u>VYNDAMAX</u>						
+	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019	May NEWA
<u>TAFAMIDIS MEGLUMINE</u>						
<u>CAPSULE;ORAL</u>						
<u>VYNDAQEL</u>						
+	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	May NEWA
<u>TAZAROTENE</u>						
<u>CREAM;TOPICAL</u>						
<u>TAZAROTENE</u>						
AB	FOUGERA PHARMS INC	0.1%	A211175	001	Jan 28, 2019	May CPOT
AB		1%	A211175	001	Jan 28, 2019	Jan NEWA
<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>						
<u>INJECTABLE;INJECTION</u>						
<u>TECHNESCAN MAG3</u>						
+	CURIUM	N/A	N019882	001	Jun 15, 1990	Jan CAHN
<u>TECHNETIUM TC-99M OXIDRONATE KIT</u>						
<u>INJECTABLE;INJECTION</u>						
<u>TECHNESCAN</u>						
+	CURIUM	N/A	N018321	001		Jan CAHN
<u>TECHNETIUM TC-99M PYROPHOSPHATE KIT</u>						
<u>INJECTABLE;INJECTION</u>						
<u>TECHNESCAN PYP KIT</u>						
AP	CURIUM	N/A	N017538	001		Jan CAHN
<u>TECHNETIUM TC-99M RED BLOOD CELL KIT</u>						
<u>INJECTABLE;INJECTION</u>						
<u>ULTRATAG</u>						
+	CURIUM	N/A	N019981	001	Jun 10, 1991	Jan CAHN
<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>						
<u>SOLUTION;INTRAVENOUS</u>						
<u>ULTRA-TECHNEKOW FM</u>						
+	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN
<u>SOLUTION;INTRAVENOUS, ORAL</u>						
<u>TECHNETIUM TC 99M GENERATOR</u>						
+	@ GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Feb DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

>D>	AB	CIPLA	20MG	A078710	001	Jan 08, 2014	Jun	DISC
>A>		@	20MG	A078710	001	Jan 08, 2014	Jun	DISC
	AB		20MG	A078710	001	Jan 08, 2014	Feb	CAHN
		@	40MG	A078710	002	Jan 08, 2014	Feb	CAHN
		@	80MG	A078710	003	Jan 08, 2014	Feb	CAHN
	AB	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Feb	NEWA
	AB		40MG	A207843	002	Feb 19, 2019	Feb	NEWA
	AB		80MG	A207843	003	Feb 19, 2019	Feb	NEWA
		@ MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar	DISC
		@	40MG	A207016	002	Oct 03, 2017	Mar	DISC
		@	80MG	A207016	003	Oct 03, 2017	Mar	DISC
		@ WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb	DISC

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

	@	APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan	DISC
	@		20MG	A204159	002	Jul 05, 2018	Jan	DISC
	@		100MG	A204159	003	Jul 05, 2018	Jan	DISC
	@		140MG	A204159	004	Jul 05, 2018	Jan	DISC
	@		180MG	A204159	005	Jul 05, 2018	Jan	DISC
	@		250MG	A204159	006	Jul 05, 2018	Jan	DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

	@	APOTEX INC	300MG	A206481	001	Jul 26, 2018	Jan	DISC
--	---	------------	-------	---------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

>A>	AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Jun	CAHN
>A>	AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Jun	CAHN
>A>	AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Jun	CAHN
>A>	AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Jun	CAHN
>D>	AB	APOTEX	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun	CAHN
>D>	AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun	CAHN
>D>	AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun	CAHN
>D>	AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun	CAHN
		@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb	CAHN
		@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb	CAHN
		@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb	CAHN
		@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb	CAHN
	AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar	CAHN
	AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar	CAHN
	AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar	CAHN
	AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar	CAHN
>A>	AB	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun	CAHN
>A>	AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun	CAHN
>A>	AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun	CAHN
>A>	AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun	CAHN
>D>	AB	SANDOZ	EQ 1MG BASE	A074823	001	Mar 30, 1998	Jun	CAHN
>D>	AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Jun	CAHN
>D>	AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Jun	CAHN
>D>	AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Jun	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

	AB	HERITAGE PHARMA	EQ 250MG BASE	A076377	001	Jul 02, 2007	May	CAHN
--	----	-----------------	---------------	---------	-----	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

	@	DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004	May	CAHN
--	---	-----------	--------	---------	-----	--------------	-----	------

TERCONAZOLE

CREAM;VAGINAL		TERCONAZOLE							
BX	+!	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	May	CAHN	
SUPPOSITORY;VAGINAL		TERCONAZOLE							
AB	!	PERRIGO ISRAEL	80MG	A077149	001	Mar 17, 2006	May	CAHN	

TERIFLUNOMIDE

TABLET;ORAL		TERIFLUNOMIDE							
AB		ALEMBIC PHARMS LTD	7MG	A209572	001	Apr 19, 2019	Apr	NEWA	
AB			14MG	A209572	002	Apr 19, 2019	Apr	NEWA	
	@	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb	DISC	
	@		14MG	A209613	002	Sep 28, 2018	Feb	DISC	
	@	APOTEX INC	7MG	A209601	001	Nov 02, 2018	Jan	DISC	
	@		14MG	A209601	002	Nov 02, 2018	Jan	DISC	
	@	AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb	DISC	
	@		14MG	A209638	002	Oct 26, 2018	Feb	DISC	
AB		MSN LABS PVT LTD	7MG	A209623	001	Apr 24, 2019	Apr	NEWA	
AB			14MG	A209623	002	Apr 24, 2019	Apr	NEWA	
	@	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar	DISC	
	@		14MG	A209700	002	Sep 04, 2018	Mar	DISC	
	@	WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb	DISC	
	@		14MG	A209549	002	Jul 27, 2018	Feb	DISC	
	@	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	May	DISC	
	@		14MG	A209668	002	Nov 30, 2018	May	DISC	

TESTOSTERONE

GEL;TRANSDERMAL		TESTOSTERONE							
	@	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Mar	DISC	
GEL, METERED;TRANSDERMAL		TESTOSTERONE							
AB		ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM ACTUATION)	A204570	001	Apr 10, 2019	Mar	NEWA	
AB		AMNEAL PHARMS LLC	1.62% (20.25MG/1.25GM ACTUATION)	A207373	001	Apr 10, 2019	Mar	NEWA	
AB		DR REDDYS	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Mar	NEWA	
AB		LUPIN ATLANTIS	1.62% (20.25MG/1.25GM ACTUATION)	A208560	001	Apr 10, 2019	Mar	NEWA	

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION		TESTOSTERONE CYPIONATE							
AO		LUITPOLD	200MG/ML	A207742	001	Jun 16, 2017	May	CMFD	
	@		200MG/ML	A207742	001	Jun 16, 2017	Feb	DISC	
	@	MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Mar	DISC	
AO		WILSHIRE PHARMS INC	200MG/ML	A206368	001	Apr 24, 2019	Apr	NEWA	

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL		JATENZO							
	+	CLARUS	158MG	N206089	001	Mar 27, 2019	Mar	NEWA	
	+		198MG	N206089	002	Mar 27, 2019	Mar	NEWA	
	+!		237MG	N206089	003	Mar 27, 2019	Mar	NEWA	

TETRABENAZINE

TABLET;ORAL		TETRABENAZINE							
	@	LUPIN LTD	12.5MG	A210544	001	Apr 20, 2018	Feb	DISC	
	@		25MG	A210544	002	Apr 20, 2018	Feb	DISC	
AB		WEST-WARD PHARMS INT	12.5MG	A209739	001	Apr 08, 2019	Mar	NEWA	
AB			25MG	A209739	002	Apr 08, 2019	Mar	NEWA	

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC		TETRACAINE HYDROCHLORIDE							
		BAUSCH	0.5%	N210821	001	Mar 12, 2019	Apr	CAHN	
		VALEANT PHARMS	0.5%	N210821	001	Mar 12, 2019	Mar	NEWA	

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201

AP +! CURIUM 1mCi/ML N018150 001 Jan CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB ! HERITAGE PHARMA 100MG A089807 001 Apr 30, 1990 Feb CAHN
AB 300MG A089763 001 Apr 30, 1990 Feb CAHN
AB @ 450MG A081236 001 Nov 09, 1992 Feb CAHN

THIOTHIXENE

CAPSULE;ORAL
THIOTHIXENE

AB MYLAN 1MG A071093 002 Jun 23, 1987 Mar CTEC
AB 2MG A071093 003 Jun 23, 1987 Mar CTEC
AB 10MG A071093 001 Jun 23, 1987 Mar CTEC
AB NOVITIUM PHARMA 1MG A211642 001 Apr 05, 2019 Mar NEWA
AB 2MG A211642 002 Apr 05, 2019 Mar NEWA
AB 10MG A211642 004 Apr 05, 2019 Mar NEWA

TICAGRELOR

TABLET;ORAL
BRILINTA

>D> AB + ASTRAZENECA PHARMS 60MG N022433 002 Sep 03, 2015 Jun CTEC
>A> + 60MG N022433 002 Sep 03, 2015 Jun CTEC
TICAGRELOR
>D> AB AMNEAL PHARMS CO 90MG A208531 001 Jan 23, 2019 Jun DISC
>A> @ 90MG A208531 001 Jan 23, 2019 Jun DISC
AB 90MG A208531 001 Jan 23, 2019 Jan NEWA
AB HISUN PHARM HANGZHOU 90MG A208575 001 Jan 23, 2019 Jan NEWA
@ WATSON LABS INC 60MG A208390 001 Sep 04, 2018 Feb DISC
@ 90MG A208390 002 Sep 04, 2018 Feb DISC

TIGECYCLINE

POWDER;INTRAVENOUS
TIGECYCLINE

AP AUROBINDO PHARMA LTD 50MG/VIAL A206335 001 Jun 11, 2019 May NEWA

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
TIMOPTIC

AT + VALEANT PHARMS INTL EQ 0.25% BASE N018086 001 Jan CAHN
AT1 + EQ 0.5% BASE N018086 002 Jan CAHN
TIMOPTIC IN OCUDOSE
+! VALEANT PHARMS INTL EQ 0.25% BASE N019463 001 Nov 05, 1986 Jan CAHN
+! EQ 0.5% BASE N019463 002 Nov 05, 1986 Jan CAHN
TABLET;ORAL
BLOCADREN
+ @ MERCK 5MG N018017 001 Apr CRLD
+ @ 10MG N018017 002 Apr CRLD
+ @ 20MG N018017 004 Apr CRLD
TIMOLOL MALEATE
AB INVATECH PHARMA 5MG A207556 001 May 02, 2019 Apr NEWA
AB 10MG A207556 002 May 02, 2019 Apr NEWA
AB 20MG A207556 003 May 02, 2019 Apr NEWA
AB MYLAN 5MG A072668 002 Jun 08, 1990 Apr CTEC
AB 10MG A072668 003 Jun 08, 1990 Apr CTEC
AB ! 20MG A072668 001 Jun 08, 1990 Apr CTEC

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL
THIOLA EC

>A> + MISSION PHARMACAL CO 100MG N211843 001 Jun 28, 2019 Jun NEWA
>A> +! 300MG N211843 002 Jun 28, 2019 Jun NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019	Mar	NEWA
AB		EQ 4MG BASE	A212196	002	Mar 27, 2019	Mar	NEWA
AB		EQ 6MG BASE	A212196	003	Mar 27, 2019	Mar	NEWA
AB	CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019	Mar	NEWA
AB		EQ 4MG BASE	A210021	002	Mar 26, 2019	Mar	NEWA
AB		EQ 6MG BASE	A210021	003	Mar 26, 2019	Mar	NEWA
AB	RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb	NEWA
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb	NEWA
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb	NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan	NEWA
AB		EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan	NEWA
	@ ANI PHARMS INC	EQ 2MG BASE	A076283	001	Jul 12, 2002	May	CAHN
	@	EQ 2MG BASE	A076371	001	Apr 09, 2003	May	CAHN
	@	EQ 4MG BASE	A076283	002	Jul 12, 2002	May	CAHN
	@	EQ 4MG BASE	A076371	002	Apr 09, 2003	May	CAHN
	@ PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar	DISC
	@	EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar	DISC

TOBRAMYCIN

SOLUTION;INHALATION

BETHKIS

>D>	+!	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Jun	CFTG
>A>	AN	+!	300MG/4ML	N201820	001	Oct 12, 2012	Jun	CFTG
		TOBRAMYCIN						
	AN	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Mar	CMFD
		@	300MG/5ML	A207080	001	Jul 09, 2018	Jan	DISC
>A>	AN	TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Jun	NFTG

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	ALEMBIC PHARMS LTD	0.3%	A211847	001	Apr 19, 2019	Apr	NEWA
----	--------------------	------	---------	-----	--------------	-----	------

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	May	CHRS
---	-------------	-------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

>D>	@	ACP NIMBLE	100MG	N018894	001	Nov 02, 1984	Jun	CAHN
>D>	@		250MG	N018894	002	Nov 02, 1984	Jun	CAHN
>D>	@		500MG	N018894	003	Nov 02, 1984	Jun	CAHN
>A>	@	COSETTE	100MG	N018894	001	Nov 02, 1984	Jun	CAHN
>A>	@		250MG	N018894	002	Nov 02, 1984	Jun	CAHN
>A>	@		500MG	N018894	003	Nov 02, 1984	Jun	CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+!	BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar	CAHN
	@		200MG	N020697	002	Jan 29, 1998	Mar	CAHN

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

@ ANI PHARMS INC

EQ 400MG BASE	A073308	001	Jan 24, 1992	May	CAHN
---------------	---------	-----	--------------	-----	------

TABLET;ORAL

TOLMETIN SODIUM

@ ANI PHARMS INC

EQ 600MG BASE	A073527	001	Jun 30, 1992	May	CAHN
---------------	---------	-----	--------------	-----	------

TOLVAPTAN

TABLET;ORAL

JYNARQUE

>D>	+	OTSUKA PHARM CO LTD	45MG	N204441	003	Apr 23, 2018	Jun	CHRS
>A>	+!		45MG	N204441	003	Apr 23, 2018	Jun	CHRS
>D>	+!		90MG	N204441	005	Apr 23, 2018	Jun	CHRS

		TABLET;ORAL							
		JYNARQUE							
>A>	+		90MG		N204441	005	Apr 23, 2018	Jun	CHRS
		<u>TOPIRAMATE</u>							
		CAPSULE, EXTENDED RELEASE;ORAL							
		QUDEXY XR							
BC	+	UPSHER SMITH LABS	25MG		N205122	001	Mar 11, 2014	Feb	CTEC
BC	+		50MG		N205122	002	Mar 11, 2014	Feb	CTEC
BC	+		100MG		N205122	003	Mar 11, 2014	Feb	CTEC
BC	+		200MG		N205122	005	Mar 11, 2014	Feb	CTEC
		TROKENDI XR							
BC	+	SUPERNUS PHARMS	200MG		N201635	004	Aug 16, 2013	Apr	CTEC
		<u>TRAMADOL HYDROCHLORIDE</u>							
		TABLET;ORAL							
		TRAMADOL HYDROCHLORIDE							
>A>	AB	POLYGEN PHARMS	50MG		A206706	001	Jul 02, 2019	Jun	NEWA
>A>	AB	RUBICON	50MG		A208708	001	Jun 28, 2019	Jun	NEWA
>A>	AB		100MG		A208708	002	Jun 28, 2019	Jun	NEWA
		<u>TRANEXAMIC ACID</u>							
		INJECTABLE;INJECTION							
		TRANEXAMIC ACID							
AP		ACIC PHARMS	100MG/ML		A209326	001	Feb 22, 2019	Feb	NEWA
	+	EXELA PHARMA SCS LLC	10MG/ML		N212020	001	Apr 15, 2019	Apr	NEWA
AP		MICRO LABS	100MG/ML		A206713	001	Jun 27, 2017	Mar	CAHN
		SOLUTION;INTRAVENOUS							
		TRANEXAMIC ACID							
	+	EXELA PHARMA SCS LLC	1GM/100ML (10MG/ML)		N212020	001	Apr 15, 2019	May	CPOT
		<u>TREPROSTINIL DIOLAMINE</u>							
		TABLET, EXTENDED RELEASE;ORAL							
		ORENITRAM							
	+	UNITED THERAP	EQ 1MG BASE		N203496	003	Dec 20, 2013	Feb	CHRS
	+		EQ 2.5MG BASE		N203496	004	Dec 20, 2013	Feb	CHRS
		<u>TRETINOIN</u>							
		CREAM;TOPICAL							
		TRETINOIN							
AB1		TARO PHARMS	0.05%		A211644	001	Jan 25, 2019	Jan	NEWA
AB			0.1%		A211645	001	Jan 22, 2019	Jan	NEWA
		<u>TRIAMCINOLONE ACETONIDE</u>							
		CREAM;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
AT		SAPTALIS PHARMS	0.025%		A040671	001	Jun 09, 2006	May	CAHN
AT			0.1%		A040671	002	Jun 09, 2006	May	CAHN
AT		STRIDES PHARMA	0.025%		A210346	001	Feb 11, 2019	Jan	NEWA
AT			0.1%		A210346	002	Feb 11, 2019	Jan	NEWA
AT			0.5%		A210346	003	Feb 11, 2019	Jan	NEWA
		INJECTABLE;INJECTION							
		KENALOG-80							
	+	APOTHECON	80MG/ML		N014901	002	Apr 12, 2019	Apr	NEWA
		TRIAMCINOLONE ACETONIDE							
	@	TEVA PHARMS USA	40MG/ML		A209852	001	Oct 05, 2018	Mar	DISC
		LOTION;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
AT		SAPTALIS PHARMS	0.1%		A040672	002	Dec 13, 2006	May	CAHN
		<u>TRICLABENDAZOLE</u>							
		TABLET;ORAL							
		EGATEN							
	+	NOVARTIS PHARMS CORP	250MG		N208711	001	Feb 13, 2019	Feb	NEWA
		<u>TRIENTINE HYDROCHLORIDE</u>							
		CAPSULE;ORAL							
		TRIENTINE HYDROCHLORIDE							
AB		AMNEAL PHARMS LLC	250MG		A210619	001	Feb 08, 2019	Feb	NEWA
>A>	AB	DR REDDYS LABS LTD	250MG		A211076	001	Jul 03, 2019	Jun	NEWA
AB		MSN LABS PVT LTD	250MG		A211134	001	May 22, 2019	May	NEWA

	CAPSULE;ORAL							
	TRIENTINE HYDROCHLORIDE							
AB	ZYDUS PHARMS	250MG	A211554	001	Apr 26, 2019	Apr	NEWA	
	<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	TRIMETHOBENZAMIDE HYDROCHLORIDE							
AB	LUPIN	300MG	A076546	001	Aug 20, 2003	Feb	CAHN	
	INJECTABLE; INJECTION							
	TIGAN							
	+!	PAR STERILE PRODUCTS 100MG/ML	N017530	001			May	CTEC
		TRIMETHOBENZAMIDE HYDROCHLORIDE						
	@	LUITPOLD 100MG/ML	A091330	001	Mar 08, 2011	Feb	DISC	
		TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE						
	@	LUITPOLD 100MG/ML	A091329	001	Mar 08, 2011	Feb	DISC	
	<u>URSODIOL</u>							
	CAPSULE;ORAL							
	URSODIOL							
>D>	@	AMNEAL PHARMS CO 300MG	A211301	001	Oct 16, 2018	Jun	CMFD	
>A>	AB	300MG	A211301	001	Oct 16, 2018	Jun	CMFD	
	@	300MG	A211301	001	Oct 16, 2018	Apr	DISC	
	<u>VALACYCLOVIR HYDROCHLORIDE</u>							
	TABLET;ORAL							
	VALACYCLOVIR HYDROCHLORIDE							
	@	WATSON LABS INC EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr	DISC	
	@	EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr	DISC	
	<u>VALPROATE SODIUM</u>							
	INJECTABLE; INJECTION							
	DEPACON							
	+ @	ABBVIE EQ 100MG BASE/ML	N020593	001	Dec 30, 1996	Apr	DISC	
		VALPROATE SODIUM						
AP	!	HIKMA FARMACEUTICA EQ 100MG BASE/ML	A078523	001	Feb 17, 2010	Apr	CHRS	
	<u>VALPROIC ACID</u>							
	SYRUP;ORAL							
	VALPROIC ACID							
	@	PD PARTNERS 250MG/5ML	A077105	001	Jul 29, 2005	May	CAHN	
	<u>VALRUBICIN</u>							
	SOLUTION; INTRAVESICAL							
	VALRUBICIN							
AO	CUSTOPHARM INC	40MG/ML	A206430	001	Apr 19, 2019	Apr	NFTG	
		VALSTAR PRESERVATIVE FREE						
AO	+!	ENDO PHARM 40MG/ML	N020892	001	Sep 25, 1998	Apr	CFTG	
	<u>VALSARTAN</u>							
	TABLET;ORAL							
	VALSARTAN							
AB	ALKEM LABS LTD	40MG	A205536	001	Mar 12, 2019	Feb	NEWA	
AB		80MG	A205536	002	Mar 12, 2019	Feb	NEWA	
AB		160MG	A205536	003	Mar 12, 2019	Feb	NEWA	
AB		320MG	A205536	004	Mar 12, 2019	Feb	NEWA	
	<u>VANCOMYCIN HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	VANCOMYCIN HYDROCHLORIDE							
AB	ORIENT PHARMA CO LTD	EQ 125MG BASE	A210729	001	Apr 29, 2019	Apr	NEWA	
AB		EQ 250MG BASE	A210729	002	Apr 29, 2019	Apr	NEWA	
	INJECTABLE; INJECTION							
	VANCOMYCIN HYDROCHLORIDE							
AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	May	NEWA	
AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	May	NEWA	
	SOLUTION; INTRAVENOUS							
	VANCOMYCIN HYDROCHLORIDE							
	+!	XELLIA PHARMS APS EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019	Feb	NEWA	
	+!	EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019	Feb	NEWA	
	+!	EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019	Feb	NEWA	
	+!	EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019	Feb	NEWA	

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

VARDENAFIL HYDROCHLORIDE

@	AMNEAL PHARMS CO	5MG	A210738	001	Oct 31, 2018	Apr	DISC
@		10MG	A210738	002	Oct 31, 2018	Apr	DISC
@		20MG	A210738	003	Oct 31, 2018	Apr	DISC

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOSTRICT

+	!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Mar	CDFR
+	!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Mar	CDFR

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

>A>	AB	ANNORA PHARMA	EQ 37.5MG BASE	A212277	001	Jul 08, 2019	Jun	NEWA
>A>	AB		EQ 75MG BASE	A212277	002	Jul 08, 2019	Jun	NEWA
>A>	AB		EQ 150MG BASE	A212277	003	Jul 08, 2019	Jun	NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

	@	MYLAN	300MG	A078306	003	Aug 09, 2007	May	DISC
		VERELAN PM						
	+	!	RECRO GAINESVILLE	N020943	003	Nov 25, 1998	May	CTEC
			300MG					
	+	@	GD SEARLE LLC	N018817	001	Sep 10, 1984	May	DISC
AB		+		N018817	002	Sep 10, 1984	May	CHRS
			120MG					
AB	!	HERITAGE PHARMS INC	120MG	A071881	001	Apr 05, 1988	May	CHRS

VIGABATRIN

FOR SOLUTION; ORAL

VIGADRONE

>A>	AA	AUCTA	500MG/PACKET	A210196	001	Jun 21, 2018	Jun	CAHN
>D>	AA	SHANGHAI	500MG/PACKET	A210196	001	Jun 21, 2018	Jun	CAHN
	AA		500MG/PACKET	A210196	001	Jun 21, 2018	Mar	CAHN

VINCRISTINE SULFATE

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+	!	ACROTECH	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012	Mar	CAHN
---	---	----------	------------------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

>D>	AP	+	!	PIERRE FABRE	EQ 10MG BASE/ML	N020388	001	Dec 23, 1994	Jun	DISC
>A>		+	@		EQ 10MG BASE/ML	N020388	001	Dec 23, 1994	Jun	DISC

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+	!	TOPROL	EQ 2.08MG BASE	N204886	001	May 08, 2014	May	CAHN
---	---	--------	----------------	---------	-----	--------------	-----	------

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VFEND

AP	+	!	PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002	May	CDFR
			VORICONAZOLE						
AP			ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	May	CDFR
AP			HAINAN POLY PHARM	200MG/VIAL	A211661	001	Nov 30, 2018	May	CDFR
AP			SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	May	CDFR
AP			ZYDUS PHARMS	200MG/VIAL	A208983	001	Jul 16, 2018	May	CDFR
AP			XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	May	CDFR

POWDER; IV (INFUSION)
VORICONAZOLE

AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Feb CTEC
TABLET; ORAL						
VORICONAZOLE						
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	Feb CAHN
AB		200MG	A206762	002	May 24, 2016	Feb CAHN
AB	CADILA	50MG	A206747	001	May 24, 2016	Apr CAHN
AB		200MG	A206747	002	May 24, 2016	Apr CAHN

XENON XE-133GAS; INHALATION
XENON XE 133

	CURIUM	10mCi/VIAL	N018327	001	Mar 09, 1982	May CAHN
		20mCi/VIAL	N018327	002	Mar 09, 1982	May CAHN

ZIDOVUDINEINJECTABLE; INJECTION
ZIDOVUDINE

	@ LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb DISC
--	------------	---------	---------	-----	--------------	----------

ZIPRASIDONE HYDROCHLORIDECAPSULE; ORAL
ZIPRASIDONE HYDROCHLORIDE

>D>	AB	CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Jun DISC
>A>		@	EQ 20MG BASE	A208988	001	Aug 22, 2017	Jun DISC
	AB		EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb CAHN
>D>	AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Jun DISC
>A>		@	EQ 40MG BASE	A208988	002	Aug 22, 2017	Jun DISC
	AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb CAHN
>D>	AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Jun DISC
>A>		@	EQ 60MG BASE	A208988	003	Aug 22, 2017	Jun DISC
	AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb CAHN
>D>	AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Jun DISC
>A>		@	EQ 80MG BASE	A208988	004	Aug 22, 2017	Jun DISC
	AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb CAHN

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
RECLAST

AP	+! NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar CDFR
ZOLEDRONIC						
AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar CDFR
ZOLEDRONIC ACID						
AP	ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar CDFR
AP	AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar CDFR
AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar CDFR
AP	APOTEX INC	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar CDFR
AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar CDFR
AP		EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar CDFR
AP	BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar CDFR
AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar CDFR
AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar CDFR
AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar CDFR
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	May CDFR
AP		EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Mar CDFR
AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar CDFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar CDFR
AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar CDFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar CDFR
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar CDFR
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar CDFR
AP		EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar CDFR
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar CDFR
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar CDFR
AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar CDFR
AP	SAGENT PHARMS	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar CDFR
AP	SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Apr NEWA

	INJECTABLE; INTRAVENOUS								
	ZOLEDRONIC ACID								
	@	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar	CDFR	
	@		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar	CDFR	
>A>	AP	USV	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Jun	CAHN	
>D>	AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Jun	CAHN	
	AP		EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CDFR	
	ZOMETA								
	+	@ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar	CDFR	
AP	+	!	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar	CDFR	
AP	+	!	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar	CDFR	
	INJECTABLE; IV (INFUSION)								
	ZOLEDRONIC ACID								
AP		DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar	CDFR	
	SOLUTION; INTRAVENOUS								
	ZOLEDRONIC ACID								
		HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar	CDFR	
	<u>ZOLPIDEM TARTRATE</u>								
	SPRAY, METERED; ORAL								
	ZOLPIMIST								
	+	!	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008	Feb	CAHN
	TABLET; ORAL								
	ZOLPIDEM TARTRATE								
	@	STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007	Apr	CAHN	
	@		10MG	A076062	002	Apr 23, 2007	Apr	CAHN	
	TABLET; SUBLINGUAL								
	INTERMEZZO								
	+	@	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	Mar	DISC
	+	@		3.5MG	N022328	002	Nov 23, 2011	Mar	DISC
	ZOLPIDEM TARTRATE								
AB	!	NOVEL LABS INC	3.5MG	A204299	002	Jun 03, 2015	Mar	CHRS	
	<u>ZONISAMIDE</u>								
	CAPSULE; ORAL								
	ZONISAMIDE								
AB		BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Apr	CAHN	
AB			50MG	A077813	002	Aug 16, 2006	Apr	CAHN	
AB			100MG	A077813	003	Aug 16, 2006	Apr	CAHN	

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

ACP NIMBLE	120MG	N018060	001		Feb	CAHN
@	325MG	N018060	003	Dec 18, 1986	Feb	CAHN
@	650MG	N018060	002		Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

GRANULES INDIA LTD	650MG	A211544	001	Apr 16, 2019	Apr	NEWA
@ HERITAGE PHARMA	650MG	A207035	001	May 31, 2018	Mar	DISC

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

QUAGEN	5MG/5ML	A212266	001	May 16, 2019	May	NEWA
--------	---------	---------	-----	--------------	-----	------

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	NEWA
@ PD PARTNERS	5MG/5ML	A090188	002	Apr 22, 2008	May	CAHN
TORRENT	5MG/5ML	A090474	002	Mar 30, 2009	Jan	CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ PD PARTNERS	5MG/5ML	A090188	001	Apr 22, 2008	May	CAHN
TORRENT	5MG/5ML	A090474	001	Mar 30, 2009	Jan	CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007	May	CAHN
@	10MG	A078615	004	Dec 28, 2007	May	CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	May	DISC
-------------------	-----------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

CHLORHEXIDINE GLUCONATE

BAJAJ	0.75%	N020111	001	Sep 11, 1997	Apr	CTNA
	0.75%	N020111	001	Sep 11, 1997	Jan	CMFD

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

! AVANTHI INC	12MG	A040829	001	May 13, 2009	Jan	CHRS
---------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019	Jan	NEWA
----------------------	--	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019	Apr	NEWA
-----------------	------------	---------	-----	--------------	-----	------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019	May	NEWA
------------------	--------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

@ ACTAVIS ELIZABETH	EQ 20MG BASE	A209202	001	Mar 05, 2019	Apr	DISC
	EQ 20MG BASE	A209202	001	Mar 05, 2019	Feb	NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
FLUTICASONE PROPIONATE
HI TECH

0.05MG/SPRAY

A208024 001 Apr 17, 2019 Apr NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN

@ OHM LABS INC
@

600MG
1.2GM

A209254 001 Jul 16, 2018 Mar DISC
A209254 002 Jul 16, 2018 Mar DISC

IBUPROFEN

SUSPENSION;ORAL
IBUPROFEN

@ GUARDIAN DRUG

100MG/5ML

A210149 001 Aug 17, 2018 Feb DISC

TABLET;ORAL
IBUPROFEN

>D>
>A>

PERRIGO R AND D
!
MOTRIN IB
+ J AND J CONSUMER INC

200MG
200MG
200MG

A077349 001 Jun 21, 2005 Jun CHRS
A077349 001 Jun 21, 2005 Jun CHRS
N019012 003 Dec 17, 1990 May CHRS

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL
ZURAGARD

+! ZUREX PHARMA

70% (10.5ML)

N210872 001 Apr 26, 2019 May CMS2

KETOCONAZOLE

SHAMPOO;TOPICAL
NIZORAL A-D

+! KRAMER

1%

N020310 001 Oct 10, 1997 Jan CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
ZADITOR

! ALCON PHARMS LTD

EQ 0.025% BASE

A077200 001 Sep 02, 2008 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE
PERRIGO R AND D

5MG

A211983 001 Mar 26, 2019 Mar NEWA

LEVONORGESTREL

TABLET;ORAL
LEVONORGESTREL

ACCORD HLTHCARE
@ APOTEX INC
>D> FDN CONSUMER
>A> @
! L PERRIGO CO

1.5MG
1.5MG
1.5MG
1.5MG
0.75MG

A207660 001 May 02, 2019 Apr NEWA
A205329 001 Sep 18, 2018 Jan DISC
A200670 001 Jul 12, 2012 Jun DISC
A200670 001 Jul 12, 2012 Jun DISC
A090740 001 Dec 30, 2010 May CAHN

LORATADINE

CAPSULE;ORAL
LORATADINE

@ BIONPHARMA INC

10MG

A202538 001 Dec 21, 2018 Mar DISC

SYRUP;ORAL
LORATADINE

@ PD PARTNERS

1MG/ML

A075565 001 Oct 05, 2004 May CAHN

TABLET;ORAL
LORATADINE

GUARDIAN DRUG
NEWGEN PHARMS LLC

10MG
10MG

A207569 001 Mar 12, 2019 Mar CAHN
A207569 001 Mar 12, 2019 Feb NEWA

TABLET, CHEWABLE;ORAL
LORATADINE

PERRIGO PHARMA INTL
SUN PHARM

5MG
5MG

A210033 001 Jun 12, 2019 May NEWA
A210088 001 Apr 16, 2018 Mar CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL						
LORATADINE AND PSEUDOEPHEDRINE SULFATE						
@ HERITAGE PHARMA	5MG;120MG	A 076208	001	Jan 28, 2004	May	CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL						
MINOXIDIL (FOR WOMEN)						
TARO PHARM	5%	A 209074	002	Apr 22, 2019	Apr	NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL						
ALEVE-D SINUS & COLD						
+! BAYER	EQ 200MG BASE;120MG	N 021076	001	Nov 29, 1999	Mar	CPOT

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL						
NICOTINE POLACRILEX						
PLD ACQUISITIONS	EQ 2MG BASE	A 207868	001	Feb 07, 2019	Feb	NEWA
	EQ 4MG BASE	A 207868	002	Feb 07, 2019	Feb	NEWA
@ WATSON LABS INC	EQ 2MG BASE	A 209206	001	Jun 26, 2018	Feb	DISC
@	EQ 4MG BASE	A 209206	002	Jun 26, 2018	Feb	DISC
@ WATSON LABS TEVA	EQ 2MG BASE	A 209519	001	Jul 02, 2018	Feb	DISC
@	EQ 4MG BASE	A 209519	002	Jul 02, 2018	Feb	DISC

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL						
OMEPRAZOLE						
APOTEX INC	20MG	A 210070	001	Feb 11, 2019	Apr	CTEC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL						
GLYCOLAX						
>D>						
LANNETT CO INC	17GM/PACKET	A 090600	001	Oct 06, 2009	Jun	DISC
>A>						
@	17GM/PACKET	A 090600	001	Oct 06, 2009	Jun	DISC
>D>						
@	17GM/SCOOPFUL	A 090600	002	Oct 06, 2009	Jun	DISC
>A>						
@	17GM/SCOOPFUL	A 090600	002	Oct 06, 2009	Jun	DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL						
RANITIDINE HYDROCHLORIDE						
STRIDES PHARMA	EQ 75MG BASE	A 209160	001	Mar 05, 2018	Apr	CAHN
	EQ 150MG BASE	A 209161	001	Feb 22, 2018	Apr	CAHN

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL						
COLGATE TOTAL						
+ @ COLGATE PALMOLIVE	0.24%;0.3%	N 020231	001	Jul 11, 1997	Mar	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2019

NO JUNE 2019 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327	001				PC	Apr 29, 2019
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308	001	10292990	May 20, 2034	U-2535		
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259	001	10167291	Jul 01, 2036	DP U-2145		
		10272083	Jan 21, 2035	U-2519		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	002	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP U-2249		
		9549923	Jul 01, 2030	DS DP		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	003	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP U-2249		
		9549923	Jul 01, 2030	DS DP		
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	10034867	Jul 07, 2020	DP U-2513		
		10034867	Jul 07, 2020	DP U-2514		
		10085974	Mar 13, 2029	DP U-2513		
		7078412	Jul 07, 2020	DS DP U-2513		
		9056100	Jul 07, 2020	DP U-2513		
		9333195	Jul 07, 2020	DP U-2513		
		RE46417	Feb 10, 2025	DS DP U-2513		
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001	10034867	Jul 07, 2020	DP U-2513	NC	Mar 29, 2022
		10034867	Jul 07, 2020	DP U-2514		
		10085974	Mar 13, 2029	DP U-2513		
		6681768	Aug 07, 2022	DP		
		7078412	Jul 07, 2020	DS DP U-2513		
		7750023	Jul 07, 2020	DP U-2513		
		8051851	Apr 22, 2027	DP		
		8129405	Jul 07, 2020	DP U-2513		
		9056100	Jul 07, 2020	DP U-2513		
		9333195	Jul 07, 2020	DP U-2513		
		RE46417	Feb 10, 2025	DS DP U-2513		
<u>ACYCLOVIR - AVACLYR</u>						
N 202408	001				ODE-235	Mar 29, 2026
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	001				ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	002				ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003				ODE-230	Jan 12, 2025
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	10124131	May 18, 2031	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	10183012	Nov 26, 2028	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	10183012	Nov 26, 2028	U-2104			
<u>ALPELISIB - PIORAY</u>						
N 212526 001	>A> 8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	>A> 8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526 002	>A> 8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	>A> 8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526 003	>A> 8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	>A> 8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMIFAMPRIDINE - RUZURGI</u>						
N 209321 001					>A> ODE-244	May 06, 2026
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	10251900	May 15, 2035	U-2414			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580	Apr 19, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580	Apr 19, 2024	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-2508			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-2509			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	>A> 10322085	Oct 24, 2023	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001					NCE	Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					NCE	Oct 24, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001					PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	10220049	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					>A> NPP	Jun 18, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	7417148	Dec 11, 2025	U-1283			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	>A> 10286034	Nov 05, 2033	U-2568		>A> NCE	Jun 21, 2024
	>A> 6579968	Jun 28, 2020	DS DP			
	>A> 6794489	Jun 28, 2020	DS DP			
	>A> 9352013	Nov 05, 2033	U-2568			
	>A> 9700592	Nov 05, 2033	U-2568			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	>A> 10117951	Mar 13, 2029	DP		>A> NCE	Jun 17, 2024
	>A> 10251894	Nov 27, 2033	U-2552			
	>A> 10322139	Jan 23, 2033	DP			
	>A> 7635773	Mar 13, 2029	DP			
	>A> 8410077	Mar 13, 2029	DP			
	>A> 9200088	Mar 13, 2029	DP			
	>A> 9750822	Mar 13, 2029	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	>A> 10307419	Oct 12, 2032	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	>A> 10307419	Oct 12, 2032	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	>A> 10307419	Oct 12, 2032	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	>A> 10307419	Oct 12, 2032	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	>A> 10307419	Oct 12, 2032	DP			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	>A> 10307368	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	10201517	Jun 13, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	>A> 10307375	Sep 07, 2031	DP			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	>A> 10172802	Sep 09, 2036	U-2554			
	>A> 9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	>A> 10172802	Sep 09, 2036	U-2554			
	>A> 9707182	Sep 09, 2036	DP U-2554			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	10285910	Oct 11, 2022	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	>A> 10307376	Nov 08, 2027	U-1585			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
	>A> 10300078	Mar 14, 2034	DP			
<u>CARBOPROST TROMETHAMINE - CARBOPROST TROMETHAMINE</u>						
A 211941 001					>A> CGT	Dec 29, 2019
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	>A> 7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	>A> 7737142	Mar 27, 2027	DS DP U-2543			
	>A> 7737142	Mar 27, 2027	DS DP U-2544			
	>A> 7737142	Mar 27, 2027	DS DP U-2545			
	>A> RE47350	Jul 16, 2029	U-1750			
	>A> RE47350	Jul 16, 2029	U-2543			
	>A> RE47350	Jul 16, 2029	U-2544			
	>A> RE47350	Jul 16, 2029	U-2545			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	>A> 7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	>A> 7737142	Mar 27, 2027	DS DP U-2543			
	>A> 7737142	Mar 27, 2027	DS DP U-2544			
	>A> 7737142	Mar 27, 2027	DS DP U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	>A> 7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	>A> 7737142	Mar 27, 2027	DS DP U-2543			
	>A> 7737142	Mar 27, 2027	DS DP U-2544			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	>A> 7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	>A> 7737142	Mar 27, 2027	DS DP U-2543			
	>A> 7737142	Mar 27, 2027	DS DP U-2544			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	>A> 10028963	Sep 07, 2032	U-2565			
	>A> 10028963	Sep 07, 2032	U-2566			
	>A> 9724353	Sep 07, 2032	U-2565			
	>A> 9724353	Sep 07, 2032	U-2566			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001					NCE	Apr 29, 2019
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	10238640	May 25, 2024	DP			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10231961	Feb 07, 2037	DP			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	7229613	Apr 17, 2022	U-2516			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	7341744	Jun 02, 2022	DP U-1319			
	9585868	Oct 31, 2031	U-1319			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863 001					PC	Mar 09, 2019
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 001					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 002					NPP	May 16, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	003				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	004				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	005				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	006				NPP	May 16, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001				M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002				M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	001	6414126	Oct 04, 2020	DS DP U-493		
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	002	6414126	Oct 04, 2020	DS DP U-493		
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	003	6414126	Oct 04, 2020	DS DP U-493		
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	004	6414126	Oct 04, 2020	DS DP U-493		
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976			
	6414126	Oct 04, 2020	DS DP U-1977			
	6414126	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-1976			
	6515117	Oct 04, 2020	DS DP U-1977			
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	6936590	Oct 04, 2020	U-493			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	6414126	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 001					PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 002					PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 003					PC	Apr 05, 2019
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					M-239	Dec 12, 2021
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					M-239	Dec 12, 2021
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910 001					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910 002					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910 003					M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001					M-239	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002				M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003				M-239	Dec 12, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002	7049328		U-735		
		8703156	Jun 28, 2021	DP U-735		
			Oct 29, 2029			
<u>DESONIDE - VERDESO</u>						
N 021978	001	8460641	Aug 13, 2027	DP U-1412		
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742	001	8409606	May 14, 2030	DP	>A> I-800	Jun 20, 2022
		8563027	Feb 12, 2030	U-2487	NP	Nov 30, 2021
		9254267	Sep 11, 2024	DP		
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912	001	10159683	May 23, 2034	DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 208129	001				>A> PC	Nov 30, 2019
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	001	>A> 9763880	Sep 30, 2033	U-2558		
		>A> 9763880	Sep 30, 2033	U-2559		
		>A> 9763880	Sep 30, 2033	U-2560		
		>A> 9763880	Sep 30, 2033	U-2561		
		>A> 9763880	Sep 30, 2033	U-2562		
		>A> 9763880	Sep 30, 2033	U-2563		
		>A> 9763880	Sep 30, 2033	U-2564		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	002	>A> 9763880	Sep 30, 2033	U-2558		
		>A> 9763880	Sep 30, 2033	U-2559		
		>A> 9763880	Sep 30, 2033	U-2560		
		>A> 9763880	Sep 30, 2033	U-2561		
		>A> 9763880	Sep 30, 2033	U-2562		
		>A> 9763880	Sep 30, 2033	U-2563		
		>A> 9763880	Sep 30, 2033	U-2564		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	003	>A> 9763880	Sep 30, 2033	U-2558		
		>A> 9763880	Sep 30, 2033	U-2559		
		>A> 9763880	Sep 30, 2033	U-2560		
		>A> 9763880	Sep 30, 2033	U-2561		
		>A> 9763880	Sep 30, 2033	U-2562		
		>A> 9763880	Sep 30, 2033	U-2563		
		>A> 9763880	Sep 30, 2033	U-2564		
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994	001	8129385	Oct 05, 2027	DS DP	NC	Apr 08, 2022
		9242986	Dec 08, 2029	DS DP		
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036	001	10238620	May 18, 2027	U-620		
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036	002	10238620	May 18, 2027	U-620		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	10265293	Aug 06, 2028	DS DP			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001 >A>	10179140	Jun 28, 2031	U-2547		NP	May 23, 2022
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	>A> 10294215	Jan 07, 2033	DP U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	>A> 10294215	Jan 07, 2033	DP U-2087			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10314977	Nov 23, 2024	DP			
	>A> 10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10314977	Nov 23, 2024	DP			
	>A> 10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10314977	Nov 23, 2024	DP			
	>A> 10335549	Apr 30, 2025	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVAL</u>						
N 211109 001	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 001					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 002					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 003					PC	Nov 05, 2019
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031		U-2502	NCE*	Mar 05, 2024
	9592207	Mar 20, 2027		U-2502		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10258630	Dec 20, 2033		U-2316		
	10258630	Dec 20, 2033		U-2317		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10258630	Dec 20, 2033		U-2316		
	10258630	Dec 20, 2033		U-2317		
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032		U-2439		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	>A> 7754702	Feb 15, 2028	DP	U-1432		
	>A> 7754702	Feb 15, 2028	DP	U-2555		
	>A> 7754702	Feb 15, 2028	DP	U-2556		
	>A> 7754702	Feb 15, 2028	DP	U-2557		
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	>A> 10300039	Jul 21, 2030		U-2549	I-790	Nov 06, 2020
	5753706	Feb 03, 2020	DP	U-1577		
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029		U-1656		
	7857977	Sep 08, 2027		U-1656		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 02, 2030	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	>A> 10300229	Jul 07, 2035	DP U-2133			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	>A> 8324266	May 28, 2030	U-2546			
	>A> 8703806	May 28, 2030	U-2546			
	>A> 8808713	May 28, 2030	DP U-2546			
	>A> 8815258	Mar 17, 2031	U-2546			
	>A> 9415009	May 28, 2030	U-2546			
	>A> 9463161	May 28, 2030	DP U-2546			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	>A> 7067502	May 21, 2020	DP U-1068		>A> M-214	Dec 20, 2020
	>A> 7067502*PED	Nov 21, 2020			>A> PED	Jun 20, 2021
	>A> 7566705	May 21, 2020	DP U-1068			
	>A> 7566705*PED	Nov 21, 2020				
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	>A> 7067502	May 21, 2020	DP U-1068		>A> M-214	Dec 20, 2020
	>A> 7067502*PED	Nov 21, 2020			>A> PED	Jun 20, 2021
	>A> 7566705	May 21, 2020	DP U-1068			
	>A> 7566705*PED	Nov 21, 2020				
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	>A> 10188663	Feb 14, 2034	DP U-2540			
	>A> 9271990	May 17, 2034	DP U-2540			
	>A> 9833459	Feb 14, 2034	DP U-2540			
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001					NCE	Nov 28, 2023
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10028937	Jun 10, 2030	U-2532		ODE-232	Apr 30, 2026
	10039754	Jun 10, 2030	U-2141		ODE-233	Apr 30, 2026
	10039754	Jun 10, 2030	U-2532			
	10286029	Mar 14, 2034	U-2532			
	8648037	Jan 19, 2032	DS DP U-2141			
	8648037	Jan 19, 2032	DS DP U-2532			
	9586978	Jun 10, 2030	U-2141			
	9586978	Jun 10, 2030	U-2532			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001					CGT	Jul 16, 2019
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589 002	10238640	May 25, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10238644	Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001 >A>	10220155	Jul 17, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
>A>	6899699	Jan 02, 2022	DP			
>A>	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
>A>	8672898	Jan 02, 2022	DP			
>A>	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
>A>	8920383	Jul 17, 2026	DP			
>A>	8937042	May 05, 2029	DP			
>A>	9108002	Jan 20, 2026	DP			
>A>	9132239	Feb 01, 2032	DP			
>A>	9457154	Sep 27, 2027	DP			
>A>	9486588	Jan 02, 2022	DP			
>A>	9616180	Jan 20, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	>A> 9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
	>A> RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9011391	Mar 26, 2024		U-1923		
	9011391	Mar 26, 2024		U-2496		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672	Aug 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672	Aug 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672	Aug 02, 2030	DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001					NP	Apr 26, 2022
<u>IVABRADINE - CORLANOR</u>						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694		NP	Apr 22, 2022
	7867996	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7879842	Feb 22, 2026	DS DP U-1694		PED	Oct 15, 2020
					PED	Oct 22, 2022
					PED	Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVACAFTOR - KALYDECO</u>						
N 203188 002					NPP	Jul 31, 2020
					ODE-186	Feb 21, 2021
					ODE-187	Dec 29, 2021
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024
					ODE-199	Aug 15, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		>A> ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		>A> ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		ODE-188	Jul 31, 2024
	8324242	Aug 05, 2027	U-1311		ODE-189	May 17, 2024
	8324242	Aug 05, 2027	U-1906		ODE-190	May 15, 2025
	8324242	Aug 05, 2027	U-2527		ODE-199	Jul 31, 2020
	8354427	Jul 06, 2026	U-1311		>A> ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10206877	Apr 14, 2035	DP U-2498			
	10239867	Apr 09, 2027	DS DP U-2512			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034	U-1631			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	9474779	Aug 19, 2033	DS DP U-2350		>A> ODE-242	May 02, 2026
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	>A> 10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	>A> 10285993	Nov 16, 2035	U-2470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	>A> 10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	>A> 10285993	Nov 16, 2035	U-2470			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	>A> 10172861	Nov 16, 2035	DS		NCE	Nov 26, 2023
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028	U-2400			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524		NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP U-1524		NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-2550		>A> ODE-241	May 28, 2026
	>A> 7468363	Oct 07, 2023	U-2551		>A> ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	>A> 8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	>A> 9155730	May 15, 2023	U-2550			
	>A> 9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-2550		>A> ODE-241	May 28, 2026
	>A> 7468363	Oct 07, 2023	U-2551		>A> ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	>A> 8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	>A> 9155730	May 15, 2023	U-2550			
	>A> 9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-2550		>A> ODE-241	May 28, 2026
	>A> 7468363	Oct 07, 2023	U-2551		>A> ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	>A> 8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	>A> 9155730	May 15, 2023	U-2550			
	>A> 9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-2550		>A> ODE-241	May 28, 2026
	>A> 7468363	Oct 07, 2023	U-2551		>A> ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	>A> 8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	>A> 9155730	May 15, 2023	U-2550			
	>A> 9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-2550		>A> ODE-241	May 28, 2026
	>A> 7468363	Oct 07, 2023	U-2551		>A> ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	>A> 8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	>A> 9155730	May 15, 2023	U-2550			
	>A> 9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	>A> 7468363	Oct 07, 2023	U-2550		>A> ODE-241	May 28, 2026
	>A> 7468363	Oct 07, 2023	U-2551		>A> ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	>A> 8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	>A> 9155730	May 15, 2023	U-2550			
	>A> 9393238	May 15, 2023	U-2550			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8962630	Dec 09, 2029	U-2505			
	9416136	Aug 20, 2029	U-2505			
	9868739	Nov 09, 2031	U-2505			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8470367	Oct 31, 2027	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8470367	Oct 31, 2027	DP			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	9782376	Dec 01, 2036	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		>A> NPP	Jun 17, 2022
	6268343*PED	Feb 22, 2023			>A> PED	Dec 17, 2022
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	6268343	Aug 22, 2022	DS DP U-1255			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			
	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9486588	Jan 02, 2022	DP			
	9486588*PED	Jul 02, 2022				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISINAPRIL - OBRELS</u>						
N 208401 001	10265370	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001 >A>	10201663	Mar 10, 2034	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002 >A>	10201663	Mar 10, 2034	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	10226471	Aug 31, 2031	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001 >A>	8779187	Jan 23, 2027	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	8628799	Jul 13, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	8628799	Jul 13, 2025	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10231927	Jan 02, 2033	U-1349			
	10231927	Jan 02, 2033	U-1699			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	10307417	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP		Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP		Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
	>A> 10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
	>A> 10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
	>A> 10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	>A> 10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
	>A> 10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10238634	Jun 28, 2032	DP			
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
	8809322	Jan 18, 2028	DP		>A> ODE-243	May 17, 2026
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	>A> 10314850	Aug 22, 2038	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10251873	May 30, 2038	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					PC	Aug 21, 2019
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	>A> 10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	>A> 10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	>A> 10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	>A> 10314788	Aug 12, 2028	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	>A> 10322239	Feb 28, 2031	U-1907			
	>A> 10335549	Apr 30, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	>A> 10322239	Feb 28, 2031	U-1907			
	>A> 10335549	Apr 30, 2025	DP			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10233154	Sep 25, 2035	DS			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2020	DP			
	5948818	May 13, 2020	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	10272061	Apr 26, 2020	U-2525			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9060976	Aug 06, 2022	DP	Y		
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001 >A>	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002 >A>	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003 >A>	10314788	Aug 12, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	>A> 10335391	Jun 11, 2035	U-2567			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2020	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PENICILLAMINE - PENICILLAMINE</u>						
A 210976 001				>A> CGT		Dec 22, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002					NCE	Apr 29, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024		DP		
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024		DP		
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024		DP		
	8557993*PED	Aug 02, 2024				
<u>PREGABALIN - LYRICA</u>						
N 021446 001				>A> NPP		May 23, 2022
				>A> PED		Nov 23, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 002					>A> NPP >A> PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 003					>A> NPP >A> PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 004					>A> NPP >A> PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 005					>A> NPP >A> PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 006					>A> NPP >A> PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 007					>A> NPP >A> PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 008					>A> NPP >A> PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 022488 001					>A> NPP >A> PED	May 23, 2022 Nov 23, 2022
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028		U-1988		
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	RE47301	Feb 02, 2027	DP			
	RE47351	Jun 22, 2019	DS DP U-869			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	>A> 10314828	Oct 02, 2029		U-1481		
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10278974	Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10278974	Feb 10, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10278974	Feb 10, 2031	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	10016429	Jun 12, 2028	U-2536		>A> I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		>A> ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	10016429	Jun 12, 2028	U-2536		>A> I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		>A> ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	10016429	Jun 12, 2028	U-2536		>A> I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		>A> ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028	U-2536		>A> I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		>A> ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028	U-2536		>A> I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		>A> ODE-238	May 24, 2026
<u>SELENIOUS ACID - SELENIOS ACID</u>						
N 209379 001					NCE	Apr 30, 2024
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP			
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 212260 001					CGT	Nov 27, 2019
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033		U-2499	ODE-231	Oct 26, 2025
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	9913860	Oct 22, 2033	DS	U-2312		
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	9913860	Oct 22, 2033	DS	U-2312		
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 001	>A> 10195151	Sep 05, 2037	DP		>A> NCE	Jun 17, 2024
	>A> 8440715	Aug 25, 2027	U-2548			
	>A> 8877806	Jun 07, 2026	U-2548			
	>A> 9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 002	>A> 10195151	Sep 05, 2037	DP		>A> NCE	Jun 17, 2024
	>A> 8440715	Aug 25, 2027	U-2548			
	>A> 8877806	Jun 07, 2026	U-2548			
	>A> 9604917	Jun 07, 2026	U-2548			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	10232061	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	Jul 01, 2025	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020		U-883		
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020		U-883		
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020		U-883		
	7211600*PED	Jun 22, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 003	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		>A> ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		>A> ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001					NCE	Jul 07, 2019
					PED	Jan 07, 2020
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		>A> ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020			ODE-37	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320		PED	Jun 21, 2020
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				
	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			
	9993528*PED	May 01, 2026				
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642	001				CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642	002				CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642	003				CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642	004				CGT	Oct 02, 2019
<u>TICAGRELOR - BRILINTA</u>						
N 022433	001	>A> 10300065	Jan 27, 2036	U-2541		
		>A> 10300065	Jan 27, 2036	U-2542		
<u>TICAGRELOR - BRILINTA</u>						
N 022433	002	>A> 10300065	Jan 27, 2036	U-2541		
		>A> 10300065	Jan 27, 2036	U-2542		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981	001	RE46284	Dec 16, 2026	U-1751	I-794	Feb 24, 2022
		RE46284	Dec 16, 2026	U-2503	ODE-229	Feb 22, 2026
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981	002	RE46284	Dec 16, 2026	U-1751	I-794	Feb 24, 2022
		RE46284	Dec 16, 2026	U-2503	ODE-229	Feb 22, 2026
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001	>A> 10314790	Nov 16, 2027	DP U-1675		
		>A> 10314790	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002	>A> 10314790	Nov 16, 2027	DP U-1675		
		>A> 10314790	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	003	>A> 10314790	Nov 16, 2027	DP U-1675		
		>A> 10314790	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004	>A> 10314790	Nov 16, 2027	DP U-1675		
		>A> 10314790	Nov 16, 2027	DP U-1992		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001	8703781	Oct 15, 2030	DS DP U-1712		
		8703781	Oct 15, 2030	DS DP U-2020		
		8703781	Oct 15, 2030	DS DP U-2037		
		8703781	Oct 15, 2030	DS DP U-2302		
		8703781	Oct 15, 2030	DS DP U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002	8703781	Oct 15, 2030	DS DP U-1712		
		8703781	Oct 15, 2030	DS DP U-2020		
		8703781	Oct 15, 2030	DS DP U-2037		
		8703781	Oct 15, 2030	DS DP U-2302		
		8703781	Oct 15, 2030	DS DP U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003	8703781	Oct 15, 2030	DS DP U-1712		
		8703781	Oct 15, 2030	DS DP U-2020		
		8703781	Oct 15, 2030	DS DP U-2037		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 001					>A> PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 002					>A> PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 003					>A> PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 004					>A> PC	Sep 21, 2019
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	6517847	Aug 03, 2020	DP U-2368			
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE ODE-228	Feb 13, 2024 Feb 13, 2026
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	10159681	Apr 13, 2030			U-2510	
	9844510	Dec 08, 2028	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-237 PED	Feb 22, 2022 Aug 22, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	002				M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	001 >A> 9539251	Sep 06, 2033	U-2538		I-795 >A> ODE-239	May 15, 2022 May 15, 2026
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	002 >A> 9539251	Sep 06, 2033	U-2538		I-795 >A> ODE-239	May 15, 2022 May 15, 2026
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	003 >A> 9539251	Sep 06, 2033	U-2538		I-795 >A> ODE-239	May 15, 2022 May 15, 2026
<u>VORICONAZOLE - VFEND</u>						
N 021266	001				>A> NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021266	002				>A> NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021267	001				>A> NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021630	001				>A> NPP	Jan 29, 2022

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm